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Abstract  
 
Tolerance of T cells to self-antigen is crucial to prevent the development of autoimmune 
disease. How self-tolerance is controlled at the transcriptional level is, however, 
unknown. We discovered that the transcription factor Early Growth Response 2 (Egr-2) 
was expressed by tolerant T cells, and by CD4+CD44high T cells in the absence of overt 
antigen stimulation, in vivo. To investigate the roles of Egr-2 in T cells, we generated 
CD2 cell specific Egr-2 deficient (Egr-2 cKO) mice. The proliferation of Egr-2 cKO 
CD44high T cells in vivo was markedly increased leading to progressive accumulation as 
the mice aged. By 15 months of age CD4+CD44high cells constituted the predominant T 
cell population in the peripheral lymphoid organs of Egr-2 cKO mice and expressed 
high levels of the activation markers CD25 and CD69. In addition to this 
lymphoproliferative disorder, 15 month old Egr-2 cKO mice showed signs of lupus-like 
autoimmune disease. This autoimmune syndrome was characterised by 
glomerulonephritis and proteinuria, infiltration of T cells into internal organs and, 
crucially, auto-antibodies directed against nuclear components; the hallmark of lupus. 
We observed decreased expression of the cyclin-dependent kinase inhibitor p21cip1 in 
Egr-2 cKO CD4+CD44high T cells while TCR stimulation induced IFN-γ, and, in 
particular, IL-17A and IL-17F expression was markedly increased. Consistent with 
these findings, we observed increased numbers of IFN-γ and IL-17 producing CD4+ T 
cells in Egr-2 cKO mice. The numbers of IFN-γ and IL-17 producing CD4+ T cells 
further increased as the mice aged in parallel with the gradual development of 
symptoms of lupus-like disease. These results demonstrate that Egr-2 is an intrinsic 
regulator of both T cell homeostasis and T cell tolerance. 
4 
Acknowledgements 
 
I would like to thank my supervisor Professor Ping Wang for all his support and also Dr 
Mark Sanderson for the initial introduction. Much of this work was done in 
collaboration with my good friend Dr Bo Zhu and I owe him a large debt of gratitude. 
Thank you to everyone, past and present, from the Centre for Gastroenterology for all 
their help and kindness; I have many fond memories of these friends and colleagues.  
 
Thank you to Bill Mansfield for all his help and expertise in generation of Egr-2 Tg 
mice and to Dr Gary Warnes for assistance with flow cytometry and FACS. Thanks also 
to Professor Jo Martin and colleagues and everyone at the Genome Centre for help with 
histopathology and microarray respectively. 
 
Thank you to Dr Suling Li for all her help in our collaboration. Thanks also to Professor 
David Wraith and colleagues for samples from Tg4 mice. 
 
Thank you to Dr Dimitris Kioussis for hCD2-Cre mice and Dr Patrick Charnay for Egr-
2loxP/loxP mice. Thanks also to Professor Kristjan Jessen for pBABE-EGFP and pBABE-
Egr-2-EGFP plasmids and Phoenix cells.  
 
Finally, thanks to my parents, Pat and Mike, and my sisters, Janine and Dawn, for all 
their love and support. 
5 
Table of Contents 
 
Title Page..................................................................................................................1 
Declaration ...............................................................................................................2 
Abstract ....................................................................................................................3 
Acknowledgements...................................................................................................4 
Table of Contents......................................................................................................5 
List of Figures and Tables ........................................................................................7 
Abbreviations ...........................................................................................................8 
Chapter 1: INTRODUCTION.............................................................................9 
1.1 T CELL DEVELOPMENT AND CENTRAL TOLERANCE .................10 
1.1.1 Double Negative cells and -selection ...................................................11 
1.1.2 Double Positive cells and Positive and Negative selection......................13 
1.2 MATURE T CELLS AND PERIPHERAL TOLERANCE......................14 
1.2.1 T cell activation .....................................................................................15 
1.2.2 T cell homeostasis .................................................................................18 
1.2.3 Peripheral T cell tolerance .....................................................................21 
1.2.3.1  Anergy and adaptive tolerance ...............................................................22 
1.2.3.1.1 Antigen-induced adaptive tolerance .......................................................25 
1.2.3.1.2 Maintenance of adaptive tolerance .........................................................26 
1.2.3.1.3 NFAT and clonal anergy........................................................................27 
1.3 EARLY GROWTH RESPONSE TRANSCRIPTION FACTORS...........29 
1.3.1 DNA binding specificity of Egr proteins ................................................30 
1.3.2 Egr-2 in the nervous system...................................................................31 
1.3.3 Egr family proteins in T cells .................................................................32 
1.3.3.1  Egr proteins in thymocyte -selection ...................................................32 
1.3.3.2  Egr proteins in thymocyte positive selection .........................................33 
1.3.3.3  Mechanisms of Egr function in thymocytes...........................................33 
1.3.3.4  Egr proteins in mature T cells ...............................................................34 
1.3.3.5  Egr-2 and Egr-3 and FasL .....................................................................35 
1.3.3.6  Signalling pathways controlling Egr-2 expression.................................36 
1.3.3.7  Egr-2 in tolerance and anergy ...............................................................36 
1.4 CRE LOXP SYSTEM OF TISSUE SPECIFIC KO MICE ......................37 
Chapter 2: MATERIALS and METHODS.......................................................41 
2.1 TG4 TRANSGENIC MICE....................................................................41 
2.2 EGR-2 CONDITIONAL KNOCKOUT MICE........................................41 
2.3 HCD2 EGR-2 TRANSGENIC MICE .....................................................42 
2.4 GENOTYPING......................................................................................43 
2.5 ISOLATION OF CD4+ CELLS..............................................................44 
2.6 CELL CULTURE AND STIMULATION ..............................................45 
2.7 RNA EXTRACTION.............................................................................46 
2.8 REVERSE TRANSCRIPTION ..............................................................47 
2.9 REAL TIME RT-PCR............................................................................47 
2.9.1 Primer design.........................................................................................48 
2.9.2 Data analysis .........................................................................................50 
2.10 PROTEIN EXTRACTION.....................................................................50 
2.11 SDS PAGE AND WESTERN BLOTTING ............................................51 
2.12 PROLIFERATION ASSAY...................................................................53 
2.13 FLOW CYTOMETRY...........................................................................54 
2.14 FLUORESCENCE ACTIVATED CELL SORTING (FACS) .................56 
6 
2.15 IN VIVO PROLIFERATION.................................................................56 
2.16 ANALYSIS OF AUTOIMMUNE DISEASE..........................................57 
2.17 RETROVIRAL TRANSDUCTION........................................................58 
2.18 ELECTROPHORETIC MOBILITY SHIFT ASSAY ..............................60 
2.19 CHROMATIN IMMUNOPRECIPITATION..........................................61 
2.20 MICROARRAY ....................................................................................63 
Chapter 3: RESULTS........................................................................................64 
3.1 EGR-2 IS EXPRESSED IN TOLERANT T CELLS ...............................64 
3.2 GENERATION OF EGR-2 CKO AND TG MICE ..................................65 
3.3 EGR-2 IN T CELL DEVELOPMENT....................................................68 
3.4 PERIPHERAL T CELL POPULATIONS...............................................74 
3.5 EGR-2 IN T CELL ACTIVATION IN VITRO.......................................80 
3.6 APOPTOSIS INDUCTION AND FASL EXPRESSION.........................81 
3.7 EGR-2 IN CD44HIGH T CELLS IN VIVO...............................................83 
3.8 T CELLS IN OLDER EGR-2 CKO MICE ..............................................87 
3.9 LUPUS-LIKE AUTOIMMUNITY IN OLDER EGR-2 CKO MICE........90 
3.10 AUTO-ANTIBODY PRODUCTION IS T CELL DEPENDENT............94 
3.11 EGR-2 AND P21CIP1 .............................................................................96 
3.12 MICROARRAY ANALYSIS OF EGR-2 CKO T CELLS..................... 101 
3.12.1 Genes up-regulated in Egr-2 cKO cells ................................................ 105 
3.12.1.1 Proinflammatory cytokines and related genes ...................................... 105 
3.12.1.2 Anti-inflammatory and pro-homeostatic cytokines............................... 108 
3.12.2 Genes down-regulated in Egr-2 cKO cells ........................................... 109 
3.12.2.1 TH2 cytokines ...................................................................................... 109 
3.12.2.2 Anti-apoptotic genes ............................................................................ 110 
3.13 CYTOKINE PROFILE OF EGR-2 CKO T CELLS............................... 111 
Chapter 4: DISCUSSION................................................................................ 115 
4.1 EGR-2 IN T CELL DEVELOPMENT.................................................. 115 
4.2 EGR-2 IN PERIPHERAL T CELLS..................................................... 117 
4.3 EGR-2 IN T CELL ACTIVATION ...................................................... 118 
4.4 EGR-2 IN CD44HIGH CELLS................................................................ 119 
4.4.1 Egr-2 in the homeostasis of CD44high cells ........................................... 120 
4.5 LUPUS-LIKE AUTOIMMUNITY IN EGR-2 CKO MICE ................... 122 
4.6 HOMEOSTASIS AND TOLERANCE................................................. 124 
4.7 OTHER EGR-2 KO DATA.................................................................. 126 
4.8 MECHANISMS OF EGR-2 FUNCTION ............................................. 128 
4.8.1 Egr-2 regulation of p21cip1 ................................................................. 128 
4.8.2 Microarray analysis of Egr-2 cKO T cells ............................................ 130 
4.8.3 Effector T cell subsets in Egr-2 cKO mice ........................................... 132 
4.9 FUTURE WORK................................................................................. 133 
4.10 CONCLUSIONS AND MODEL FOR EGR-2 FUNCTION.................. 134 
Bibliography......................................................................................................... 142 
Publications derived from this work .................................................................... 152 
 
7 
List of Figures and Tables 
 
Figure 1.1:  T cell development .................................................................................13 
Figure 1.2:  Schematic of TCR signalling ..................................................................16 
Table 1.1:  Comparison of clonal anergy and adaptive tolerance ..............................24 
Figure 1.3:  The zinc finger domain of Egr-1.............................................................29 
Figure 1.4:  Cre loxP system of tissue specific KO mice............................................39 
Table 2.1:  Genotyping primer sequences.................................................................44 
Table 2.2:  Real Time PCR primer sequences...........................................................49 
Table 2.3:  ChIP primer sequences ...........................................................................62 
Figure 3.1:  Egr-2 expression in tolerant T cells.........................................................64 
Figure 3.2:  Generation of Egr-2 cKO mice ...............................................................66 
Figure 3.3:  Generation of Egr-2 Tg mice ..................................................................67 
Figure 3.4:  T cell development in Egr-2 cKO mice...................................................69 
Figure 3.5:  T cell development in Egr-2 Tg mice......................................................71 
Figure 3.6:  Thymic CD8+ and DN populations in Egr-2 Tg mice..............................73 
Figure 3.7:  Splenic B cell and T cell populations in Egr-2 cKO mice........................75 
Figure 3.8:  Splenic B cell and T cell populations in Egr-2 Tg mice...........................77 
Figure 3.9:  Aberrant splenic CD8+ population in Egr-2 Tg mice...............................79 
Figure 3.10:  Response of Egr-2 cKO CD4+ T cells to TCR stimulation ......................81 
Figure 3.11:  Apoptosis induction and FasL expression in Egr-2 cKO CD4+ T cells ....82 
Figure 3.12:  Egr-2 expression in CD44high T cells in vivo ...........................................84 
Figure 3.13:  Hyper-proliferation of CD44high T cells in Egr-2 cKO mice ....................86 
Figure 3.14:  Intrinsic hyper-proliferation of CD44high Egr-2 cKO T cells....................87 
Figure 3.15:  Accumulation of effector phenotype T cells in Egr-2 cKO mice .............89 
Figure 3.16:  Lupus-like autoimmunity in older Egr-2 cKO mice ................................92 
Figure 3.16:  Lupus-like autoimmunity in older Egr-2 cKO mice (cont’d) ...................93 
Figure 3.17:  Development of autoantibodies in Egr-2 cKO mice ................................95 
Figure 3.18:  Expression of p21cip1 in tolerant and Egr-2 cKO T cells........................98 
Figure 3.19:  Interaction of Egr-2 with the p21cip1 promoter in vitro and in vivo ......100 
Figure 3.20:  Microarray results for well characterised T cell markers and Egr-2.......102 
Figure 3.21:  Microarray results for other Egr family genes.......................................103 
Figure 3.22:  IL-2 and IFN-γ mRNA expression in Egr-2 cKO CD4+ T cells .............104 
Figure 3.23:  IL-17A and IL-17F mRNA expression in Egr-2 cKO CD4+ T cells.......106 
Figure 3.24:  IL-1α, CCR6 and IL-21 mRNA expression in Egr-2 cKO CD4+ T cells 107 
Figure 3.25:  IL-15 and IL-10 mRNA expression in Egr-2 cKO CD4+ T cells ...........109 
Figure 3.26:  IL-4 and IL-13 mRNA expression in Egr-2 cKO CD4+ T cells .............110 
Figure 3.27:  Bcl-2 mRNA expression in Egr-2 cKO CD4+ T cells ............................111 
Figure 3.28:  Cytokine production by CD4+ T cells in Egr-2 cKO mice .....................113 
Figure 3.28:  Cytokine production by CD4+ T cells in Egr-2 cKO mice (cont’d)........114 
Figure 4.1:  A model for Egr-2 function ..................................................................135 
 
8 
Abbreviations 
 
AICD  Activation induced cell death 
AP-1  Activator protein 1 
APC  Antigen presenting cell 
Bcl-2  B cell lymphoma 2 
Bcl-XL  B cell lymphoma X, long isoform 
CD  Cluster of differentiation 
DKO  Double knockout 
DN  Double negative 
DP  Double positive 
EGFP  Enhanced green fluorescent protein 
Egr  Early growth response 
ERK  Extracellular signal regulated kinase 
FoxP3  Forkhead box P3 
IFN  Interferon 
Ig  Immunoglobulin 
IL  Interleukin 
i.n.  Intranasal 
ISP  Immature single positive 
KO  Knockout 
LCR  Locus control region 
MAPK  Mitogen activated protein kinase 
MHC  Major histocompatibility complex 
NFAT  Nuclear factor of activated T cells 
NF-κB  Nuclear factor of kappa-light-chain-enhancer of activated B cells 
NK  Natural killer 
PD-1  Programmed death 1 
RAG  Recombination activating gene 
SOCS  Suppressor of cytokine signalling 
SP  Single positive 
STAT  Signal transducer and activator of transcription 
T-bet  T-box expressed in T cells 
TCR  T cell receptor 
Tg  Transgenic 
TNF  Tumour necrosis factor 
 
9 
Chapter 1: INTRODUCTION 
 
The immune system provides protection from infection by pathogenic microorganisms 
and viruses. The importance of this system is demonstrated by the severity of acquired 
and congenital immunodeficiencies. The immune system is divided into two arms; the 
innate and adaptive systems. While the innate system responds in an identical fashion 
each time it encounters a given pathogen, the adaptive immune system responds more 
rapidly upon re-exposure to the same pathogen. A vital part of the adaptive system is 
cells called lymphocytes. The two main subsets of lymphocytes are B cells and T cells. 
B cells produce immunoglobulins (Ig), or antibodies, that are vitally important in host 
defence, while the various subsets of T cells serve a myriad of roles. Classical T cells 
are defined by the expression of a T Cell Receptor (TCR) consisting of α and  chains 
(Allison et al., 1982; Haskins et al., 1983; Kappler et al., 1983; Hedrick et al., 1984) 
and these α T cells are generally confined to the lymphatic system in the absence of 
pathogen infection. Conversely, T cells bearing a TCR composed of  and  chains are 
non-classical and these  T cells are located in peripheral tissues even in the absence of 
an active infection (Koning et al., 1987; Stingl et al., 1987; Goodman and Lefrancois, 
1988). The two main subsets of classical α T cells are distinguished by the expression 
of the markers CD4 and CD8 (Cantor and Boyse, 1975). CD8+ T cells can kill cells that 
have been infected with viruses while CD4+ T cells orchestrate the immune response as 
they can provide assistance to other cells types such as B cells and macrophages (Cantor 
and Boyse, 1975).   
 
Unlike B cells that recognise intact antigen in its native conformation, αT cells 
recognise antigen as processed peptides in the context of Major Histocompatibility 
10 
Complex (MHC) molecules (Watts et al., 1984; Babbitt et al., 1985). CD4+ T cells and 
CD8+ T cells are restricted to recognising antigen as peptides loaded on MHC class II 
and MHC class I respectively (Okada and Henney, 1980; Meuer et al., 1982). Unlike 
class I molecules that are ubiquitously expressed, class II molecules are confined to a 
small number of “professional” antigen presenting cells (APCs) such as dendritic cells 
which take up and process exogenous antigen for presentation on class II.  
 
MHC molecules can bind both self and non-self peptides. T cells need to discriminate 
between self and non-self so as to provide protective immunity against the latter but not 
react against the former. This state of non-reactivity to self is termed self-tolerance and 
is vital to avoid autoimmune destruction of self-tissues. As many other cells require 
help from CD4+ T cells, tolerance induction in CD4+ T cells is very important. Most of 
the self-reactive CD4+ T cells are eliminated during their development in the thymus in 
a process termed central tolerance (Kappler et al., 1987; Ashton-Rickardt et al., 1994). 
However, a few self-reactive CD4+ T cells do escape from central tolerance and are 
controlled in the periphery via peripheral tolerance mechanisms (Liu et al., 1995).  
 
1.1 T cell development and central tolerance 
 
T cells are derived from progenitors in the bone marrow which migrate to the thymus 
where they develop into mature T cells. A unique feature of T, and also B, lymphocytes 
is that the molecules they use for pathogen detection are not germline encoded; instead 
they are generated by recombination of DNA segments (Early et al., 1980). During T 
cell development in the thymus the T cell precursors, called thymocytes, rearrange their 
TCR genes. A mature α TCR consists of both α and  chains; the genes encoding both 
of these chains are rearranged during T cell development. The Variable (V) region of 
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both the TCR α and  genes consists of multiple gene segments which are spliced 
together to form the final complete V region exon. Both α and  genes have Variable 
(V) and Joining (J) segments while the  gene also has Diversity (D) segments. Proteins 
called Recombination Activating Genes (RAG) 1 and 2 direct the recombination 
machinery to the TCR loci resulting in the splicing of these V(D)J segments together to 
form the mature V region exon (Schatz et al., 1989; Oettinger et al., 1990; Shinkai et 
al., 1992). Each recombination event involves the breakage and rejoining of the DNA 
sequence. Each time the DNA is broken and rejoined additional nucleotides can be 
incorporated into the DNA sequence. The addition of nucleotides is random and, if the 
number of inserted nucleotides is not a multiple of 3, can result in a frameshift mutation 
and a non-functional TCR α or  chain polypeptide. Thus, selection events are required 
to select only those cells that have functional TCR chains. In addition, thymocytes are 
selected for cells that weakly recognise self-MHC molecules loaded with self-peptide 
(Ashton-Rickardt et al., 1994; Hogquist et al., 1994). These steps that select only those 
cells that have a functional  chain and those cells that recognise self-peptide/MHC 
molecules are termed -selection and positive selection respectively. Furthermore, due 
to the nature of the process that generates TCR chains, potentially auto-reactive cells are 
generated. During T cell development many of these potentially autoreactive cells are 
deleted in a process called negative selection (Kappler et al., 1987; Ashton-Rickardt et 
al., 1994). This series of selection events is termed thymic education. 
 
1.1.1 Double Negative cells and -selection  
 
Initially, thymocytes express neither CD4 nor CD8 and are referred to as Double 
Negative (DN) cells (see Figure 1.1). The DN cell stage can be subdivided into 4 stages 
based on the expression of the cell surface markers CD25 and CD44 (Godfrey et al., 
12 
1993). The earliest DN stage, termed DN1, expresses only CD44, while the next stage, 
DN2, expresses both CD25 and CD44 (Godfrey et al., 1993). DN3 cells express CD25 
but not CD44, while the final DN stage, DN4, expresses neither CD25 nor CD44 
(Godfrey et al., 1993). During the DN stages the thymocyte rearranges its TCR  genes. 
Due to the possibility of producing a non-functional  chain, the developing T cells 
undergo a process of selection which permits only those cells that possess a successfully 
rearranged  gene to develop further. This step is referred to as the -selection 
checkpoint and occurs at the DN3 to DN4 transition. The  chain is transcribed from the 
rearranged  locus and pairs with an invariant germline encoded pre-TCRα chain 
(Groettrup et al., 1993; Fehling et al., 1995; Fehling et al., 1997). If the rearranged  
chain polypeptide can successfully form a heterodimer with the pre-TCRα chain the 
complex signals through associated CD3 chains and the cell is selected to further 
develop (Groettrup et al., 1993; Fehling et al., 1995; Fehling et al., 1997).  
13 
 
 
1.1.2 Double Positive cells and Positive and Negative selection 
 
The thymocytes that have successfully rearranged their TCR  genes proceed from the 
DN stage to an intermediate stage called Immature Single Positive (ISP) (Miyazaki, 
1997). These cells express CD8 but are immature and do not express a TCR complex. In 
normal mice the cells quickly pass through the ISP stage to the next major stage of T 
cell development: the Double Positive (DP) stage. DP cells express both CD4 and CD8 
and it is at this stage that the cells rearrange their TCR α genes and undergo a number of 
further selection events (see Figure 1.1). These selection events are dependent on the 
Figure 1.1: T cell development. During T cell development in the thymus the T 
cell precursors, called thymocytes, pass through a series of stages which can 
be identified by their cell surface markers. The major thymocyte subsets are 
distinguished by their differential expression of CD4 and CD8 (A). Initially, the 
thymocytes express neither CD4 nor CD8 and are termed Double Negative 
cells (DN). The CD4−CD8− DN stage can be further subdivided based on the 
expression of CD44 and CD25 (B). See text for further details. Based on figures 
from (Janeway et al., 2001). 
B 
DN1 DN2 DN3 DN4 
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ability of the thymocyte’s TCR to recognise self-MHC molecules loaded with self-
peptide. Thymocytes that do not recognise self-peptide/MHC complexes at all receive 
no stimulation and die from “neglect”. Thymocytes possessing a TCR that strongly 
recognises self-peptide/MHC complexes are deleted by apoptosis; this process is termed 
negative selection (Kappler et al., 1987; Ashton-Rickardt et al., 1994). Only thymocytes 
that weakly recognise self-peptide/MHC complexes survive and mature into naïve CD4+ 
or CD8+ T cells (Ashton-Rickardt et al., 1994; Hogquist et al., 1994). This step is 
referred to as positive selection. Hence there are two thresholds; if the TCR stimulus 
exceeds the first the thymocyte is selected to become a mature cell but if the second is 
also exceeded the cell is deleted (Ashton-Rickardt et al., 1994). This removal of highly 
self-reactive T cells from the repertoire by negative selection is termed central 
tolerance.  
 
1.2 Mature T cells and peripheral tolerance 
 
Once T cells have completed their maturation in the thymus they migrate to the 
periphery. Although these T cells are mature, they are termed immunologically naïve as 
they have not been activated in the periphery. These naïve T cells express molecules, 
such as CD62L (Gallatin et al., 1983), that facilitate their circulation through the blood 
and secondary lymphoid tissues such as lymph nodes and the white pulp of the spleen. 
In these secondary lymphoid tissues the naïve T cells encounter APC presenting 
peptides on MHC molecules. The interaction with APC can induce one of several 
different responses in the T cells. The level of stimulation that the T cell receives upon 
interaction with the APC presenting peptide-MHC molecules determines the response 
of that T cell. If the T cell receives a strong signal, such as might be delivered upon 
interaction with an APC presenting a foreign peptide, then the T cell will become 
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activated and induce an immune response. If the T cell receives only a weak signal, 
such as typically occurs when encountering an APC presenting self-antigen, then it will 
not induce an immune response but such interactions may be important for the cell’s 
survival and homeostasis. However, while central tolerance induces the deletion of 
highly auto-reactive T cells (see section 1.1), some potentially auto-reactive cells with a 
relatively low avidity for self-antigen escape central tolerance (Liu et al., 1995). These 
potentially auto-reactive T cells are controlled in the periphery in healthy individuals by 
various peripheral tolerance mechanisms.  
 
1.2.1 T cell activation 
 
If the antigen presented by the APC is of sufficiently high affinity it will induce a strong 
signal in the T cell which is sufficient to surpass the threshold for T cell activation. In 
such cases a cascade of signalling molecules is activated which, in turn, leads to the 
generation or release of second messengers, such as Ca2+. This signalling cascade 
eventually results in the induction of transcription factors, such as members of the 
Fos/Jun (Halazonetis et al., 1988; Sassone-Corsi et al., 1988), Nuclear Factor of 
Activated T cells (NFAT) (Shaw et al., 1988) and Early Growth Response (Egr) (Harris 
et al., 2004; Safford et al., 2005; Anderson et al., 2006) protein families (see Figure 
1.2). These transcription factors initiate the process of proliferation and also induce the 
expression of the cytokine Interleukin-2 (IL-2). IL-2 is a T cell growth factor that can 
act in an autocrine fashion to promote the proliferation of the cell that produces it 
(Ruscetti et al., 1977). This forms the basis of two of the main assays of CD4+ T cell 
activation; analysis of proliferation and IL-2 secretion. 
16 
 
Figure 1.2: Schematic of TCR signalling. Upon engagement of the TCR with 
a high affinity peptide-MHC ligand a signalling cascade is activated that results 
in T cell activation. The Src family kinases Lck and Fyn phosphorylate 
Immunoreceptor Tyrosine Activation Motifs (ITAMs) in the CD3 and ζ chains 
that are associated with the TCR. This creates docking sites for other signalling 
proteins the action of which leads to the generation or release of second 
messengers such as DiAcylGlycerol (DAG) and Ca2+. These in turn lead to the 
activation of downstream enzymes such as the MAPKs (Mitogen Activated 
Protein Kinases) and the Ca2+ dependent phosphatase Calcineurin.  These 
downstream effectors induce the activation of a cascade of transcription factors 
including members of the NFAT (Nuclear Factor of Activated T cells), Fos/Jun 
and Egr protein families. These transcription factors induce the expression of 
genes involved in T cell activation and proliferation such as IL-2. N.B This 
schematic is greatly simplified and many crucial signalling molecules are 
omitted. Based on figures from (Janeway et al., 2001). 
1. TCR Proximal Kinases and 
     other signalling proteins e.g.  
 
2. Second messengers e.g. 
3. Downstream enzymes e.g. 
4. Transcription Factors e.g. 
5. Target genes e.g. 
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MAPK Calcineurin 
NFAT 
TCR 
CD3 
CD4 
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Ca2+ 
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IL-2 gene 
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ZAP-70 
LAT SLP-76 
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Following initial antigen encounter CD4+ T cells differentiate into effector cells which 
provide cytokines and other signals to other cell types such as B cells and macrophages. 
Based upon the cytokines produced these effector cells can be classified into different 
categories. CD4+ T cells that secrete the cytokine Interferon gamma (IFN-γ) are termed 
TH1 cells while those that produce the cytokine Interleukin 4 (IL-4) are designated TH2 
cells (see Murphy and Reiner, 2002). CD4+ T cells that secrete IL-17 (also called IL-
17A) have recently been reported to represent a distinct type of effector cell and are 
often referred to as TH17 cells (see Dong, 2008). Furthermore, CD4+ T cells that provide 
help to B cells in germinal centres, which have been designated T Follicular Helper 
(TFH) cells, are another type of effector cell although their relationship to other T cell 
subsets remains unclear (see Vinuesa et al., 2005). These TFH cells are not defined by 
their cytokine profile but by their expression of the chemokine receptor CXCR5 which 
promotes localisation to lymphoid follicles in secondary lymphoid tissues (see Vinuesa 
et al., 2005). However, while distinct TH1, TH2 and TH17 cells can be generated using 
specific culture conditions in vitro, the situation is not as clear-cut in vivo and there 
appears to be a degree of plasticity. CD4+ T cells that produce both IFN-γ and IL-17 
have been observed in many models (see Dong, 2008) while IL-17 production by cells 
with a TFH phenotype has also been documented (Hsu et al., 2008; Wu et al., 2008). 
 
These various subsets of effector cells provide assistance to other cell types such as B 
cells and macrophages and thereby help to resolve the infection. After the inciting 
antigen has been eliminated, the majority of the responding T cells die but a small 
cohort of cells persists. These cells, termed memory cells, can respond more rapidly 
than naïve T cells upon re-exposure to the same antigen in vivo (Veiga-Fernandes et al., 
2000).  
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1.2.2 T cell homeostasis 
 
The total number of T cells present in the periphery remains relatively constant over 
time despite the influx of newly matured T cells, the numbers of which varies 
considerably with age, from the thymus (see Surh and Sprent, 2008). This implies the 
existence of mechanisms that serve to maintain T cell numbers and to support the 
survival of individual cells. This maintenance of a constant total number of T cells is 
termed T cell homeostasis. Hence phenomena such as the deletion of the majority of the 
responding T cells at the termination of an immune response and the hyper-proliferation 
of T cells in response to lymphopaenia can both be classified as homeostatic 
mechanisms but I will focus here on the maintenance of T cell populations in the steady 
state. 
 
Initial studies of T cell homeostasis focussed on the role of peptide-MHC in the 
maintenance of T cells (Kirberg et al., 1997; Ernst et al., 1999). Several early studies 
concluded that the self-peptide/MHC ligands responsible for positive selection in the 
thymus were also necessary for the survival of mature but immunologically naïve T 
cells in the periphery (Kirberg et al., 1997; Ernst et al., 1999). However, these studies 
used adoptive transfer of T cells into lymphopaenic recipients to demonstrate this and 
were therefore complicated by the concomitant proliferation that occurs in 
lymphopaenia (see Surh and Sprent, 2008). Subsequently, two reports found that 
transferred naïve CD4+ T cells survived for at least 4-6 weeks in I-A−/− mice on a H-2b 
background (Clarke and Rudensky, 2000; Dorfman et al., 2000). Since mice on this 
background have a point mutation in the I-Eα gene, H-2b I-A−/− mice have traditionally 
been considered MHC class II deficient and hence the authors concluded that 
interactions with MHC class II molecules are not required for the survival of naïve 
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CD4+ T cells in the periphery (Clarke and Rudensky, 2000; Dorfman et al., 2000). 
However, this interpretation has been called into question by recent findings: two 
independent groups found considerable differences in the responses of T cells in H-2b I-
A−/− mice and mice that have null mutations in all 4 MHC class II chain genes (Martin 
et al., 2003; Purton et al., 2007) which has been attributed to the formation of an 
heterodimer from the remaining I-Aα and I-E chains in H-2b I-A−/− mice (Martin et 
al., 2003). Therefore, interactions with this non-classical MHC molecule may have 
supported the homeostasis of T cells in H-2b I-A−/− mice and the survival of the T cells 
in these mice does not exclude a role for peptide-MHC in naïve CD4+ T cell 
homeostasis. More recent work has demonstrated that the half-life of naïve CD4+ T cells 
in nonlymphopaenic mice is increased two fold in the presence of MHC class II 
molecules (Martin et al., 2006). Therefore, collectively the data suggests that 
interactions with peptide-MHC complexes are involved in the survival of both naïve 
CD4+ and naïve CD8+ T cells in normal conditions. Consistent with this, peripheral 
ablation of the expression of both of the Src family kinases Lck and Fyn, which are 
required for signal transduction downstream of the TCR, resulted in the gradual 
disappearance of naïve T cells (Seddon and Zamoyska, 2002). Thus, TCR signals, 
presumably induced by interactions with peptide-MHC, are necessary for the survival of 
naïve T cells. However, TCR signals are not the only factor involved in the homeostasis 
of naïve T cells. Several studies have found that the IL-2 related cytokines IL-7 and IL-
15 are also involved in the homeostasis of naïve T cells in the periphery (Kennedy et 
al., 2000; Schluns et al., 2000; Tan et al., 2001; Berard et al., 2003). While IL-7 is 
important for both naïve CD4+ and naïve CD8+ T cells, IL-15 is apparently only 
involved in the survival of naïve CD8+ T cells (Kennedy et al., 2000; Berard et al., 
2003). Therefore, for naïve T cells TCR signals coupled with the cytokine IL-7, and 
also IL-15 for naïve CD8+ T cells, jointly regulates their survival. 
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However, it has become apparent that those cells that have encountered antigen are 
controlled differently. The marker CD44 is expressed at low levels on immunologically 
naïve cells but is upregulated after antigen encounter. Therefore CD44high cells are 
generally considered to be effector cells or memory cells (see Surh and Sprent, 2008). 
Two different approaches have been used to investigate the homeostatic requirements of 
CD44high T cells and these have yielded different results. The first approach uses a 
monoclonal T cell population, i.e. expressing a specific TCR, generated by transgenic 
techniques (see section 1.2.3.1.1) coupled with intentional immunisation and are termed 
“antigen specific memory” cells (see Surh and Sprent, 2008). The alternative approach 
uses a polyclonal population of CD44high T cells, where the T cells express a range of 
different TCRs, isolated from mice that have not been intentionally immunised. These 
CD44high cells are presumably generated in response to self-antigen or environmental 
antigens, such as commensal flora, and have been designated “memory phenotype” or 
“MP” cells (see Surh and Sprent, 2008). Studies using antigen specific memory cells 
found that these cells still persist in the absence of MHC molecules (Murali-Krishna et 
al., 1999; Swain et al., 1999). Therefore, it was concluded that peptide-MHC ligands 
are not required for the survival of CD44high cells and that instead CD44high cells require 
the cytokines IL-7 and IL-15 (Kennedy et al., 2000; Schluns et al., 2000; Berard et al., 
2003). While most studies of MP CD8+ CD44high cells concur with this view, one report 
found that a subset of the MP CD8+ CD44high population was dependent on the presence 
of MHC class I for their homeostasis (Boyman et al., 2006). In addition, the 
homeostatic proliferation of MP CD4+CD44high cells is reduced in the absence of TCR 
signalling (Seddon et al., 2003). Whether this reflects a role for peptide-MHC for the 
homeostasis of all CD4+CD44high T cells (Seddon et al., 2003; Robertson et al., 2006) or 
only for particular subsets of this population (Purton et al., 2007) remains unclear. In 
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any case, these results demonstrate that, in addition to the cytokines IL-7 and IL-15, 
TCR signals are involved in the homeostasis of at least some subsets of CD44high cells. 
 
1.2.3 Peripheral T cell tolerance 
 
Potentially self-reactive T cells do escape central tolerance (see section 1.1) due to a 
relatively low avidity for self-peptide/MHC (Liu et al., 1995) and migrate to the 
periphery where they could potentially cause autoimmune disease. In healthy 
individuals these T cells are effectively controlled by various mechanisms that are 
collectively termed peripheral tolerance. These mechanisms fall into two categories; cell 
extrinsic, where the activation or effector function of the cell is suppressed by other 
cells, and cell intrinsic, where the cell either does not respond or dies due to inherent 
mechanisms. An important cell extrinsic mechanism is the suppression of T cell 
responses by regulatory T (TReg) cell populations such as CD4+CD25+FoxP3+ TReg cells 
and TR1 cells. CD4+CD25+FoxP3+ TReg cells are a subset of CD4+ T cells that can 
inhibit the proliferation of other T cells and the development of autoimmune disease 
(Fontenot et al., 2003; Hori et al., 2003). While the suppressive activity of 
CD4+CD25+FoxP3+ TReg cells is now well established, the mechanisms that these cells 
utilise to inhibit other cells are less clear. TR1 cells respond to TCR stimulation by 
secreting the anti-inflammatory cytokine IL-10 and are capable of inhibiting the 
proliferation of other T cells and the induction of autoimmune disease (Groux et al., 
1997). TR1 cells were first induced in vitro by chronic antigen stimulation in the 
presence of IL-10 (Groux et al., 1997) but similar cells can be induced in vivo by 
repeated antigen administration (Sundstedt et al., 2003). Immune deviation is another 
process that can regulate immune responses but this influences effector function rather 
than activation. Immune deviation is the process where one T cell subset regulates the 
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development and/or activity of another e.g. TH1 and TH2 cells secrete cytokines, IFN- 
and IL-4 respectively, that negatively regulate the development of the other subset. The 
other type of peripheral tolerance mechanism is cell intrinsic and includes ignorance, 
deletion/Activation Induced Cell Death (AICD) and anergy. The cell intrinsic 
mechanisms are, like thymic education, dependent on the level of stimulation that the 
cell receives upon encountering antigen. This includes not only TCR signalling (“signal 
1”) but also the “second signals” provided by accessory molecules present on the 
surface of APCs. These second signals can be either stimulatory, such as ligation of 
CD28 by B7 molecules, or inhibitory such as those transduced by PD-1 upon interaction 
with PD-L1 or PD-L2 (see Sharpe and Freeman, 2002). These two types of second 
signal are termed co-stimulation and co-inhibition respectively. In addition the 
cytokines present in the environment can also influence T cell activation. If the level of 
the self-peptide/MHC is low the TCR signal will not surpass the threshold for activation 
and will be insufficient to induce effector functions; the T cell is said to be ignorant of 
the antigen. However, as mentioned above (see section 1.2.2) such covert interactions 
with self-peptide/MHC have an important role in maintaining the peripheral T cell 
repertoire (Kirberg et al., 1997; Ernst et al., 1999; Seddon and Zamoyska, 2002; Surh 
and Sprent, 2008). AICD occurs when the T cell is activated through the TCR and 
proliferates but receives such a strong signal that the progeny die by apoptosis. This is 
thus analogous to negative selection in the thymus.  
 
1.2.3.1  Anergy and adaptive tolerance 
 
Anergy is a state of T cell hyporesponsiveness to antigen where proliferation and IL-2 
production in response to TCR stimulation is impaired, but the cells remain alive (see 
Schwartz, 2003). Various types of anergy have been documented and have been 
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classified by Schwartz into 2 broad categories: clonal anergy and adaptive tolerance; the 
former has only been documented in vitro while the latter is an in vivo state (2003) (see 
also Table 1.1). While in clonal anergy the cells merely seem to be unable to proliferate 
or produce IL-2, in adaptive tolerance effector functions also appear to be impaired (see 
Schwartz, 2003). The biochemical alterations in clonal anergy and adaptive tolerance 
are different indicating that the mechanisms responsible for their induction and 
maintenance are probably different (Anderson et al., 2006; Chiodetti et al., 2006). 
Clonal anergy can be induced in vitro by TCR ligation in the absence of co-stimulation 
(Jenkins et al., 1990), while adaptive tolerance is induced in vivo in an environment that 
is presumably low in co-stimulation and/or high in co-inhibition (see Schwartz, 2003). 
In adaptive tolerance the T cells initially proliferate in response to antigen but after a 
few days many of these cells die with the remaining population down-regulating their 
responses. In addition in many models of adaptive tolerance the T cells respond to TCR 
stimulation by secreting the anti-inflammatory cytokine IL-10 in a similar fashion to 
TR1 cells (see Schwartz, 2003). In the absence of antigen (e.g. transferring to a host not 
expressing the antigen), the responsiveness of the adaptively tolerant cells is restored 
indicating that the persistence of antigen is required to maintain the tolerant state 
(Tanchot et al., 2001). However, transferring adaptively tolerant T cells into another 
host expressing higher levels of the same antigen leads to the induction of a more 
profound hyporesponsiveness (Tanchot et al., 2001; Singh and Schwartz, 2003). It is 
these findings that led to the terminology of “adaptive” tolerance (see Schwartz, 2003) 
since the T cells appear to be changing their activation threshold in response to 
environmental signals. 
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  Clonal anergy Adaptive tolerance 
Induction in vitro in vivo 
Induction signalling pathway  Ca2+/NFAT Unknown 
Proliferation with induction No Yes 
Impaired proliferation Yes Yes 
Impaired IL-2 production Yes Yes 
Impaired effector cytokine production No Yes 
Production of IL-10 No Some models 
Major signalling pathways blocked  Ras/MAPK Ca2+/Tyr kinase 
Antigen persistence required  No Yes 
 
 
Adaptive tolerance was first observed following injection of superantigens, which bind 
independently of the peptide binding regions of the MHC to a largely invariant part of 
the TCR (see Schwartz, 2003). However, due to the unusual nature of the TCR contact, 
whether this state could be induced with other antigens was unclear. Since then similar 
adaptive tolerance states have been induced in a number of different models with 
antigens that utilise a more conventional TCR contact. Schwartz and colleagues induced 
adaptive tolerance by transferring T cells expressing a transgenic TCR with affinity for 
pigeon cytochrome C into a T cell deficient host expressing the antigen (Tanchot et al., 
2001). Sarukhan and co-workers induced tolerance by crossing a TCR transgenic mouse 
containing T cells that respond to a peptide derived from haemaggulutinin (HA) with a 
mouse that expressed this antigen under the control of an Ig- promoter (Lanoue et al., 
1997). However, in this model the HA antigen would be expressed in the thymus so 
tolerance may have been at least partially established centrally. Adaptive tolerance has 
also been induced by repeated administration of peptide in a model developed by 
Wraith and colleagues. 
 
 
 
Table 1.1: Comparison of clonal anergy and adaptive tolerance. Based on a 
more comprehensive table from (Schwartz, 2003). 
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1.2.3.1.1 Antigen-induced adaptive tolerance 
 
This model was developed from studies on Experimental Autoimmune 
Encephalomyelitis (EAE), a mouse model of Multiple Sclerosis. EAE is characterised 
by CD4+ T cells directed against peptides from nervous system proteins such as myelin 
basic protein (MBP). Injection of spinal cord homogenate with a suitable adjuvant 
induces EAE in H-2u mice (Metzler and Wraith, 1993). However, one intranasal (i.n.) 
administration of the immunodominant peptide from MBP (Ac1-9), or a high affinity 
analogue (Ac1-9[4Y]), is sufficient to render the mice resistant to subsequent EAE 
induction (Metzler and Wraith, 1993). The low frequency of the T cells that respond to 
this peptide makes analysis of this population difficult; therefore a TCR transgenic 
mouse model was established (Liu et al., 1995). The T cells that respond to Ac1-9 were 
isolated and their TCR α and  chain genes cloned. These cloned genes were inserted 
into constructs so that their expression was under the control of the human CD2 
promoter and locus control region (LCR). These two constructs were then introduced 
into fertilised mouse ova which were then injected into pseudo-pregnant female mice. 
The resulting progeny in which these genes had integrated into the mouse genome were 
identified and served as founders for TCR transgenic lines. The hCD2 regulatory 
elements drive expression of the TCR α and  chain genes in developing thymocytes 
and in mature T cells of these TCR transgenic mice. One of these lines, termed Tg4, 
expresses the transgenic TCR  chain gene on more than 90% of developing CD4+ SP 
thymocytes (Liu et al., 1995). Thus, in these Tg4 TCR transgenic mice the majority of 
CD4+ T cells bear a TCR with affinity for Ac1-9 hence providing a largely homogenous 
population of cells for analysis. These transgenic mice can be tolerised by repeated i.n. 
administration of Ac1-9[4Y] (Burkhart et al., 1999). When these peptide induced 
tolerant CD4+ T cells are stimulated with antigen in vitro they exhibit only minimal 
26 
proliferation and IL-2 production (Burkhart et al., 1999); the hallmarks of adaptive 
tolerance. Instead the cells respond to TCR stimulation by secreting the anti-
inflammatory cytokine IL-10 and can suppress the activation of other T cells which, at 
least in vivo, requires IL-10 (Sundstedt et al., 2003). Thus these cells are not only 
hyporesponsive they also have suppressive capabilities.  
 
1.2.3.1.2 Maintenance of adaptive tolerance  
 
Antigen persistence is required to maintain the tolerant state suggesting that repeated 
TCR signalling is required to synthesise, or activate, so called “anergic factors” 
responsible for maintaining the hyporesponsive state of the cell (see Schwartz, 2003). 
Global analysis of gene expression in tolerant cells has revealed a distinct gene 
expression programme suggesting that this is regulated, at least in part, at the 
transcriptional level (Lechner et al., 2001; Anderson et al., 2006).  However, the 
activation of many of the well characterised transcription factors that function in T cell 
activation, such as NF-κB and AP-1, is impaired in tolerant T cells and no transcription 
factors have so far been identified that are specific to the tolerant state (Anderson et al., 
2006; Chiodetti et al., 2006). Therefore, the prevailing hypothesis is that the 
transcription factors that are involved in the establishment and maintenance of tolerance 
are also present during normal T cell activation but that they only serve to promote 
hyporesponsiveness in the absence of other signals (see Schwartz, 2003). Thus far, 
however, the identities of the transcription factors that are involved in the establishment 
and maintenance of the hyporesponsive state are unknown. 
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Recent studies of models of clonal anergy have identified the Nuclear Factor of 
Activated T cells (NFAT) family of transcription factors as important in the induction of 
clonal anergy. 
 
1.2.3.1.3 NFAT and clonal anergy 
 
In resting T cells NFAT proteins are heavily phosphorylated and localised to the cytosol 
and hence are unable to activate transcription. TCR engagement results in an increase in 
intracellular Ca2+ which, in turn, induces activation of the Ca2+/calmodulin dependent 
phosphatase calcineurin. This phosphatase dephosphorylates the cytosolic 
phopshorylated form of NFAT. This dephosphorylation allows NFAT to translocate to 
the nucleus where it can initiate transcription of target genes. Ca2+ signalling is induced 
by TCR stimulation alone with little contribution from co-stimulatory pathways. Thus 
NFAT activation occurs under the conditions that promote clonal anergy induction 
making it a potential candidate for an anergic factor. Indeed, the drug cyclosporine and 
it’s derivatives that function by inhibiting calcineurin and hence NFAT activation can 
inhibit clonal anergy induction (Jenkins et al., 1990). Furthermore, Rao and colleagues 
found that clonal anergy was not induced in NFAT1 knockout (KO) T cells indicating 
that NFAT is essential for the induction of hyporesponsiveness (Macian et al., 2002). 
Using a pharmacological model that mimics clonal anergy, Rao and colleagues 
proposed that the mechanism for NFAT function in the induction of hyporesponsiveness 
was upregulation of E3 Ubiquitin ligase expression (Heissmeyer et al., 2004). E3 
Ubiquitin ligases are enzymes that target specific proteins and tag them with the small 
peptide Ubiquitin. Such Ubiquitylated proteins are then recognised by the proteasesome 
which initiates their degradation. Thus E3 Ubiquitin ligases target specific proteins for 
degradation. Among the E3 Ubiquitin ligases that were increased in this model were 
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Cbl-b, Itch and GRAIL; all of which have been found to be involved in the negative 
regulation of T cell function (Chiang et al., 2000; Fang et al., 2002; Anandasabapathy et 
al., 2003). 
 
However, in adaptive tolerance the Ca2+/calcineurin/NFAT pathway is inhibited 
(Anderson et al., 2006; Chiodetti et al., 2006) indicating that NFAT does not have a role 
in the maintenance of the tolerant state. Thus the transcriptional mechanisms that are 
involved in the maintenance of the hyporesponsiveness of tolerant T cells in vivo are 
unknown. Recent work from our group and from other laboratories has identified the 
transcription factor Early Growth Response 2 (Egr-2) as a potential candidate for 
maintaining tolerance (Harris et al., 2004; Safford et al., 2005; Anderson et al., 2006). 
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1.3 Early Growth Response transcription factors 
 
The Egr family of proteins consists of 4 members; Egr-1 (also called NGFI-A, Zif268, 
Znf225 or Krox-24), Egr-2 (also called Krox-20), Egr-3 (also called PILOT) and Egr-4 
(also called NGFI-C). Egr proteins are rapidly induced in many cell types in response to 
stimulation. Indeed, Egr-2 was first identified as a gene that was induced in quiescent 
fibroblasts after serum stimulation (Chavrier et al., 1988). Egr proteins are zinc finger 
transcription factors which contain 3 C2H2 type 
zinc finger motifs. Each zinc finger consists of 2 
Cysteine and 2 Histidine residues co-ordinating a 
zinc ion (see Figure 1.3). The co-ordination of the 
zinc ion is important for structural stability since 
the motif has only limited hydrophobic 
interactions (Luisi, 1992). Structurally, the zinc 
finger motif consists of two anti-parallel  strands 
and an α helix (Pavletich and Pabo, 1991) (see also 
Figure 1.3). The α helix makes contacts to DNA 
base pairs in the major groove. Each zinc finger 
motif makes contacts with 3 base pairs (bp) of 
DNA; therefore the DNA binding sequence for 
Egr proteins is 9 bp in length.  
 
In addition to their DNA binding domains, Egr proteins have both transactivation and 
repressor domains, and so they can function both as transcriptional activators and 
repressors (see Thiel and Cibelli, 2002). Egr proteins have often been found to co-
operate with other transcription factors in regulating target gene expression. For 
Figure 1.3: The zinc finger 
domain of Egr-1. 2 Cys (red) 
and 2 His (blue) co-ordinate a 
zinc ion (green). Data 
downloaded from Protein data 
bank (PDB ID: 1zaa) (Pavletich 
and Pabo, 1991) and displayed 
using Rasmol. 
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example, Egr-1 was reported to synergise with NFAT leading to an increase in NFAT 
transcriptional transactivation of an IL-2 reporter construct while Egr-1 alone had little 
effect (Decker et al., 1998). For some transcription factors, Egr proteins have been 
reported to both enhance and antagonise target gene expression. Egr-1 has been reported 
to co-operate with the zinc finger transcription factor SP-1 to increase expression of IL-
2 receptor  (Lin and Leonard, 1997) but also to interfere with the activity of the same 
transcription factor by binding to overlapping SP-1 Egr protein binding sites and 
inhibiting SP-1 protein binding (Huang et al., 1997). These two examples used different 
cell types and looked at different genes but serve to illustrate the complexity of 
transcriptional networks. 
 
1.3.1 DNA binding specificity of Egr proteins 
 
Egr-2 was first reported to bind to the sequence GCGGGGGCG (Chavrier et al., 1990). 
An in vitro study, in which random PCR based mutagenesis of the Egr binding site was 
coupled to affinity based selection, identified the sequence GCGTGGGCG as the 
optimal binding site for Egr-2 (Swirnoff and Milbrandt, 1995). This is often described 
as the Egr-2 “consensus” site. The structural basis for this preference is not known. So 
far, Egr-1 is the only one of the Egr proteins for which the crystal structure of the DNA 
binding domain has been solved. The crystal structure of the DNA binding domain of 
Egr-1 bound to DNA (see Figure 1.3) revealed 11 important hydrogen bonds between 
amino acids in the Egr-1 protein and the G bases of residues at the 1, 3, 5, 6, 7, and 9 
positions in the oligonucleotide (Pavletich and Pabo, 1991). The DNA binding domains 
of the Egr proteins are highly conserved, with approximately 90% identity, suggesting 
that the other Egr proteins bind to DNA in a similar fashion. Indeed, in the random PCR 
and affinity based selection study described above all the Egr proteins showed a 
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preference for G at all of these positions suggesting that these contacts are functionally 
important (Swirnoff and Milbrandt, 1995). Although many studies have reported Egr-2 
binding to non-canonical binding sites, some of which differ considerably from the 
“consensus”, most experimentally validated binding sites for Egr-2 also maintain this 
pattern of G residues (e.g. Mittelstadt and Ashwell, 1998;1999). However, notably in 
one of the more recently identified sites the G residue at the 1 position is not conserved 
(Laslo et al., 2006). As more Egr-2 binding sites are found and experimentally validated 
it should be possible to determine the relative importance of each residue in the 
“consensus” binding site. 
 
1.3.2 Egr-2 in the nervous system 
 
Egr-2 has been extensively studied in the nervous system. Egr-2 KO mice die soon after 
birth due to defects in brain development; rhombomeres r3 and r5 fail to form properly 
demonstrating a critical role for Egr-2 in brain development (Schneider-Maunoury et 
al., 1993). In addition, there are defects in peripheral nerve myelination in Egr-2 KO 
mice indicating that Egr-2 is essential for terminal Schwann cell differentiation (Topilko 
et al., 1994). Indeed, Egr-2 has been proposed to be a master regulator gene of Schwann 
cell differentiation since it can induce expression of myelin genes even in fibroblasts 
(Parkinson et al., 2004). Ectopic expression of Egr-2 in fibroblasts also inhibits stimuli-
induced proliferation and confers protection from apoptosis (Parkinson et al., 2004). 
Notably these phenotypes are similar to that of tolerant T cells; cell cycle arrested cells 
that remain alive for extended periods. Preliminary work by our group and others 
indicated that Egr-2 was expressed in tolerant T cells (Harris et al., 2004; Safford et al., 
2005; Anderson et al., 2006) suggesting the intriguing possibility that Egr-2 may have 
similar functions in T cells. 
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1.3.3 Egr family proteins in T cells 
 
Egr-1, Egr-2 and Egr-3 are all expressed in DN thymocytes after the -selection 
checkpoint correlating with pre-TCR signalling (Carleton et al., 2002). They are also 
expressed both by DP thymocytes and mature T cells upon TCR stimulation (Shao et 
al., 1997; Harris et al., 2004; Safford et al., 2005; Anderson et al., 2006). Although the 
expression of Egr family proteins in response to pre-TCR and TCR signalling is well 
documented the roles of these proteins in the cell, and particularly the mechanisms of 
action, are less clear.  
 
1.3.3.1  Egr proteins in thymocyte -selection 
 
In DN cells, Egr proteins are involved in the traversal of the -selection checkpoint. 
Transgenic over-expression of Egr proteins in RAG-1−/− or RAG-2−/− thymocytes, 
which are arrested at the DN3 stage due to a lack of pre-TCR signalling, enables the 
cells to pass through the -selection checkpoint to the DN4 and ISP stages (Miyazaki, 
1997; Xi and Kersh, 2004). Conversely, dominant negative Egr-1 proteins can interfere 
with the development of DN cells to the DP stage (Carleton et al., 2002). Thus Egr 
proteins are involved in thymocyte -selection. However, there appears to be a degree 
of functional redundancy amongst the Egr proteins at this stage. Egr-1 KO mice have an 
increase in the total number of thymocytes but have normal percentages of DN 
thymocyte subsets and do not appear to have any defects in -selection (Bettini et al., 
2002). Thymocytes from Egr-3 KO mice on the B6.AKR background do have 
decreased numbers of DN4 cells but this was attributed to decreased proliferation after 
-selection rather than a defect in differentiation (Xi and Kersh, 2004). Similarly, Egr-1, 
Egr-3 double KO (DKO) mice on the C57BL/6 background have a decrease in the 
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number of DN4 thymocytes and decreased proliferation of DN4 cells (Carter et al., 
2007). This study also found increased apoptosis of DN4 cells which was not reported 
for Egr-3 KO mice on the B6.AKR background. Taken together these studies show that, 
while Egr proteins are involved in thymocyte -selection, differentiation through the -
selection checkpoint occurs in the absence of individual Egr proteins suggesting that 
there is redundancy amongst the Egr proteins. 
 
1.3.3.2  Egr proteins in thymocyte positive selection 
 
Studies of Egr-1 KO and Tg mice revealed a role for Egr-1 in thymocyte positive, but 
not negative, selection (Miyazaki and Lemonnier, 1998; Bettini et al., 2002). Both Egr-
1 KO mice and TCR transgenic Egr-1 KO mice have decreased numbers of positively 
selected CD4+ and CD8+ SP thymocytes while clonal deletion proceeded normally 
(Bettini et al., 2002). Conversely, expression of an Egr-1 transgene in TCR transgenic T 
cells allows their selection on normally non-selecting backgrounds (Miyazaki and 
Lemonnier, 1998). No selection was observed in mice lacking all MHC molecules 
indicating that enhanced Egr-1 expression on its own is not sufficient (Miyazaki and 
Lemonnier, 1998).  
 
1.3.3.3  Mechanisms of Egr function in thymocytes 
 
While roles for Egr proteins in thymocyte development are now well established, the 
mechanisms by which Egr proteins function in thymocytes are not as clear. Egr proteins 
have been reported to induce expression of the helix-loop-helix protein Id3 in 
thymocytes (Bain et al., 2001; Xi et al., 2006). Id3 is an inhibitor of E protein 
transcription factors which are required for thymocyte development (see Murre, 2005). 
34 
Id3 binds to E proteins and inhibits the binding of E proteins to DNA (see Murre, 2005). 
Ectopic expression of Egr-1 (Bain et al., 2001) or Egr-3 (Xi et al., 2006) in a murine DP 
thymocyte cell line, termed 16610D9, resulted in increased Id3 mRNA. Similarly, 
primary thymocytes from Egr-3 transgenic (Tg) mice have elevated Id3 mRNA and 
protein levels (Xi et al., 2006). However, Egr-1, Egr-3 DKO mice on the C57BL/6 
background reportedly have normal expression of Id3 (Carter et al., 2007) calling into 
question the importance of Egr proteins in inducing Id3 expression under physiological 
conditions. As noted above, this study observed increased apoptosis of DN4 cells 
suggesting that supporting the survival of cells after -selection may be an important 
function of Egr proteins. However, there were no obvious target genes that were altered 
in this study that would explain this effect. Instead, the authors reported a decrease in 
the expression of several metabolic enzymes suggesting that Egr proteins may serve to 
support survival indirectly via modulation of metabolism (Carter et al., 2007). In 
addition, the authors found defective expression of the transcription factors Myc, and to 
a lesser extent, E2F1 and Runx, in DN3 cells from Egr-1, Egr-3 DKO mice and 
identified potential Egr binding sites in the promoters of these genes suggesting that this 
effect of Egr proteins may be secondary to induction of other transcription factors 
(Carter et al., 2007). Hence a clearly defined mechanism of action for Egr proteins in 
thymocyte development is currently lacking. 
 
1.3.3.4  Egr proteins in mature T cells 
 
Egr-1 has been reported to be involved in T cell proliferation. Antisense 
oligonucleotides against Egr-1 mRNA partially inhibited the proliferative response of 
Rat lymphocytes induced by IL-2, phorbol esters or lectins (Perez-Castillo et al., 1993). 
Subsequently, Egr-1 was reported to be involved in the expression of IL-2 (Decker et 
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al., 1998) and IL-2 receptor  (Lin and Leonard, 1997), providing a potential 
explanation for the decreased proliferation. However, lymphocytes from Egr-1 KO mice 
proliferate normally in response to lectin or anti-CD3 stimulation in vitro (Lee et al., 
1995). Similarly, purified CD8+ cells from Egr-1 KO mice respond normally to anti-
CD3 stimulation in vitro (Singh et al., 2004). Furthermore, this study found increased 
levels of IL-2 production by Egr-1 KO T cells. These data indicate that Egr-1 is not 
required for T cell proliferation or, at least for CD8+ cells, for IL-2 expression after 
TCR stimulation. 
 
1.3.3.5  Egr-2 and Egr-3 and FasL 
 
Fas is a TNF receptor family death receptor that is induced on T cells after TCR 
stimulation. Fas ligand (FasL) is a membrane associated cytokine of the TNF family 
that is also induced after TCR engagement and can bind to the Fas receptor. Ligation of 
the Fas receptor with its ligand induces a signalling cascade that results in the induction 
of apoptotic cell death (see Siegel et al., 2000). Both Fas and FasL are expressed after 
TCR stimulation and this pathway plays an important role in the deletion of effector T 
cells at the end of an immune response. Egr-2 and Egr-3 have been reported to be 
involved in FasL induction in response to TCR stimulation (Mittelstadt and Ashwell, 
1998;1999; Rengarajan et al., 2000). This group found that Egr-2 and Egr-3 bound to a 
sequence from the FasL promoter in vitro, that they termed the FasL Response Element 
(FLRE). Although at first glance the minimal FLRE site (5’-GTGGGTGT-3’) appears 
to be substantially different from the Egr-2 “consensus” site, in the FasL promoter it is 
flanked by 5’-GA-3’ at its 5’ end which would maintain the pattern of G residues that 
appear to be functionally important in Egr protein binding (see above). Over-expression 
of Egr-2 or Egr-3 could drive expression of a FasL reporter construct in both T cell 
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hybridomas and non-lymphoid cell lines (Mittelstadt and Ashwell, 1998;1999), 
indicating that Egr-2 and Egr-3 have a role in FasL expression. 
 
1.3.3.6  Signalling pathways controlling Egr-2 expression 
 
Several studies have implicated NFAT in the induction of Egr-2 expression following 
TCR engagement. Cyclosporine treatment, which inhibits calcineurin and hence NFAT 
activation, partially inhibits Egr-2 expression (Mittelstadt and Ashwell, 1999). 
Furthermore, CD4+ T cells from NFAT1, NFAT4 double KO mice have a defect in Egr-
2 and Egr-3, but not Egr-1, expression following TCR stimulation while NFAT proteins 
can drive expression of Egr-2 and Egr-3 promoter reporter constructs in hybridoma or 
lymphoma cell lines (Rengarajan et al., 2000). However, there was still low but 
detectable Egr-2 expression in both cyclosporine treated and NFAT1, NFAT4 deficient 
cells following TCR engagement (Mittelstadt and Ashwell, 1999; Rengarajan et al., 
2000). In addition, tolerant T cells have impaired induction of NFAT activity following 
TCR stimulation but still strongly induce Egr-2 expression (Anderson et al., 2006). 
These data suggest that, while NFAT is important for induction of Egr-2, there are 
additional pathways that can regulate Egr-2 expression in T cells. 
 
1.3.3.7  Egr-2 in tolerance and anergy 
 
While we were working on this project two other groups published their initial findings 
on the role of Egr-2 in tolerance and anergy. One group used RNAi technology to 
“knockdown” Egr-2 expression in an established T cell line which partially inhibited the 
induction of clonal anergy by anti-CD3 treatment (Harris et al., 2004). Egr-2 
“knockdown” also increased the response of pre-activated cells to restimulation with 
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anti-CD3 and anti-CD28 indicating that the function of Egr-2 was not limited to clonal 
anergy (Harris et al., 2004). Another group took an alternative approach using a 
lentiviral system to over-express Egr-2 and this treatment resulted in reduced production 
of IL-2 after T cell activation in vitro (Safford et al., 2005). The latter group also 
observed slightly elevated levels of the E3 Ubiquitin ligase Cbl-b in Egr-2 transduced T 
cells and proposed the hypothesis that Egr-2 regulates TCR signalling through induction 
of E3 Ubiquitin ligases (Safford et al., 2005). Given that NFAT has been reported to 
induce E3 Ubiquitin ligases in clonal anergy and given the data supporting a role for 
NFAT in Egr-2 expression, this hypothesis is thus analogous to that proposed for NFAT 
and Egr-2 and Egr-3 in FasL expression. However, these hypotheses have not been 
tested in vivo since Egr-2 knockout mice die perinatally due to defects in hindbrain 
development (Schneider-Maunoury et al., 1993). Thus, the functions of physiological 
levels of Egr-2 in T cells in vivo have not been studied. To assess the functions of Egr-2 
in T cells in vivo, we established Egr-2 conditional knockouts (Egr-2 cKO), in which 
the Egr-2 gene was deleted specifically in CD2+ lymphocytes, using the Cre loxP 
system. 
 
1.4 Cre loxP system of tissue specific KO mice 
 
The Cre loxP system can be used to generate tissue specific knockout mice (reviewed in 
Lewandoski, 2001) (see also Figure 1.4). This system uses the Cre recombinase from 
bacteriophage P1. Cre recognises 34bp DNA sequences termed loxP sites and catalyses 
recombination between them. If 2 loxP sites are arranged in the same orientation, this 
results in the deletion of the intervening DNA. Generation of tissue specific KO mice 
requires the establishment of two genetically modified mouse lines; one where loxP 
sites are introduced in the gene of interest and another where the expression of the Cre 
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transgene is restricted to a particular tissue. To generate the first line, loxP sites are 
introduced into introns of the gene of interest and this construct is used to replace the 
endogenous gene in embryonic stem (ES) cells by homologous recombination. ES cells 
where this has occurred are selected and then injected into the blastocoele of a mouse 
embryo where they can contribute to the tissues of the resulting mouse. If the ES cell 
contributes to the germline of the resulting animal the mouse will transmit the targeted 
gene to some of its progeny. These progeny which possess the targeted gene are 
selected and bred to homozygosity to obtain a loxP/loxP line. This line is then crossed 
with a line that expresses Cre under the control of a tissue specific promoter. This 
second line can be generated by cloning the Cre gene downstream of a tissue specific 
promoter and then introducing this construct into fertilised ova. In some of the ova the 
construct will integrate into the host genome; the mice that derive from these ova are 
identified by genotyping and serve as founders for tissue specific Cre lines. These two 
lines are then crossed to generate loxP/loxP Cre transgenic mice. Expression of Cre 
under the control of a tissue specific promoter results in deletion of the targeted gene 
occurring only in that tissue.  
 
Egr-2loxP/loxP mice have two loxP sites flanking exon 2 of the Egr-2 gene which encodes 
the majority of the protein including the DNA binding domain (Taillebourg et al., 
2002). hCD2-Cre mice have expression of Cre driven by the promoter and LCR of the 
human CD2 gene (de Boer et al., 2003). These regulatory elements drive expression of 
the Cre transgene in lymphocytes in a copy number dependent and integration site 
independent fashion (de Boer et al., 2003). This means that the expression of the Cre 
gene is dependent upon the number of copies in the genome irrespective of where the 
hCD2-Cre construct has integrated. 
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Figure 1.4: Cre loxP system of tissue specific KO mice. This system 
requires the generation of two mouse lines; one with two loxP sites introduced 
into introns of the target gene (Egr-2loxP/loxP mice, top left) and the other with the 
expression of Cre under the control of tissue specific regulatory regions (hCD2-
Cre mice, top right); which are then interbred. The enzyme Cre recognises the 
loxP sites in the target gene and catalyses recombination between them 
resulting in the deletion of the intervening DNA (exon 2 of the Egr-2 gene). 
Limiting Cre expression to a specific tissue (lymphocytes), due to the use of the 
tissue specific regulatory regions (hCD2), results in the deletion of the target 
gene only occurring in that tissue; hence yielding tissue specific KO mice. See 
text for further details. Based on figures from (Lewandoski, 2001). 
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These two lines were crossed to generate Egr-2loxP/loxP hCD2-Cre mice which have 
deletion of Egr-2 only in lymphocytes. These mice should therefore be viable and 
permit the analysis of T cell populations. The aims of this project were to analyse the 
phenotype of these Egr-2loxP/loxP hCD2-Cre mice and to investigate the mechanisms of 
Egr-2 function. 
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Chapter 2: MATERIALS and METHODS 
 
2.1 Tg4 Transgenic Mice 
 
Tg4 transgenic mice, a TCR Tg line where the CD4+ T cells bear a TCR with affinity 
for the acetylated N-terminal peptide of MBP Ac1-9 (Liu et al., 1995), on the B10.PL 
background (Anderson et al., 2006) were maintained at the University of Bristol. 
Tolerance was induced in Tg4 transgenic mice by ten intranasal (i.n.) administrations of 
25µl of a 4mg/ml solution of the high affinity Ac1-9 analogue, Ac1–9[4Y], at 3-4 day 
intervals as described (Anderson et al., 2006). Total splenocytes were extracted from 
Tg4 mice before (A0) and 2 hours after (A2) the first i.n. Ac1-9[4Y] peptide 
administration and before (T0) and after (T2) the tenth treatment as described 
(Anderson et al., 2006). Total RNA and protein were then isolated at the University of 
Bristol by Professor D. Wraith and colleagues and were given to us for analysis. 
 
2.2 Egr-2 conditional knockout mice 
 
Egr-2loxP/loxP mice and hCD2-Cre mice were kind gifts from Dr P. Charnay, Institut 
National de la Santé et de la Recherche Médicale, Ecole Normale Supérieure, Paris, and 
Dr D. Kioussis, National Institute for Medical Research, London, respectively 
(Taillebourg et al., 2002; de Boer et al., 2003). Egr-2 conditional knockout mice (Egr-2 
cKO) were generated by crossing Egr-2loxP/loxP mice with hCD2-Cre transgenic mice. 
All Egr-2 cKO mice used in this study were backcrossed at least three times to 
C57BL/6. All Egr-2 cKO mice used in this study were aged 3-4 months unless 
otherwise stated. Egr-2 cKO mice were maintained in the Biological Services Unit, 
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Barts and The London School of Medicine, and used according to established 
institutional guidelines under the authority of a UK Home Office project licence 
(Guidance on the Operation of Animals, Scientific Procedures Act 1986). 
 
2.3 hCD2 Egr-2 transgenic mice 
 
To generate hCD2 Egr-2 transgenic mice, the Egr-2 gene was first cloned by PCR 
amplification of the Egr-2 gene in the pBABE-Egr-2 EGFP plasmid (a kind gift from 
Professor K. Jessen, University College London) using primers sense 5’-
TGACGAATTCATGATGACCGCCAAGGC-3’ and antisense 5’-
CACACCCTAACTGACACACATTCC-3’ and the Phusion High Fidelity PCR kit 
(New England Biolabs) by Dr B. Zhu as per the manufacturer’s instructions. The sense 
primer contains an EcoRI site towards the 5’ end while the location of the antisense 
primer was chosen so that an EcoRI site present in the pBABE-Egr-2 GFP plasmid was 
also present in the PCR product. The PCR product and the hCD2 VA vector (a kind gift 
from Dr D. Kioussis, National Institute for Medical Research, London) (Zhumabekov et 
al., 1995) were both digested with EcoRI (New England Biolabs) by Dr B. Zhu 
according to the manufacturer’s instructions. The vector and the PCR product were then 
mixed together with T4 DNA ligase (New England Biolabs) by Dr B. Zhu as per the 
manufacturer’s instructions. The ligation reaction was then used to transform DH10α 
Escherichia coli bacteria by heat shock by Dr B. Zhu. Briefly, the ligation reaction was 
added to 60μl of DH10α bacteria, the sample heated to 42°C for 2 minutes and then 
placed on ice for 2 minutes followed by incubation at 37°C for 30 minutes in lysogeny 
broth (LB) medium before transfer to agar plates. Four clones were selected and the 
orientation of the insert in the construct was analysed by sequential restriction digestion 
with SmaI (25°C) and then BamHI (37°C) (both New England Biolabs) by Dr B. Zhu 
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according to the manufacturer’s instructions. Plasmids were isolated from the clones 
with the correct orientation by mini-prep using the QIAquick spin mini-prep kit 
(Qiagen) and then digested with NotI and SalI (New England Biolabs) using the 
manufacturer’s protocols by Dr B. Zhu. The resulting mixture was separated by 
electrophoresis and a band of 14.2kb in size, representing the hCD2 Egr-2 construct, 
was extracted from the gel and purified using the Geneclean turbo kit (Qbiogene) 
according to the manufacturer’s protocol by Dr B. Zhu. The hCD2 construct was then 
injected into pro-nuclei of fertilised oocytes of a C57BL/6 × CD1 background by Mr W. 
Mansfield of the Transgenic core facility, Queen Mary, University of London. 
Transgenic mice were identified as below and two founder lines, Tg14 and Tg18, were 
established by backcrossing at least three times to C57BL/6. All hCD2-Egr-2 Tg mice 
used in this study were aged 3-4 months unless otherwise stated. Egr-2 Tg mice were 
maintained in the Biological Services Unit, Barts and The London School of Medicine, 
and used according to established institutional guidelines under the authority of a UK 
Home Office project licence (Guidance on the Operation of Animals, Scientific 
Procedures Act 1986). 
 
2.4 Genotyping 
 
Mice tails were collected and genomic DNA extracted using the REDExtract-N-Amp 
Tissue PCR Kit (Sigma) by Dr B. Zhu according to the manufacturer’s instructions. 
Egr-2loxP/loxP hCD2-Cre mice and hCD2-Egr-2 Tg mice were identified by polymerase 
chain reaction (PCR), a technique that allows selective exponential amplification of 
DNA sequences. This procedure takes advantage of a thermostable DNA polymerase 
from Thermus aquaticus termed Taq. This enzyme is not denatured at temperatures that 
denature DNA and so it is possible to perform several rounds of extension without 
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adding new DNA polymerase enzyme each cycle. Since DNA synthesis must be 
primed, the use of primers specific for a particular gene allows this technique to 
selectively amplify that locus. Taq extends the primers by incorporating dNTPs 
complementary to the pre-existing strand thus producing a copy of the DNA. PCR was 
performed as per the manufacturer’s protocol with a final primer concentration of 
0.5µM. Genotyping primer sequences are shown in Table 2.1. Egr-2 locus primer 
sequences were provided by Dr P. Charnay, Institut National de la Santé et de la 
Recherche Médicale, Ecole Normale Supérieure, Paris. hCD2-Cre primers were 
designed to amplify a 133bp fragment of the codon optimised Cre recombinase gene 
(Genbank Accession number: AY056050); a version of Cre that has been altered via 
synonymous mutations to better reflect mammalian codon usage (Shimshek et al., 
2002). hCD2-Egr-2 construct primers were designed so that the sense primer annealed 
to exon 1 of the human CD2 gene while the antisense primer annealed to a region just 
upstream of the Egr-2 transcriptional start site.  
 
Primer Sequence 
sense 5’-AGTTGACAGCCCGAGTCCAGTGG-3’ Egr-2 locus antisense 5’-GGGAGCGAAGCTACTCGGATACGG-3’  
sense 5’-CCAACAACTACCTGTTCTGCCG-3’ hCD2-Cre 
antisense 5’-TCATCCTTGGCACCATAGATCAGG-3’  
sense 5’-CCACCAGTCTCACTTCAGTTCC-3’ hCD2-Egr-2 construct 
antisense 5’-CAGCTGGTGCATAAAACCACTG-3’  
 
2.5 Isolation of CD4+ cells  
 
Lymphoid organ extraction was performed by Dr B. Zhu. When using splenocytes, 
erythrocytes were lysed using the ACK Lysing Buffer (Lonza) according to the 
manufacturer’s instructions. This buffer uses a hypotonic solution to lyse the 
Table 2.1: Genotyping primer sequences. 
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erythrocytes while maintaining the viability of the lymphocytes. CD4+ cells were then 
isolated by Magnetic Activated Cell Sorting (MACS) using a positive selection kit 
(Miltenyi) according to the manufacturer’s instructions. Total splenocytes were 
incubated with anti-CD4 antibodies attached to magnetic beads at 4°C for 30 minutes in 
Phosphate Buffered Saline (PBS) containing 3% Foetal Bovine Serum (FBS). This 
labels any CD4+ cells with magnetic beads. The cells were then washed and run through 
a magnetic column. CD4+ cells are retained on the column due to the magnetic beads 
while the unlabelled cells pass through the column. The column was washed three times 
with PBS containing 3% FBS to remove any non-specifically bound cells and then the 
CD4+ cells were eluted by removing the column from the magnetic field and washing 
with PBS containing 3% FBS. B220+ cells were also isolated by MACS using a positive 
selection kit (Miltenyi) by Dr S. Li at Brunel University (Zhu et al., 2008). 
 
2.6 Cell culture and stimulation  
 
T cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium 
containing 300mg/L L-glutamine supplemented with 10% FBS, 50µM 2-
mercaptoethanol (2-ME), and 50 units/ml penicillin and 50µg/ml streptomycin (all from 
Invitrogen). CD4+ T cells, and MF2.2D9 cells, were stimulated with beads coated with 
1µg/ml anti-CD3ε antibody (clone 145-2C11; BD Biosciences) and 1µg/ml anti-CD28 
antibody (clone 37.51; BD Biosciences), or plates coated with 5µg (or different amounts 
as indicated) anti-CD3ε antibody with or without 2.5µg/ml of soluble anti-CD28 
antibody as indicated. B220+ cells were stimulated with anti-surface Ig antibody for 6 
hours by Dr S. Li at Brunel University (Zhu et al., 2008). 
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2.7 RNA Extraction 
 
Total RNA was extracted using the Trizol reagent (Invitrogen). This method is an 
adaptation of the Phenol Chloroform extraction method to separate nucleic acids from 
other cellular components. This protocol uses acidic conditions which results in the 
separation of the RNA from the DNA and proteins following Phenol Chloroform 
extraction. The solution also contains Guanidinium thiocyanate; a strong denaturing 
agent which denatures any proteins, such as RNAse, present in the sample. RNA 
extraction was performed according to the manufacturer’s protocol. Briefly, cells were 
pelleted and then lysed in 1ml of Trizol per 107 cells and then incubated at room 
temperature for 10 minutes. 200µl of Chloroform was then added, the sample mixed 
vigorously, incubated at room temperature for 5 minutes and then centrifuged. After 
centrifugation the sample separated into a red organic phase and a clear aqueous phase 
separated by a white interphase. The RNA separated into the aqueous phase while 
proteins and DNA remained in the organic phase or interphase. The aqueous phase was 
transferred to a new tube and the RNA was precipitated by the addition of 2 volumes of 
100% ethanol. Nucleic acids are not soluble in alcohol and so the RNA precipitates out 
of solution. In addition, in situations where the initial cell number was low, glycogen 
was added; glycogen is also not soluble in alcohol and co-precipitates with the RNA 
aiding visualisation of the RNA pellet. The RNA was incubated at −20°C for 1 hour and 
then spun down. After centrifugation the RNA forms a pellet at the bottom of the tube. 
The pellet was washed with 70% ethanol and then resuspended in RNAse-free water. 
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2.8 Reverse Transcription 
 
RNA was converted to first strand cDNA using a reverse transcriptase enzyme from 
Murine Moloney Leukaemia Virus (MMLV-RT) (Promega). This enzyme catalyses the 
formation of a complementary cDNA strand using the RNA strand as a template. Oligo-
dT nucleotides anneal to the poly-A tails of mRNA and these oligo-dT nucleotides act 
as primers for reverse transcriptase. The amount of nucleic acid present in these samples 
was detected by measuring the absorbance at 260nm on a nanodrop spectrophotometer. 
Volumes of solutions were chosen to give 2µg RNA per reaction and 0.5µg of oligo-dT 
was added to each tube. These were then heated to 70C for 10 minutes to denature any 
secondary structures present in the RNA, facilitating the binding of the oligo-dT 
primers. The samples were then placed on ice. Reagents were added to give a final 
concentration of 500µM of each of dATP, dTTP, dCTP and dGTP, 1 Unit/µl of RNAse 
Inhibitor and 10 Units/µl of MMLV-RT in 1x RT buffer (all Promega). The reactions 
were then heated to 37°C for 1 hour and then to 70°C for 10 minutes to inactivate the 
MMLV-RT enzyme. 80µl of ddH20 was then added to each sample to give a final 
volume of 100µl and the samples were then stored at −20°C. 
 
2.9 Real Time RT-PCR 
 
Real Time PCR uses the same principle as normal PCR described above but allows the 
quantitative comparison of samples. A molecule which fluoresces when intercalated 
into dsDNA, called SYBR Green, was added to the reaction mixture. After each round 
of product synthesis the amount of product is calculated by measuring the fluorescence. 
Real Time PCR was performed with the QuantiTect SYBR Green PCR kit (Qiagen) as 
per the manufacturer’s instructions using 1µl of relevant cDNA and a final 
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concentration of 0.2µM of relevant sense and antisense primers in 1x SYBR Green 
Master Mix. Real Time PCR was performed on a Rotor-Gene system (Corbett Robotics) 
using the program listed below: 
 
1. 95°C for 10min 
2. 95°C for 20s 
3. 58°C for 30s 
4. 72°C for 20s 
2-4 40 cycles 
 
The initial 95°C step, in addition to denaturing the DNA, also denatures the antibody 
that is bound to the DNA polymerase allowing the enzyme to catalyse DNA synthesis 
during the elongation phase. During each elongation phase fluorescence data was 
collected. After the cycles had finished a melting curve analysis was performed in 
which the fluorescence was continually monitored as the temperature increased from 
50°C to 99°C. When the temperature reaches the melting temperature (Tm) for each 
DNA molecule 50% of that molecule is denatured which is detectable as a decrease in 
fluorescence. This can be used to calculate the Tm of each product allowing detection of 
non-specific products such as primer dimers. In addition, once the PCR reaction had 
completed the products were routinely run on an agarose gel to confirm that there was 
only one band of the correct size. 
 
2.9.1 Primer design 
 
For Real Time PCR, primers were designed to have approximately 20 nucleotides with 
around 50% G/C content. It is important that the 3’ end binds stably to the cDNA to 
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allow the polymerase to extend the chain; hence the last 6 nucleotides at the 3’ end were 
designed to contain at least 3 G/Cs. The sense and antisense primers were designed so 
that they anneal to different exons of the sequence of interest. This allows identification 
of genomic DNA contaminants as these will contain the intervening introns in addition 
to the exons so will be larger and thus detectable via electrophoresis. The Tm of each 
primer was estimated using the Wallace rule (Tm = 4 × [G + C] + 2 × [A + T]) and the 
annealing temperature was initially set to Tm − 2°C and altered as necessary. Real Time 
PCR primer sequences are shown in Table 2.2.  
 
Primer Sequence 
sense 5’-CTTCAGCCGAAGTGACCACC-3’ Egr-2 
antisense 5’-GCTCTTCCGTTCCTTCTGCC-3’  
sense 5’-TTGCACTCTGGTGTCTGAGC-3’ p21cip1 
antisense 5’-GAGGACCAATCTGGGCTTGG-3’  
sense 5’-CCATCAGCAACAACATAAGC-3’ IFN-γ 
antisense 5’-AGCTCATTGAATGCTTGGCG-3’  
sense 5’-GCATGTTCTGGATTTGACTC-3’ IL-2 
antisense 5’-CAGTTGCTGACTCATCATCG-3’ 
sense 5’-AGCGTGTCCAAACACTGAGG-3’ IL-17A 
antisense 5’-CTATCAGGGTCTTCATTGCG-3’  
sense 5’-AACCAGGGCATTTCTGTCCC-3’ IL-17F 
antisense 5’-TTTCTTGCTGAATGGCGACG-3’  
sense 5’-ATGTATGCCTACTCGTCGGG-3’ IL-1α 
antisense 5’-ATGAGGTCGGTCTCACTACC-3’  
sense 5’-GACTGGAGCTGTTCTTTGGG-3’ CCR6 
antisense 5’-CACTTTGCCCGTGTTGACCG-3’  
sense 5’-CTCAAGCCATCAAACCCTGG-3’ IL-21 
antisense 5’-CATACGAATCACAGGAAGGG-3’  
sense 5’-GGTTGCCAAGCCTTATCGGA-3’ IL-10 
antisense 5’-ACCTGCTCCACTGCCTTGCT-3’  
sense 5’-AGAAACGTGCTCTACCTTGC-3’ IL-15 
antisense 5’-GATGAACATTTGGACAATGCG-3’  
sense 5’-CAAACGTCCTCACAGCAACG-3’ IL-4 
antisense 5’-CTTGGACTCATTCATGGTGC-3’  
sense 5’-ATTCCCTGACCAACATCTCC-3’ IL-13 
antisense 5’-GTTGCTTTGTGTAGCTGAGC-3’  
sense 5’-CGTCAACAGGGAGATGTCACC-3’ Bcl-2 
antisense 5’-GGAGAAATCAAACAGAGGTCGC-3’  
sense 5’-AATCGTGCGTGACATCAAAG-3’ β-actin 
antisense 5’-ATGCCACAGGATTCCATACC-3’ 
 
Table 2.2: Real Time PCR primer sequences. 
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2.9.2 Data analysis 
 
The data were analysed using the Rotor-Gene Software. In each reaction there is an 
exponential phase, when the number of copies of the DNA molecule doubles (at least 
theoretically) during each cycle, and a plateau phase when the amount of one of the 
reagents becomes limiting and the increase is small. Analysis was performed by 
choosing a threshold value which is still in the exponential phase and calculating how 
many cycles (Ct) it takes for the florescence to reach the threshold for each sample. 
These Ct values were then compared to the Ct values for a reference gene the 
expression of which does not change significantly; this normalisation corrects for small 
variances in mRNA amount and permits the comparison of different samples. -actin 
was used as a reference gene and relative expression was calculated by the Ct 
method using: relative expression=2^(Ct(β-actin)−Ct(target))×10,000. All samples were run 
in duplicate. 
 
2.10 Protein extraction 
 
To obtain protein extracts, the cells were swelled on ice for 15 minutes in a hypotonic 
buffer containing 10mM HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulphonic 
acid], 10mM KCl, 0.1mM EDTA [ethylenediaminetetraacetic acid], 0.2mM DTT 
[dithiothreitol], 0.5mM PMSF [phenylmethylsulphonyl fluoride] and protease and 
phosphatase inhibitors (Roche). Then the detergent Igepal CA-630 (Sigma) was added 
to a final concentration of 1% and the samples mixed. This relatively mild detergent 
lyses the plasma membrane but does not break the nuclear membrane. The tubes were 
then centrifuged to pellet the nuclei. The supernatant containing the cytosolic extract 
was transferred to a new tube. The pellet containing the nuclei was resuspended in a 
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buffer containing 20mM HEPES, 0.4M NaCl, 1mM EDTA, 1mM EGTA [ethylene 
glycol tetraacetic acid], 1mM DTT, 1mM PMSF and protease and phosphatase 
inhibitors (Roche). The nuclei were vigorously agitated in this buffer for 10 minutes at 
room temperature and then spun down. Following centrifugation the nuclear proteins 
were located in the supernatant which was transferred to a new tube. This nuclear 
extract and the cytosolic extract were aliquoted and stored at −80°C. 
 
2.11 SDS PAGE and Western blotting 
 
SDS PAGE (Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis) is a 
technique that separates proteins based on their size. The migration of a molecule 
through an electric field is dependent upon its charge and its size. Unlike DNA 
molecules where the charge is proportional to the size due to the similar nature of the 
monomers, there is no relationship between charge and size for proteins. To overcome 
this proteins are treated with the detergent SDS which results in coating of the proteins 
with negatively charged sulphate groups. This is because the hydrophobic dodecyl 
chains of SDS interact with hydrophobic amino acids in the proteins. The amount of 
hydrophobic residues is usually proportional to the size of the protein; hence the amount 
of associated SDS and consequently the degree of negative charge is also proportional 
to the size. Therefore, once in an electric field SDS treated proteins will migrate 
depending on their size and can be separated by electrophoresis using a Polyacrylamide 
gel. 
 
Western blotting was performed as per the protocol from (Sambrook et al., 1989) using 
a 10% resolving gel; composed of 10% acrylamide: 0.26% bisacrylamide solution 
(ProtoGel), 0.1% SDS, 0.1% APS [Ammonium Persulphate], 0.04% Temed [N,N,N',N'-
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tetramethylethylene diamine] and 380mM Tris [tris(hydroxymethyl)aminomethane] 
pH8.8; and a 5% stacking gel; composed of 5% acrylamide: 0.13% bisacrylamide 
solution (ProtoGel), 0.1% SDS, 0.1% APS, 0.1% Temed and 187.5mM Tris pH6.8. 
 
The protein samples were mixed with loading buffer containing SDS and 2-
mercaptoethanol and then heated to 95°C for 5 minutes to denature and reduce the 
proteins. The protein samples, and 5µl of Rainbow molecular marker (Amersham), were 
loaded into the wells of the gel and a potential difference of 100V was applied for 1.5 
hours. After separation by electrophoresis the proteins were transferred to a 
nitrocellulose membrane by a wet transfer protocol. The gel was placed on top of a 
nitrocellulose membrane (Amersham) and this was sandwiched between two pieces of 
filter paper. This was placed in a cassette in the wet transfer system and a current of 
300mA applied for 1 hour. The negatively charged proteins move towards the anode but 
are unable to pass through the nitrocellulose membrane and hence are retained on this 
surface in the same orientation as in the gel. 
 
To prevent antibody binding non-specifically, the membrane was blocked in 5% milk in 
TBST (Tris Buffered Saline with 0.1% Tween 20 [a detergent]) for 1 hour at room 
temperature. The membrane was then incubated overnight at 4°C with the relevant 
primary antibody against p21cip1 (Santa Cruz Biotechnology), Egr-2 (Covance), 
Histone H3 (Abcam) or β-actin (Sigma) in 5% milk in TBST at a 1:100 dilution (β-
actin), 1:200 dilution (p21cip1 and Egr-2) or 1:1000 dilution (Histone H3). These 
antibodies were raised by immunising a rabbit with a peptide derived from the protein 
of interest. Therefore the antibody will bind to any protein containing this sequence 
present on the membrane. The following day any unbound primary antibody was 
removed by washing the membrane 3 times in TBST. The membrane was then 
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incubated with a polyclonal goat anti-rabbit IgG HRP (horseradish peroxidase) 
conjugated secondary antibody (Biorad) in 5% milk in TBST, at a 1:2000 dilution, for 1 
hour at 4°C with rotation. This secondary antibody, raised in goat against rabbit 
antibody, is conjugated to the reporter enzyme HRP to enable detection. The membrane 
was then washed 3 times in TBST and once in TBS to remove any unbound secondary 
antibody and then transferred onto cling film. The immune complexes were detected by 
chemiluminescence using the ECL Plus kit (Amersham) according to the 
manufacturer’s instructions. This reagent contains a substrate that is oxidised, catalysed 
by HRP, producing a luminescent signal. Following exposure to ECL Plus for 5 
minutes, the luminescence was detected by exposing photographic film to the 
membrane and then developing the film. Analysis of FasL, pERK and total ERK 
expression by western blot was performed by Dr B. Zhu. 
 
2.12 Proliferation assay 
 
To analyse proliferation of T cells tritiated thymidine ([3H]TdR) incorporation was 
measured by Dr B. Zhu. This technique takes advantage of the fact that as cells 
proliferate they replicate their DNA. This technique uses the nucleotide thymidine 
(TdR) that is labelled with a radioactive isotope of hydrogen called tritium (3H). As the 
cells proliferate they take up this [3H]TdR and incorporate it into their DNA. Thus 
tritium incorporation is proportional to DNA synthesis and hence to proliferation. To 
measure [3H]TdR incorporation, purified CD4+ T cells (5×104 cells/200µl) in 96-well 
plates were stimulated in triplicate for 72 hours. 1µCi of [3H]TdR was added to each 
well for the last 8 hours of culture, then the DNA was harvested onto glass fibre filters 
and unincorporated [3H]TdR was washed away. Tritium incorporation was measured by 
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scintillation counting; tritium emits  radiation which excites scintillation fluid causing 
it to emit light which can then be detected.  
 
2.13 Flow cytometry 
 
Flow cytometry permits the investigation of the expression of cellular markers by a 
mixed population of cells. This technique uses antibodies that have high affinity for the 
protein of interest. These antibodies are usually directly conjugated to a fluorescent 
marker to enable detection. Total splenocytes or thymocytes were incubated with the 
indicated fluorescently labelled antibodies on ice for 30-60 minutes in PBS containing 
3% FBS. Flourescein isothiocyanate (FITC)-conjugated antibodies to CD3, CD4 and 
CD62L; phycoerythrin (PE)-conjugated antibodies to B220, CD4, CD8, CD25 and 
CD69; allophycocyanin (APC)-conjugated antibody to CD44 and peridinin chlorophyll 
protein (PerCP)-conjugated antibody to CD3 were all from BD Biosciences while APC-
conjugated antibodies to NK1.1, CD5, CD11b and CD25 and PE-Cy5-conjugated 
antibody to TCR- were all from eBioscience. The cells were then washed and 
resuspended in PBS and run through the flow cytometer. The cells are passed through a 
nozzle to create a stream of single cells. The machine uses lasers of particular 
wavelengths to excite the fluorochromes attached to the antibodies which then emit at a 
longer wavelength. PhotoMultiplier Tubes (PMT) detect these emissions for each cell 
that passes through the machine. The computer then plots this data so that the 
expression of the markers by the cells can be quantified. In addition the computer can be 
directed to show only those cells in a certain population; a process termed gating. In this 
study we gated on CD4+ or CD8+ populations to investigate the expression of various 
markers and on CD4−CD8− cells to examine DN cell subpopulations.  
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To determine apoptosis induction, cells were stained with Annexin V; a protein that 
binds the phospholipid phosphatidylserine. This phospholipid is normally confined to 
the interior surface of the cell membrane but is externalised in apoptotic cells. Thus 
Annexin V stains cells undergoing apoptosis. The cells were also stained with 
Propidium Iodide (PI) to exclude those cells that were already dead; PI binds to nucleic 
acids but can only gain access to this material if the cell has lost membrane integrity, 
thus PI positive cells are dead cells. Staining was performed according to the protocol 
supplied by BD Biosciences. Briefly, cells were resuspended in a buffer containing 
10mM Hepes (pH 7.4), 140mM NaCl, 2.5mM CaCl2, and APC conjugated Annexin V 
and PI were added. The cells were incubated for 15 min at room temperature in the 
dark, then diluted in the same buffer and analysed by flow cytometry.  
To examine cytokine expression we stimulated splenocytes with 20ng/ml Phorbol 12-
myristate 13-acetate (PMA) and 0.5µg/ml Ionomycin for 5 hours in the presence of 
Brefeldin A, an inhibitor of cytokine secretion, and then stained for surface markers. We 
then performed intracellular cytokine staining using the Fixation & Permeabilisation Kit 
from eBioscience according to the manufacturer’s protocol. Briefly, the cells were fixed 
with paraformaldehyde and then permeabilised using the relevant buffers in the Kit 
before incubation with FITC labelled antibody against IFN-γ, or PE labelled antibody 
against IL-4 or IL-2 (eBioscience). Cells were gated on the CD4+ population. Analysis 
of intracellular IL-17 was performed by Dr S. Li at Brunel University (Zhu et al., 2008). 
To determine FoxP3 expression, we used the Foxp3 Staining Buffer Set from 
eBioscience according to the manufacturer’s instructions. Briefly, cells were stained 
with surface markers and then fixed and permeabilised using the relevant buffers in the 
Set before incubation with PE labelled antibody against FoxP3 (clone FJK-16s; 
eBioscience). Cells were gated on the CD4+ population. 
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Flow cytometry data was generated using a BD LSR II and initially analysed using the 
BD FACSDiva software. Where applicable, data was further analysed using FlowJo 
software (TreeStar Inc.). 
 
2.14 Fluorescence Activated Cell Sorting (FACS) 
 
Variants of flow cytometry machines can be used to sort cells based on the expression 
of markers. This technique is called Fluorescence Activated Cell Sorting (FACS). 
FACS is similar to normal flow cytometry but after the cells have passed the PMT and 
the expression of the markers has been analysed, a charge is placed upon the cell, if it 
expresses a given marker, which directs it down one side of a deflection screen thus 
separating it from cells that do not express that marker. In this study, CD4+ 
CD25−CD44low and CD4+CD25−CD44high cells were isolated by FACS from MACS 
enriched CD4+ populations. In addition, retrovirally transduced Enhanced Green 
Fluorescent Protein (EGFP) positive cells (see section 2.17) were isolated from non-
transduced EGFP− cells. 
 
2.15 In vivo proliferation 
 
To analyse the proliferation of T cells in vivo, the BrdU flow kit from BD Biosciences 
was used. This kit uses an analogue of the nucleotide thymidine called 
bromodeoxyuridine (BrdU). This nucleotide analogue is taken up by proliferating cells 
and incorporated into their DNA. The cells that have incorporated BrdU can then be 
detected using anti-BrdU antibodies and flow cytometry. BrdU labelling and detection 
was performed as per the manufacturer’s protocol by Dr B. Zhu (Zhu et al., 2008). 
Briefly, mice were supplied with 0.8 mg/ml BrdU in drinking water for 9 days and then 
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splenocytes were extracted. The splenocytes were first stained with APC-conjugated 
anti-CD44 antibody and either PE-conjugated anti-CD4 or anti-CD8 antibody, and then 
fixed, permeabilised and treated with DNAse using the buffers supplied in the BrdU 
flow kit (BD Biosciences). The cells were then stained with FITC-conjugated anti-BrdU 
antibody and the percentage of T cells that had incorporated BrdU was analysed by flow 
cytometry.  
Examination of the proliferation of adoptively transferred CD4+ or CD8+ T cells in wild 
type C57BL/6 mice was performed by Dr S. Li at Brunel University using 
Carboxyfluorescein succinimidyl ester (CFSE) labelling (Zhu et al., 2008). To label the 
cells with CFSE, they were first treated with Carboxyfluorescein diacetate succinimidyl 
ester (CFDA-SE); a cell membrane permeable fluorescent molecule. Upon entering the 
cell, esterases cleave the acetate groups from CFDA-SE generating CFSE which is cell 
membrane impermeable; hence cells retain CFSE within their cytoplasm. Upon 
cyokinesis, the CFSE molecules are divided amongst the two daughter cells leading to a 
two fold decrease in the relative fluorescence intensity compared to the parent cell. 
Thus, the number of cell divisions that the cells have undergone, and hence their 
proliferation, can be determined by analysing CFSE dilution. CD4+ or CD8+ T cells 
were extracted from Egr-2 cKO and Egr-2loxP/loxP mice, labelled with CFSE and 
transferred into 12-week-old C57BL/6 mice. Three to four weeks later, CD4+ or CD8+ T 
cells were purified from the spleens of recipients and stained with PE-conjugated anti-
CD44 antibody and CFSE dilution was analysed. 
 
2.16 Analysis of autoimmune disease 
 
Histological analysis was performed by Professor J. Martin and colleagues of the 
Pathology department, Queen Mary, University of London (Zhu et al., 2008). For 
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immunohistochemistry, paraffin embedded kidney sections were deparaffinised and 
rehydrated by incubating first in xylene and then decreasing concentrations of ethanol. 
Antigen retrieval was performed by boiling the slides in 10mM sodium citrate pH 6.0 
for 20 minutes. The slides were then blocked with 3% Bovine Serum Albumin (BSA) in 
PBS and then stained with rabbit anti-human CD3 (DAKO) and rat anti-mouse B220 
(BD biosciences) in 3% BSA in PBS. After washing, sections were stained with Alexa 
Fluor 594-conjugated donkey anti-rabbit IgG and FITC-conjugated donkey anti-rat IgG 
secondary antibodies (both Jackson Immunoresearch), followed by counterstaining with 
DAPI. Detection of immunoglobulin deposition in the glomeruli, detection of 
proteinuria and analysis of immunoglobulin subclass distribution and anti-nuclear 
antibodies was performed by Dr S. Li at Brunel University (Zhu et al., 2008).  
 
2.17 Retroviral transduction 
 
Retroviruses infect mammalian cells and integrate their DNA into the host genome. 
This fact makes them a useful tool for the long term expression of exogenous proteins in 
the cell. Current retroviral expression systems use a system where the gag, pol and env 
gene products, which are required to produce mature viral particles that are capable of 
infecting target cells and integrating into their genome, are provided in trans by a 
packaging cell line (Pear et al., 1993; Shaw et al., 1997; Swift et al., 2001). The 
expression of the gag, pol and env gene products in trans ensures that once the first 
target cell has been infected no infectious viral particles are produced. The gene of 
interest is cloned between two viral Long Terminal Repeat (LTR) regions which serve 
to facilitate expression of the integrated provirus. In this study the vector pBABE-Egr-
2-EGFP and the empty control vector pBABE-EGFP (Morgenstern and Land, 1990) 
(both kindly provided by Professor K. Jessen, University College London) were used. 
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These constructs were transfected into the packaging cell line Phoenix-E (Shaw et al., 
1997; Swift et al., 2001) (also a kind gift from Professor K. Jessen, University College 
London) using FuGENE (Roche) according to the manufacturer’s instructions. 
FuGENE is a lipid based reagent that coats the DNA allowing it to pass through the 
plasma membrane and into the cell. Once the constructs are inside the cell, viral RNA is 
expressed from the vector. A packaging sequence present in the viral RNA, termed , is 
recognised by gag gene products which package the viral RNA with gag, pol and env 
gene products into infectious virions which then bud from the cell. 48 hours after 
transfection the supernatant, containing retroviral particles, was harvested from the 
cells. This supernatant was then used to infect the target cells using Retronectin 
(Takara) according to the manufacturer’s instructions. Retronectin is a recombinant 
fragment of fibronectin that can be bound by cell surface receptors and by retroviral 
particles. Thus this molecule serves to bring the virus into contact with the cell. 24 well 
plates were coated with 25µg of Retronectin for 2 hours at room temperature. After 
washing, retroviral supernatant was added to the wells and incubated at 32°C for 4 
hours. During this time the viral particles bind to the Retronectin protein. The plates 
were then washed with PBS and 7.5x104 MF2.2D9 T hybridoma cells added. Once the 
virus has infected the cell the viral RNA is reverse transcribed and the resulting cDNA 
integrated into the host genome. The viral LTRs then direct the transcription of the gene 
of interest. The pBABE-Egr-2-EGFP and pBABE-EGFP vectors also encode EGFP; 
EGFP is derived from a protein from Jellyfish that fluoresces when excited by 
ultraviolet (UV) light. Thus to detect whether transduction has occurred EGFP 
expression can be monitored. Cells were expanded and EGFP positive transduced cells 
were isolated by FACS (see section 2.14). 
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2.18 Electrophoretic Mobility Shift Assay 
 
Electrophoretic Mobility Shift Assay (EMSA) is a technique that detects protein binding 
to a DNA sequence. The DNA oligonucleotide is labelled with a radioisotope and then 
incubated with a protein mixture. The samples are then run on a non-denaturing 
Polyacrylamide gel. If the DNA oligonucleotide is bound by a protein its migration 
through the gel will be retarded; hence this technique allows the investigation of Protein 
DNA interactions. Oligonucleotides matching the sense and antisense strands of the 
sequence of interest from the p21 promoter (p21 probe (5’-
GGGCTGCCTCTGAGGGGGCGGGGC-3’)) were designed with an extra 3 G 
nucleotides at the 5’ ends. 40µM of these sense and antisense oligonucleotides were 
mixed together, heated to 95°C for 5 minutes and then allowed to cool to room 
temperature. Heating to 95°C denatures any secondary structures that may be present in 
the oligonucleotides so that they can bind to the complementary sequence upon cooling. 
This process results in a double stranded probe that has 3 G nucleotide overhangs at 
both 5’ ends. These overhangs were then filled in using the Ready-to-Go DNA labelling 
beads (Amersham) according to the manufacturer’s instructions. Radioactive [α-
32P]dCTP nucleotides were added to the mixture and the Klenow fragment from DNA 
polymerase I present in the kit fills in the overhanging ends of the probes with this 
nucleotide, resulting in the radioactive labelling of the probe. Labelled probes were then 
purified using ProbeQuant G-50 microcolumns (Amersham) according to the 
manufacturer’s instructions. These gel filtration columns contain Sephadex G-50 beads. 
Single nucleotides can enter the pores of these beads but the larger probe cannot. 
Therefore, the probe passes through the column faster than the nucleotides and is eluted 
first, while the single nucleotides are retained in the column. After purification, the 
labelled probe was incubated with nuclear extracts from stimulated and unstimulated 
61 
MF2.2D9 cells in a buffer containing 10mM HEPES pH 7.5, 50mM KCl, 2.5mM 
MgCl2, 10mM DTT, 1µg poly(dI-dC), 10% glycerol, 0.5mM ZnCl2 and 5mM 
spermidine for 40 minutes at room temperature. For supershift reactions anti-Egr-2 
(Covance) or anti-Egr-3 (Santa Cruz Biotechnology) antibody were added after 10 
minutes of incubation. The samples were electrophoresed on 5% polyacrylamide gels in 
0.5x Tris Borate EDTA (TBE). The gels were dried under vacuum and exposed to 
autoradiographic film at −80°C overnight. The film was then developed. 
 
2.19 Chromatin Immunoprecipitation 
 
Chromatin Immunoprecipitation (ChIP) is a technique that enables detection of Protein-
DNA interactions in vivo. This technique uses an antibody to specifically precipitate the 
protein of interest and the associated DNA. ChIP was performed according to the 
protocol supplied by Upstate Biotechnology. Briefly, 108 Egr-2 and EGFP transduced 
MF2.2D9 cells were crosslinked with 1% formaldehyde for 10 minutes at room 
temperature. This chemical binds the chromatin together preventing the dissociation that 
normally occurs upon cellular lysis. Crosslinking was quenched by the addition of 125 
mM glycine and the cells were then washed twice with PBS. The cells were then lysed 
with a buffer containing 1% SDS, 10mM EDTA, 50mM Tris pH8 and transferred to 
15ml tubes.  The lysates were then sonicated with a Diagenode Bioruptor to shear the 
DNA protein complexes into lengths of less than 1Kb. Sonication was performed for a 
total of 10 minutes on the High output setting with 30 second bursts of sonication 
separated by 30 second intervals. Sonication was verified by taking a small sample of 
the chromatin, reversing crosslinks by heating to 65°C overnight and running on a 1% 
agarose gel. 500µg of sonicated chromatin was precleared for 1 hour at 4°C with salmon 
sperm DNA (ssDNA)/BSA-blocked Protein A beads (Amersham). This step aims to 
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remove any proteins or DNA that binds non-specifically to Protein A beads. The 
chromatin was then used as a template for immunoprecipitation. An anti-Egr-2 or 
irrelevant control (anti-tapasin) antibody was added to the sonicated lysate and 
incubated at 4°C overnight. The anti-Egr-2 antibody will bind to the Egr-2 protein and 
associated DNA and this antibody-protein-DNA complex can then be precipitated by 
the addition of ssDNA/BSA-blocked Protein A beads. These Protein A beads consist of 
Protein A from Staphylococcus Aureus conjugated to agarose beads. Protein A binds to 
the Fc region of Immunoglobulin and the insoluble agarose causes the 
immunocomplexes to be found in the pellet after centrifugation. After the 
immunocomplexes were pelleted and the supernatant, which contains non-specific 
chromatin, was removed, the pellet was washed in buffers of increasing ionic strength. 
After the final wash the pellet was resuspended in elution buffer containing SDS. This 
SDS will denature the antibody and Protein A resulting in the release of the 
immunoprecipitated chromatin complexes. The crosslinks were then reversed by heating 
to 65°C overnight. The DNA was then purified by phenol chloroform extraction and 
ethanol precipitation as per the protocol in (Sambrook et al., 1989) and used as template 
for PCR. ChIP primer sequences are shown in Table 2.3.  
 
Primer Sequence 
sense 5’-ATCGGTGAAGGAGTGGGTTGGTCC-3’  p21cip1 antisense 5’-ACACCTCTCGGCTGCTGCAGTTGG-3’   
sense 5’-TGTGTACTCAAGCTGGTGCAC-3’  SOCS3 
antisense 5’-CATACTGATCCAGGAACTCC-3’   
 
 
 
 
 
Table 2.3: ChIP primer sequences. 
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2.20 Microarray 
 
CD4+ T cells from 3 month old Egr-2loxP/loxP and Egr-2 cKO mice were isolated by 
MACS and stimulated for 6 hours with plate bound anti-CD3 or left unstimulated. Total 
RNA was first isolated using the trizol reagent as described above and then further 
purified using the Qiagen RNAeasy kit RNA cleanup protocol according to the 
manufacturer’s instructions. The experiment was performed ten times and the trizol 
lysates for each condition were pooled. The purified RNA was then given to the 
Genome Centre, Queen Mary, University of London who processed the samples and 
hybridised them to Illumina MouseRef-8 BeadChip expression arrays. These arrays 
consist of 50-mer oligonucleotide probes directed against ~24,000 well annotated 
RefSeq transcripts. These arrays were manufactured by chemically synthesising the 
oligonucleotide probes covalently attached to 3 micron beads which are then fixed in 
place on the array. Upon introduction of labelled test RNA sequences, the labelled RNA 
will hybridise to complementary sequences present on the array and the unbound RNA 
is then washed away. The array is then scanned to detect the bound RNA via the 
fluorescent label providing a genome wide transcriptional profile for that sample. The 
data was first normalised using the cubic spline method and then returned to us for 
further analysis. We initially focussed on genes that showed a difference of at least 
three-fold between Egr-2loxP/loxP and Egr-2 cKO CD4+ T cells and excluded genes that 
had a detection p-value greater than 0.05. The differentially expressed genes were 
classified into different groups depending upon their function as determined by 
searching the NCBI Entrez Nucleotide database. Real Time RT-PCR was performed to 
validate the results using the primers listed above (section 2.9.1). Based upon the results 
(see section 3.12) we subsequently refined our analysis and excluded genes that had a 
detection p-value greater than 0.01.  
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Chapter 3: RESULTS 
 
3.1 Egr-2 is expressed in tolerant T cells 
 
Microarray analysis found that Egr-2 was expressed in both naïve and tolerant Tg4 T 
cells 2 hours after in vivo antigen challenge (Anderson et al., 2006). To confirm this, we 
performed Real Time PCR and Western blotting analysis of naïve (A) and tolerant (T) 
Tg4 T cells that were either unstimulated (A0 and T0) or had been treated with peptide 
in vivo 2 hours previously (A2 and T2). Tolerance induction was confirmed by the 
cytokine mRNA profile; low IL-2 and high IL-10 for T2 compared to high IL-2 and low 
IL-10 for A2 (data not shown). We found that Egr-2 was indeed expressed at both the 
mRNA and protein levels 2 hours after in vivo antigen challenge in both naïve and 
tolerant T cells (Figure 3.1). Thus, unlike many other transcription factors which are not 
activated (Anderson et al., 2006), Egr-2 is expressed in tolerant T cells following TCR 
engagement suggesting it may be involved in the maintenance of tolerance. 
 
Figure 3.1: Egr-2 expression in tolerant T cells. Transgenic Tg4 T cells were 
tolerised by 10 i.n. administrations of 100µg of the Ac1-9[4Y] peptide from 
myelin basic protein as described (Anderson et al., 2006). Resting (A0 and T0) 
and in vivo stimulated (A2 and T2) naïve (A) and tolerant (T) CD4+ Tg4 T cells 
were isolated and Egr-2 expression was examined by Real Time PCR (A) and 
western blot (B). Histone H3 serves as a loading control. 
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3.2 Generation of Egr-2 cKO and Tg mice 
 
Egr-2 KO mice die soon after birth due to defects in brain development (Schneider-
Maunoury et al., 1993) precluding analysis of T cells in these mice. Therefore, to 
investigate the roles of Egr-2 in T cells in vivo, we generated mice in which the Egr-2 
gene was deleted only in CD2+ lymphocytes (see methods). Egr-2loxP/loxP mice were 
crossed with hCD2-Cre mice and Egr-2loxP/loxP hCD2-Cre mice were identified by PCR 
(Figure 3.2, A). Egr-2loxP/loxP hCD2-Cre mice were generated at the expected 
frequencies and displayed no developmental defects. To confirm that T cells from Egr-
2loxP/loxP hCD2-Cre mice have deleted Egr-2, splenic CD4+ T cells were isolated and 
stimulated with anti-CD3 and anti-CD28 and Egr-2 expression was examined by Real 
Time PCR and western blot (Figure 3.2, B and C). Figure 3.2 shows that T cells from 
Egr-2loxP/loxP mice strongly induce Egr-2 expression after stimulation while T cells from 
Egr-2loxP/loxP hCD2-Cre mice have no detectable Egr-2 protein expression confirming 
that Cre mediated deletion has occurred effectively. However, there was very weak 
mRNA expression, which may be due to incomplete Cre mediated deletion in a small 
proportion of cells. Nevertheless, the Egr-2loxP/loxP hCD2-Cre mice are effectively a 
conditional T cell KO and are hereafter designated Egr-2 cKO.  
 
Using a GFP reporter gene Kioussis and colleagues demonstrated that the hCD2 
construct also directs expression of the transgene in mature B cells, albeit at lower 
levels than in mature T cells (de Boer et al., 2003). Therefore we examined the 
expression of Egr-2 in B cells from Egr-2 cKO mice. B cells were extracted from Egr-2 
cKO and Egr-2loxP/loxP mice and stimulated with an anti-surface Ig antibody. In contrast 
to the results from T cells, substantial levels of Egr-2 transcripts could still be detected 
in B cells from Egr-2 cKO mice after stimulation (Figure 3.2, D). These results indicate 
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that deletion of Egr-2 is inefficient in B cells in Egr-2 cKO mice perhaps due to the 
weak activity of the hCD2 promoter in mature B cells (de Boer et al., 2003). 
 
 
To complement these Egr-2 cKO mice we decided to generate transgenic mice which 
constitutively over-express Egr-2 in CD2+ lymphocytes. The hCD2 construct that drives 
Figure 3.2: Generation of Egr-2 cKO mice. Egr-2loxP/loxP mice were crossed 
with hCD2-Cre mice to generate Egr-2loxP/loxP hCD2-Cre (Egr-2 cKO) mice. (A) 
Genomic DNA was extracted from tail samples and Egr-2 cKO and Egr-2loxP/loxP 
mice were identified by PCR. The box highlights an Egr-2 cKO mouse. [(B) and 
(C)] Splenic CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice and 
stimulated with anti-CD3 and anti-CD28 for 6 (B) or 16 hours (C). Egr-2 
expression was examined by Real Time PCR (B) and western blot (C). -actin 
serves as a loading control. (D) Splenic B220+ cells were isolated from Egr-2 
cKO and Egr-2loxP/loxP mice of different ages as indicated. Cells were then 
stimulated with anti-surface Ig antibody for 6 hours and Egr-2 expression 
examined by Real Time PCR. 
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Cre expression in Egr-2 cKO mice was used to drive Egr-2 expression in these 
transgenic mice so that the populations that have deleted Egr-2 in Egr-2 cKO mice will 
over-express Egr-2 in these transgenic mice. These Egr-2 transgenic (Tg) mice were 
generated by standard transgenic techniques (see methods). The progeny were checked 
for the presence of the hCD2 Egr-2 construct by PCR and two mice, Tg14 and Tg18, 
were found to have integrated the targeting construct into their genome. Egr-2 Tg mice 
were generated from these founders at the expected frequencies and displayed no 
obvious gross abnormalities. Egr-2 Tg mice were identified by PCR (Figure 3.3, A). To 
confirm that thymocytes from these Egr-2 Tg mice constitutively express Egr-2, total 
thymocytes were extracted from Egr-2 Tg and wild type mice and Egr-2 expression was 
examined by Real Time PCR and western blot (Figure 3.3, B and C). Figure 3.3 shows 
that, while thymocytes from wild type mice express low levels of Egr-2, thymocytes 
from Egr-2 Tg mice have greatly increased expression. The Egr-2 Tg14 line expressed 
greater levels of Egr-2 than the Tg18 line (Figure 3.3, B). Therefore, Egr-2 Tg mice 
constitutively express Egr-2 in thymocytes indicating that the hCD2 construct directs 
Egr-2 expression in cells of the T cell lineage. 
 
Figure 3.3: Generation of Egr-2 Tg mice. Egr-2 Tg mice were generated as 
described in the methods section. (A) Genomic DNA was extracted from tail 
samples and hCD2-Egr-2+ (Egr-2 Tg) mice were identified by PCR. [(B) and 
(C)] Thymocytes were isolated from Egr-2 Tg and wild type mice and Egr-2 
expression was examined by Real Time PCR (B) and western blot (C). -actin 
serves as a loading control. 
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3.3 Egr-2 in T cell development 
 
Next we examined T cell development in Egr-2 cKO mice. Egr-2 has been implicated in 
-selection and the related protein Egr-1 is involved in positive selection (Miyazaki and 
Lemonnier, 1998; Bettini et al., 2002; Carleton et al., 2002; Carter et al., 2007). 
However, we did not detect any significant changes in the percentages or absolute 
numbers of the major thymocyte subsets in Egr-2 cKO mice; DN, DP and SP cells were 
present at frequencies similar to Egr-2loxP/loxP mice (Figure 3.4, A and B), nor were there 
any changes in DN cells consistent with a defect in -selection (Figure 3.4, C and D). In 
addition we found that CD4+CD25+FoxP3+ TReg cells were generated in Egr-2 cKO 
mice thymi at frequencies similar to Egr-2loxP/loxP mice (Figure 3.4, E). Therefore, T cell 
development appears to be normal in Egr-2 cKO mice.  
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Figure 3.4: T cell development in Egr-2 cKO mice. Thymocytes were 
extracted from Egr-2 cKO and Egr-2loxP/loxP mice, stained with the indicated 
fluorochrome labelled antibodies and analysed by flow cytometry. [(A) and (B)] 
Percentages (A) and absolute numbers (B) of the major thymocyte subsets in 
Egr-2 cKO and Egr-2loxP/loxP mice. [(C) and (D)] Percentages (C) and absolute 
numbers (D) of the DN subsets in Egr-2 cKO and Egr-2loxP/loxP mice. In (A) and 
(C) the data is representative of at least 3 mice of each genotype at three to 
four months of age. In (B) and (D) the data is the mean ± standard deviation 
from 3 mice of each genotype at three to four months of age. (E) Examination of 
CD4+ TReg cells. Expression of CD25 and FoxP3 was examined on gated CD4+ 
cells. The numbers indicate the percentage of cells positive for both FoxP3 and 
CD25.  
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In contrast to the apparently normal thymocyte development in Egr-2 cKO mice, Egr-2 
Tg mice had striking alterations in thymocyte development. The thymus was much 
smaller in both Egr-2 Tg mice lines; in Tg18 it was around half the size of wild type 
while Tg14 was even smaller, around one third to one quarter of the size of that in wild 
type (Figure 3.5, A). Consistent with this reduced thymic size, the total number of 
thymocytes in Egr-2 Tg14 mice was also reduced to approximately one third of wild 
type mice (Figure 3.5, C). Although there was some difference between the two 
transgenic lines in terms of the exact percentages of the major thymocyte subsets, both 
had a similar pattern (see Figure 3.5, B). In both transgenic lines the percentage of DP 
cells was decreased; with ~50% in Tg18 and ~20% in Tg14 compared to ~80% in wild 
type mice. In addition, the percentages of DN and, in particular, CD8+ SP cells were 
dramatically increased. In wild type mice the DN population accounted for only ~2.5% 
of thymocytes but in the Egr-2 Tg DN cells accounted for 10-15% of thymocytes. Even 
more striking was the increase in CD8+ SP cells; this population accounted for 2-4% of 
wild type but in Egr-2 Tg18 it was 15-20% while in Egr-2 Tg14 mice CD8+ SP cells 
were the predominant population accounting for 40-50% of total thymocytes. While the 
absolute number of DN cells in Egr-2 Tg14 mice was similar to wild type, the CD4+ SP 
and DP cells were reduced in Egr-2 Tg14 mice consistent with the reduction in total 
thymocyte numbers. In stark contrast the absolute number of CD8+ SP cells was 
increased four-fold in Egr-2 Tg14 mice compared to wild type despite the decrease in 
total thymocyte numbers (Figure 3.5, C).  
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Figure 3.5: T cell development in Egr-2 Tg mice. (A) Thymus size in Egr-2 
Tg14 and Tg18 compared to wild type and Egr-2 cKO mice. [(B) and (C)] 
Thymocytes were extracted from Egr-2 Tg and wild type mice, stained with the 
indicated fluorochrome labelled antibodies and analysed by flow cytometry. (B) 
Percentages of the major thymocyte subsets in Egr-2 Tg14, Tg18 and wild type 
mice; the data is representative of at least 2 mice of each genotype at three to 
four months of age. (C) Absolute numbers of the major thymocyte subsets in 
Egr-2 Tg14 and wild type mice; the data is the mean ± standard deviation from 
3 mice of each genotype at three to four months of age. 
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To further investigate the expanded CD8+ SP population in Egr-2 Tg mice, the 
expression of the mature T cell markers CD3, TCR- and CD5 was examined. While 
more than 80% of wild type CD8+ SP cells expressed CD3, TCR- or CD5, only 20- 
50% of the CD8+ SP population from Egr-2 Tg14 mice expressed these markers (Figure 
3.6, C). In contrast, the expression of these markers by CD4+ SP cells was similar in 
wild type and Egr-2 Tg14 mice with around 90% of CD4+ SP cells expressing CD3, 
TCR- or CD5 (Figure 3.6, C). Thus, although the absolute number of CD8+ cells in 
Egr-2 Tg14 mice was increased, the absolute number of mature CD8+ SP cells was 
actually decreased in Egr-2 Tg14 mice compared to wild type (~3x106 in Egr-2 Tg14 
compared to ~5x106 in wild type). Therefore, the expansion of the CD8+ SP population 
in Egr-2 Tg mice is due to increased numbers of CD8+ ISP rather than mature CD8+ SP 
cells.  
 
While the total number of DN cells was within normal parameters, a detailed 
examination of the DN subsets revealed an increase in both the percentage and absolute 
number of DN4 cells (Figure 3.6, A and B).  
 
Therefore the main defects in Egr-2 Tg mice appear to be accumulation of cells in the 
DN4 and CD8+ ISP compartments, those stages immediately following passage through 
the -selection checkpoint. These results are markedly similar to those seen in Egr-1 Tg 
and Egr-3 Tg mice (Miyazaki, 1997; Xi and Kersh, 2004) supporting the idea that Egr 
proteins have overlapping functions during T cell development (Carter et al., 2007).  
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Figure 3.6: Thymic CD8+ and DN populations in Egr-2 Tg mice. Thymocytes 
were extracted from Egr-2 Tg14 and wild type mice, stained with the indicated 
fluorochrome labelled antibodies and analysed by flow cytometry. [(A) and (B)] 
Percentages (A) and absolute numbers (B) of the DN subsets in Egr-2 Tg14 
and wild type mice. In (A) the data is representative of 3 mice of each genotype 
at three to four months of age. In (B) the data is the mean ± standard deviation 
from 3 mice of each genotype at three to four months of age. (C) Expression of 
CD3, TCR- and CD5 was examined on gated CD8+ SP (upper) or CD4+ SP 
(lower) thymocytes from Egr-2 Tg14 and wild type mice; the data is 
representative of 2 mice of each genotype at three to four months of age.  
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3.4 Peripheral T cell populations 
 
Although T cell development appeared normal in Egr-2 cKO mice, the total number of 
CD3+ T cells in the spleen was decreased; the total number of cells in three to four  
month old Egr-2 cKO mice was only two-thirds of that seen in age matched Egr-
2loxP/loxP mice (Figure 3.7, A and C). The numbers of CD4+ and CD8+ cells in these 
young Egr-2 cKO mice were also decreased compared to Egr-2loxP/loxP mice (Figure 3.7, 
B and C); although this appeared to affect CD8+ cells more than CD4+ cells. Next we 
examined regulatory T cells in Egr-2 cKO mice. We found that CD4+CD25+FoxP3+ 
TReg cells were present in the periphery in Egr-2 cKO mice at similar frequencies to 
Egr-2loxP/loxP mice (Figure 3.7, D). We then examined the expression of activation 
markers by CD4+ cells. The percentage of CD4+ cells expressing the activation markers 
CD25 and CD69 was normal in young Egr-2 cKO mice (Figure 3.7, E). However, there 
were slight increases in the percentage of cells expressing high levels of the marker 
CD44 and in the percentage of cells expressing low levels of the marker CD62L (Figure 
3.7, E).  
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Figure 3.7: Splenic B cell and T cell populations in Egr-2 cKO mice. 
Splenocytes were extracted from Egr-2 cKO and Egr-2loxP/loxP mice, stained with 
the indicated fluorochrome labelled antibodies and analysed by flow cytometry. 
[(A) and (B)] Representative flow cytometry analysis of B220+ and CD3+ cells 
(A) and CD4+ and CD8+ cells (B). (C) Absolute numbers of CD3+ cells, CD4+ 
cells and CD8+ cells in Egr-2 cKO and Egr-2loxP/loxP mice. In (C) the data is the 
mean ± standard deviation from 5 mice of each genotype at three to four 
months of age. (D) Examination of CD4+ TReg cells. Expression of CD25 and 
FoxP3 was examined on gated CD4+ cells. The numbers indicate the 
percentage of cells positive for both FoxP3 and CD25. (E) Expression of CD69, 
CD25, CD44 and CD62L was examined on gated CD4+ cells. The data in (A), 
(B), (D) and (E) is representative of at least 3 mice of each genotype. 
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Despite the alterations in thymocyte development, the size of the spleen and the total 
number of splenocytes in Egr-2 Tg14 mice were similar to wild type (data not shown). 
However, there were marked changes in the composition of cells in Egr-2 Tg mice. 
While in wild type mice the majority of splenocytes, more than 90%, were either B220+ 
or CD3+, in Egr-2 Tg mice there were a considerable number of CD3−B220− cells; 
around 20-30% (Figure 3.8, A). Staining of total splenocytes with CD4 and CD8 
revealed that the percentage of cells that were CD4+ was reduced by about a third while 
the percentage of CD8+ cells was markedly increased in Egr-2 Tg mice with a 2.5-3 fold 
increase compared to wild type (Figure 3.8, B). Triple staining of splenocytes with 
CD3, CD4 and CD8 antibodies revealed the presence of a large population of 
CD8+CD3− cells in Egr-2 Tg mice that was not present in wild type mice; this 
CD8+CD3− population accounted for 50-60% of the peripheral CD8+ population in Egr-
2 Tg mice (Figure 3.8, C). In contrast, there were no CD4+CD3− cells in either Egr-2 Tg 
or wild type mice (Figure 3.8, D). Therefore, the presence of B220−CD3− cells and the 
increase in the percentage of CD8+ cells in the spleen of Egr-2 Tg mice is due to the 
existence of these aberrant CD8+CD3− cells.  
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Figure 3.8: Splenic B cell and T cell populations in Egr-2 Tg mice. 
Splenocytes were extracted from wild type and Egr-2 Tg14 mice, stained with 
the indicated fluorochrome labelled antibodies and analysed by flow cytometry. 
[(A) – (D)] Representative flow cytometry analysis of B220+ and CD3+ cells (A), 
CD4+ and CD8+ cells (B), CD3+ and CD8+ cells (C) and CD3+ and CD4+ cells 
(D). The data is representative of at least 2 mice of each genotype. 
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To further investigate these aberrant CD8+ cells we examined the expression of the 
mature T cell markers CD3, TCR- and CD5. While more than 90% of wild type CD8+ 
splenocytes expressed CD3, TCR- or CD5, only around half of the CD8+ population 
from Egr-2 Tg mice expressed CD3 or TCR- while only ~20% were CD5+ (Figure 3.9, 
A). In contrast, the expression of these markers by CD4+ splenocytes was similar in 
wild type and Egr-2 Tg mice with more than 90% of CD4+ cells expressing CD3, TCR-
 or CD5 (Figure 3.9, A). To determine whether these CD8+CD3− cells were of a 
different lineage, we investigated the expression of NK cell markers and markers 
typically found on cells of the innate immune system. We found that only ~2% of the 
CD8+ cells in the spleen of Egr-2 Tg mice expressed either CD11b or NK1.1 (Figure 
3.9, B). This was not due to a failure of antibody staining since there were distinct 
CD8−CD11b+ and CD8−NK1.1+ populations (data not shown). Similar results were seen 
for CD11c (data not shown). Therefore, these aberrant CD8+ cells resemble CD8+ ISP 
thymocytes rather than mature CD8+ T cells or cells of the innate immune system. 
 
In light of these gross abnormalities in T cell development and the presence of these 
aberrant CD8+CD3− cells in the periphery, we felt that further comparison with the Egr-
2 cKO would not be informative. 
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Figure 3.9: Aberrant splenic CD8+ population in Egr-2 Tg mice. Splenocytes 
were extracted from wild type and Egr-2 Tg14 mice, stained with the indicated 
fluorochrome labelled antibodies and analysed by flow cytometry. (A) 
Expression of CD3, TCR- and CD5 was examined on gated CD8+ (upper) or 
CD4+ (lower) splenocytes from Egr-2 Tg and wild type mice; the data is 
representative of 2 mice of each genotype at three to four months of age. (B) 
Expression of CD3, CD11b and NK1.1 was examined on gated CD8+ 
splenocytes from Egr-2 Tg mice.  
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3.5 Egr-2 in T cell activation in vitro 
 
Over-expression of Egr-2 in a T cell line resulted in decreased production of IL-2 and 
proliferation in response to antigen stimulation (Safford et al., 2005) suggesting that 
Egr-2 negatively regulates TCR signalling. Therefore we investigated the response of 
Egr-2 cKO CD4+ T cells to TCR stimulation. Egr-2 cKO and Egr-2loxP/loxP CD4+ T cells 
were isolated and stimulated with different concentrations of plate-bound anti-CD3. In 
contrast to the previous report, we found that primary Egr-2 cKO CD4+ T cells were not 
hyper-reactive in response to TCR stimulation in vitro (Figure 3.10, A). On the 
contrary, the Egr-2 cKO T cells were, if anything, slightly hypo-responsive, consistently 
exhibiting proliferative responses that were approximately 60-70% of the Egr-2loxP/loxP 
cells. Similar results were seen for CFSE labelled CD4+ T cells confirming that this was 
not an artefact of the [3H]TdR incorporation protocol (data not shown). These results 
suggest that Egr-2 is not simply a negative regulator of TCR signalling as has been 
proposed (Safford et al., 2005) but has a more complex role in T cell activation. 
However, the different responses do not appear to be the result of altered TCR 
signalling as the activation of the MAPK ERK in response to TCR engagement was 
normal in Egr-2 cKO T cells (Figure 3.10, B). In any case, these results demonstrate 
that physiological levels of Egr-2 do not inhibit primary T cell activation and TCR 
signalling.  
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3.6 Apoptosis induction and FasL expression 
 
The observed hypo-proliferation of Egr-2 cKO cells in response to TCR stimulation in 
vitro may be due to increased susceptibility to apoptosis. To investigate this possibility, 
CD4+ cells from Egr-2 cKO and Egr-2loxP/loxP mice were isolated and stimulated with 
anti-CD3 for 48 or 72 hours and apoptosis induction was assessed by annexin V 
staining. We found that the percentage of annexin V positive PI negative cells was 
similar in Egr-2 cKO and Egr-2loxP/loxP T cell populations at both time points (Figure 
3.11, A and B). Thus, at least under these conditions, Egr-2 cKO T cells are not more 
Figure 3.10: Response of Egr-2 cKO CD4+ T cells to TCR stimulation. 
Splenic CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice and 
stimulated as indicated. (A) CD4+ cells were stimulated with anti-CD3 at the 
indicated concentrations for 72 hours and proliferation analysed by [3H]TdR 
incorporation. The data is representative of at least 3 independent experiments. 
(B) CD4+ cells were stimulated with anti-CD3 for the indicated time periods and 
ERK activation analysed by western blot.  
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susceptible to apoptosis. Egr-2 has been reported to regulate the expression of FasL 
(Mittelstadt and Ashwell, 1999). The lack of a defect in apoptosis induction argues 
against an obligate role for Egr-2 in regulating FasL expression after TCR stimulation. 
However, this may be due to the conditions used in this assay. To directly investigate 
the expression of FasL, CD4+ cells were isolated from Egr-2loxP/loxP and Egr-2 cKO mice 
and stimulated with anti-CD3 and anti-CD28. We did not detect any difference in the 
expression of FasL between Egr-2 cKO and Egr-2loxP/loxP T cells after TCR stimulation 
(Figure 3.11, C). This normal expression of FasL in Egr-2 cKO T cells may be due to 
functional compensation by Egr-3 (Mittelstadt and Ashwell, 1998). 
 
Figure 3.11: Apoptosis induction and FasL expression in Egr-2 cKO CD4+ 
T cells. Splenic CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice 
and stimulated as indicated. [(A) and (B)] CD4+ cells were stimulated with anti-
CD3 for the indicated time periods and apoptosis induction was assessed by 
Annexin V staining. (A) Representative flow cytometry results after 48 hours 
stimulation. (B) The percentage of cells positive for Annexin V and negative for 
PI at different times after stimulation. (C) CD4+ cells were stimulated with anti-
CD3 and anti-CD28 for 16 hours and FasL expression was analysed by western 
blot. 
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3.7 Egr-2 in CD44high T cells in vivo 
 
Thus far, the results from Egr-2 cKO T cells have not shown the hyper-reactivity that 
we expected based upon the expression of Egr-2 in tolerant T cells and our hypothesis 
that Egr-2 is involved in the maintenance of tolerance (Figure 3.1). However, we did 
observe an increase in the percentage of CD4+CD44high T cells in Egr-2 cKO mice. 
Although the percentage of CD4+CD44high T cells was slightly increased in 3 month old 
Egr-2 cKO mice (Figure 3.7, E) this was even more pronounced in 8 month and 15 
month old Egr-2 cKO mice (Figure 3.15, A), suggesting that Egr-2 may be involved in 
the homeostasis of CD4+CD44high T cells. To investigate Egr-2 expression in CD44high 
and CD44low T cells, CD4+CD25−CD44high and CD4+CD25−CD44low T cells were 
isolated from Egr-2loxP/loxP mice by FACS (Figure 3.12, A). We found that the 
expression of Egr-2 mRNA in CD4+CD44high T cells was around 5 times higher than 
that of the CD4+CD44low population (Figure 3.12, B). Furthermore, Egr-2 protein was 
only detected in CD4+CD44high T cells (Figure 3.12, C). These results demonstrate that 
Egr-2 is expressed in effector phenotype T cells in vivo in the absence of overt antigen 
stimulation.  
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To investigate the effect of Egr-2 deficiency on CD44high T cells, we examined their 
proliferation in vivo in the absence of experimental immunisation. Eight month old Egr-
2loxP/loxP and Egr-2 cKO mice were supplied with BrdU for 9 days and then BrdU 
incorporation by splenic T cells was analysed. The proportion of BrdU-positive 
CD44low T cells was similar in Egr-2 cKO and Egr-2loxP/loxP mice and was less than 5% 
(Figure 3.13). However, we found that BrdU incorporation by CD44high cells was 
increased in Egr-2 cKO mice compared to Egr-2loxP/loxP mice. 29.5% of CD8+CD44high 
and 21.5% of CD4+CD44high T cells from Egr-2 cKO mice had incorporated BrdU 
Figure 3.12: Egr-2 expression in CD44high T cells in vivo. Splenic CD4+ cells 
were extracted from 8 month old Egr-2loxP/loxP mice, stained with the indicated 
fluorochrome labelled antibodies and CD4+CD25−CD44low and 
CD4+CD25−CD44high T cells isolated by FACS. In (A) the cells were first gated 
on CD4+CD25− cells. [(B) and (C)] Egr-2 expression in CD4+CD25−CD44low and 
CD4+CD25−CD44high T cells was examined by Real Time PCR (B) and western 
blot (C). -actin serves as a loading control. 
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(Figure 3.13). In contrast, the percentage of CD8+CD44high and CD4+CD44high cells that 
had incorporated BrdU from Egr-2loxP/loxP mice was 14.1% and 12.1%, respectively 
(Figure 3.13). One possible explanation for the hyperproliferation of CD44high cells is 
that it is due to extrinsic factors rather than a cell intrinsic defect in the control of the 
proliferation of CD44high cells. We performed adoptive transfer of isolated T cells into 
C57BL/6 mice in order to investigate this possibility. CD4+ or CD8+ T cells from seven 
month old Egr-2 cKO and Egr-2loxP/loxP mice were labelled with CFSE and then 
transferred. Consistent with the increased proliferation of CD44high T cells in vivo, 
CD44high T cells from Egr-2 cKO mice proliferated more than CD44high cells from Egr-
2loxP/loxP mice (Figure 3.14), indicating that the hyperproliferation of CD44high T cells 
from Egr-2 cKO mice is driven by an intrinsic mechanism.  
These results demonstrate that Egr-2 is involved in controlling the proliferation of 
CD44high effector T cells in vivo. 
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Figure 3.13: Hyper-proliferation of CD44high T cells in Egr-2 cKO mice.       
8 month old Egr-2 cKO and Egr-2loxP/loxP mice were supplied with BrdU in 
drinking water for 9 days. At the end of BrdU treatment, splenocytes were 
stained with anti-CD4, anti-CD44 and anti-BrdU (top) or anti-CD8, anti-CD44 
and anti-BrdU (bottom) and analysed by flow cytometry. BrdU positive T cells 
were quantified after gating on CD4+CD44high, CD4+CD44low, CD8+CD44high or 
CD8+CD44low cells. The data is representative of at least 3 mice of each 
genotype. 
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3.8 T cells in older Egr-2 cKO mice 
 
To determine what effect the hyper-proliferation of CD44high cells had on the peripheral 
CD4+ T cell compartment in vivo, we examined the splenic CD4+ population at 3, 8 and 
15 months of age in Egr-2loxP/loxP and Egr-2 cKO mice. As described above the 
percentages of CD4+ cells that were CD44high and CD62Llow, characteristic of effector 
phenotype T cells, were slightly increased in 3 month old Egr-2 cKO mice (Figure 3.15, 
Figure 3.14: Intrinsic hyper-proliferation of CD44high Egr-2 cKO T cells. 
CD4+ (top) or CD8+ T cells (bottom) were isolated from 7 month old Egr-2 cKO 
and Egr-2loxP/loxP mice and labelled with CFSE. The labelled cells were 
adoptively transferred into C57BL/6 mice. Three weeks after transfer, 
splenocytes were extracted, stained with anti-CD44 and analysed by flow 
cytometry. Cells were gated on the CD44high or CD44low population and CFSE 
dilution was analysed. The data is representative of at least 3 mice of each 
genotype. 
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A). In 8 month old Egr-2 cKO mice, the percentage of CD44high cells was further 
increased and by 15 months of age all of the CD4+ T cells in Egr-2 cKO mice were 
CD44high in contrast to ~20% in Egr-2loxP/loxP mice (Figure 3.15, A). CD62L showed a 
similar, but reversed, pattern with a trend towards expression of low levels of CD62L 
such that all of the CD4+ T cells were CD62Llow in 15 month old Egr-2 cKO mice 
(Figure 3.15, A). These results indicate that Egr-2 is involved in the control of the 
homeostasis of the CD44high population in vivo. 
 
Indeed, the spleens of 15 month old Egr-2 cKO mice were strikingly enlarged, with a 
size 5 to 10 times larger than those from age matched Egr-2loxP/loxP mice (Figure 3.15, 
C). Examination of the cellular composition of these spleens from Egr-2 cKO mice 
revealed that the CD4+ population was massively increased, more than three fold, 
compared to age matched Egr-2loxP/loxP mice (Figure 3.15, D). In addition to the 
expression of high levels of CD44 and low levels of CD62L, these cells in Egr-2 cKO 
mice also expressed high levels of CD25 and CD69 (Figure 3.15, A). CD8+ cells were 
also slightly increased in older Egr-2 cKO mice and had a similar increase in cells with 
an effector phenotype (Figure 3.15, B and D). 
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Figure 3.15: Accumulation of effector phenotype T cells in Egr-2 cKO 
mice. [(A) – (B)] Splenocytes were extracted Egr-2 cKO and Egr-2loxP/loxP mice 
of different ages as indicated, stained with the indicated fluorochrome labelled 
antibodies and analysed by flow cytometry. Expression of CD69, CD25, CD44 
and CD62L was examined on gated CD4+ (A) or CD8+ (B) cells. The data in (A) 
and (B) is representative of at least 2 mice of each genotype. (C) Spleen size in 
15 month old Egr-2 cKO and Egr-2loxP/loxP mice. (D) Total number of CD4+ and 
CD8+ T cells in spleens from older Egr-2 cKO and Egr-2loxP/loxP mice; presented 
as mean ± standard deviation from 3 mice of each genotype.  
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3.9 Lupus-like autoimmunity in older Egr-2 cKO mice 
 
In addition to the splenomegaly and lymphoproliferation in older Egr-2 cKO mice, we 
found that older Egr-2 cKO mice displayed symptoms of a lupus-like autoimmune 
disease. Egr-2 cKO mice aged more than 1 year displayed hair loss (Figure 3.16, A) and 
became lethargic. By 15 months of age more than half the Egr-2 cKO mice had died (12 
out of 20 mice), whereas no death was observed in age matched Egr-2loxP/loxP mice. 
Histological examination revealed an accumulation of mononuclear cells in the liver 
and kidney (Figure 3.16, B). Staining of these sections with antibodies against B and T 
cell markers revealed that the majority of the cells were T cells with B cells accounting 
for a small percentage of the cells (Figure 3.16, F). Closer examination of the 
histological sections revealed the presence of glomerular hyperplasia while 
immunohistochemistry detected the deposition of immune complexes in the glomeruli 
(Figure 3.16, D and E). In addition to these signs of glomerulonephritis, protein was 
detected in the urine of Egr-2 cKO mice (Figure 3.16, C). The total serum Ig was 
increased in Egr-2 cKO mice to around 3 times the level observed in Egr-2loxP/loxP mice 
(Figure 3.17, A). Inspection of the Ig subclasses revealed that only the TH1 dependent 
IgG2a subclass was significantly increased (Figure 3.17, A), approximately 5 fold, in 
Egr-2 cKO mice compared to Egr-2loxP/loxP mice. Importantly, we detected auto-
antibodies directed against the nuclear components histone and dsDNA in Egr-2 cKO 
mice (Figure 3.17, B); a hallmark of lupus. The titre of auto-antibodies against histone 
and dsDNA increased with age and paralleled the progressive accumulation of 
CD4+CD44high T cells (Figure 3.15, A). In Egr-2 cKO mice aged 3 months, the 
percentage of CD44high T cells in the spleen was only slightly increased and the levels of 
anti-dsDNA and -histone auto-antibodies were normal. Auto-antibodies were detected 
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after 6 months and this was further increased in 12 month old mice (Figure 3.17, B), 
mirroring the progressive accumulation of activated CD44high effector T cells (Figure 
3.15). Disease incidence was similar in male and female Egr-2 cKO mice (data not 
shown). Based upon these clinical, histological and serological findings these Egr-2 
cKO mice appear to have an autoimmune disease similar to lupus. Thus, Egr-2 
deficiency in T cells leads to the loss of self tolerance and the development of a lupus-
like autoimmune disease. 
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Figure 3.16: Lupus-like autoimmunity in older Egr-2 cKO mice. (A) Skin 
lesions in 15 month old Egr-2 cKO mice compared to age-matched Egr-2loxP/loxP 
mice. (B) Photomicrographs of spleen, liver and kidney tissues from these mice 
(×10) stained with haematoxylin-eosin (H-E). (C)  Proteinuria in age-matched 
Egr-2loxP/loxP and Egr-2 cKO mice. Data is the mean ± standard deviation of 
values from 10 mice per group. (D) Glomeruli of a 15-month old Egr-2 cKO 
mouse and an aged-matched Egr-2loxP/loxP mouse. (E) Immune complex 
deposition in glomeruli of 15-month old Egr-2 cKO but not in age-matched Egr-
2loxP/loxP mice as detected by fluorescently labelled anti-mouse Ig (red). The 
glomeruli were visualised by DAPI counterstaining in (E). (Figure continued 
overleaf). 
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Figure 3.16: Lupus-like autoimmunity in older Egr-2 cKO mice (cont’d). (F) 
Infiltration of T cells in kidney sections of Egr-2 cKO mice. Kidney tissue 
sections from Egr-2 cKO mice were stained with antibodies against CD3 (red) 
and B220 (green). The sections were counterstained with DAPI for nuclear 
staining.  
F 
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3.10 Auto-antibody production is T cell dependent 
 
In light of the normal expression of Egr-2 in B cells from Egr-2 cKO mice (Figure 3.2, 
D) and the lack of accumulation of B cells in inflamed tissues (Figure 3.16, F), we 
speculated that the CD4+ T cells may be driving the development of autoimmunity in 
Egr-2 cKO mice. To investigate this, Egr-2 cKO CD4+ T cells were isolated, mixed 
with Egr-2loxP/loxP T cell depleted splenocytes and transferred into RAG-2−/− mice. As a 
control, Egr-2loxP/loxP CD4+ T cells were isolated, mixed with Egr-2 cKO T cell depleted 
splenocytes and transferred into RAG-2−/− mice. 75 days later, auto-antibodies against 
histone and dsDNA were detected in the sera of mice that received Egr-2 cKO CD4+ T 
cells and Egr-2loxP/loxP T cell depleted splenocytes, but not those that received Egr-
2loxP/loxP CD4+ T cells and Egr-2 cKO T cell depleted splenocytes (Figure 3.17, C). 
These results demonstrate that Egr-2 cKO CD4+ T cells can direct the production of 
auto-antibodies by Egr-2loxP/loxP B cells and indicate that Egr-2 deficiency in CD4+ T 
cells is sufficient to initiate auto-antibody production and, presumably, autoimmunity.  
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Figure 3.17: Development of autoantibodies in Egr-2 cKO mice. All the 
antibodies were measured by ELISA and presented either as mg/ml or 
absorbance (O.D.). (A) Serum concentration of total Ig and Ig isotypes in Egr-2 
cKO and Egr-2loxP/loxP mice. Data represent the mean ± standard deviation, n = 
24 aged 6 - 12 months. (B) Serum concentration of IgG antibodies against 
dsDNA and histone in age matched Egr-2 cKO and Egr-2loxP/loxP mice (n = 6 per 
group). (C) Serum concentration of IgG antibodies against dsDNA and histone 
in RAG-2−/− mice that were recipients of CD4+ T cells from Egr-2 cKO and T 
cell-depleted splenocytes from Egr-2loxP/loxP mice or CD4+ T cells from Egr-
2loxP/loxPand T cell-depleted splenocytes from Egr-2 cKO (n = 5 per group).  
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3.11 Egr-2 and p21cip1 
 
Previous work by our group found that transfection of Egr-2 into the T cell hybridoma 
cell line MF2.2D9 resulted in an increase in the expression of the cyclin-dependent 
kinase inhibitor protein (CDKI) p21cip1 (Anderson et al., 2006); a negative regulator of 
cell cycle progression (see Sherr and Roberts, 1999). p21cip1 KO mice on a mixed 
129/Sv × C57BL/6 background develop a lupus-like autoimmune disease suggesting 
that p21cip1 is involved in tolerance (Balomenos et al., 2000). To investigate whether 
p21cip1 may play a role in the Tg4 mouse model of tolerance we examined the 
expression of p21cip1 in the A0, A2, T0 and T2 populations by western blot. We could 
not detect p21cip1 expression in either A0 or T0 unstimulated populations (Figure 3.18, 
A). We found that there was very little p21cip1 in A2 cells (Figure 3.18, A), perhaps 
because of the time point of stimulation (see also below). However, p21cip1 was readily 
detectable in the T2 population (Figure 3.18, A). This pattern of p21cip1 expression 
correlates with that of Egr-2; i.e. undetectable in unstimulated populations but increased 
after antigen stimulation of both activated and tolerant T cells. To investigate whether 
Egr-2 is necessary for p21cip1 induction, we examined the expression of p21cip1 after 
TCR stimulation of Egr-2 cKO and Egr-2loxP/loxP T cells by western blot and Real Time 
PCR. In contrast to Egr-2loxP/loxP T cells, which strongly upregulated p21cip1 protein 
after TCR stimulation, Egr-2 cKO T cells showed only a weak induction of p21cip1 
protein (Figure 3.18, B). Thus, Egr-2 is necessary for induction of p21cip1 protein 
expression after TCR engagement. However, when we examined the expression of 
p21cip1 at the mRNA level 6 hours after TCR engagement we could not detect any 
difference between Egr-2loxP/loxP and Egr-2 cKO T cells (Figure 3.18, C). Since Egr-2 is 
expressed rapidly after stimulation we speculated that we might see a difference at an 
earlier time point. Indeed, Egr-2loxP/loxP T cells stimulated for 2 hours had a 3 fold 
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increase in expression of p21cip1 compared to Egr-2 cKO T cells stimulated for 2 hours 
(Figure 3.18, C). Thus, the peak of p21cip1 mRNA expression observed 2 hours after 
TCR stimulation of Egr-2loxP/loxP T cells is absent in the Egr-2 cKO T cells. These data 
indicate that the immediate induction of p21cip1 after TCR stimulation is, at least 
partly, dependent upon Egr-2. 
Given that Egr-2 is expressed in CD44high T cells (Figure 3.12), and that Egr-2 
deficiency leads to hyper-proliferation and accumulation of CD44high T cells in vivo 
(Figures 3.13, 3.14 and 3.15), we considered the possibility that Egr-2 may be involved 
in the expression of p21cip1 in CD44high T cells. To investigate this, we examined the 
expression of p21cip1 in CD4+CD25−CD44high and CD4+CD25−CD44low T cells from 
Egr-2loxP/loxP and Egr-2 cKO mice. We found that the CD44high population expressed 
approximately 5 fold higher levels of p21cip1 than the CD44low population in Egr-
2loxP/loxP mice (Figure 3.18, D).  This pattern of p21cip1 expression correlates with that 
of Egr-2 in Egr-2loxP/loxP mice (Figure 3.12). In contrast, the CD44high population in Egr-
2 cKO mice had more than a 3 fold reduction in expression of p21cip1 compared to 
Egr-2loxP/loxP CD44high cells (Figure 3.18, D). These results indicate that Egr-2 is 
involved in the expression of p21cip1 by CD44high T cells and, taken together with the 
expansion of this population in Egr-2 cKO mice in vivo, suggests that Egr-2 may be 
involved in the control of the homeostasis of CD44high T cells by the induction of 
p21cip1. 
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Since Egr-2 is a transcription factor, and given the kinetics of Egr-2 and p21cip1 
expression, we hypothesised that Egr-2 might directly regulate the expression of 
p21cip1. To investigate this we examined the 10kb directly upstream of the 
transcriptional start site of the p21cip1 gene, as defined in Ensembl, for the presence of 
potential Egr-2 binding sites. We found a sequence similar to the Egr-2 “consensus” site 
Figure 3.18: Expression of p21cip1 in tolerant and Egr-2 cKO T cells. (A) 
Transgenic Tg4 T cells were tolerised by 10 i.n. administrations of 100µg of the 
Ac1-9[4Y] peptide from myelin basic protein as described (Anderson et al., 
2006). Resting (A0 and T0) and in vivo stimulated (A2 and T2) naïve (A) and 
tolerant (T) CD4+ Tg4 T cells were isolated and p21cip1 expression examined 
by western blot (A). [(B) and (C)] Splenic CD4+ cells were isolated from Egr-2 
cKO and Egr-2loxP/loxP mice and stimulated for the indicated time periods (C) or 
for 16 hours (B). p21cip1 expression was analysed by western blot (B) and 
Real Time PCR (C). (D) CD4+CD25−CD44low and CD4+CD25−CD44high T cells 
were isolated from 8 month old Egr-2 cKO and Egr-2loxP/loxP mice by FACS and 
p21cip1 expression examined by Real Time PCR. 
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defined by Swirnoff and Milbrandt (1995); nucleotides -56 to -48 relative to the 
transcriptional start site (Figure 3.19, A). Notably, this sequence GAGGGGGCG has G 
residues at the 1, 3, 5, 6, 7 and 9 positions which are important contacts in the crystal 
structure of DNA bound Egr-1 (Pavletich and Pabo, 1991); the closest homologue to 
Egr-2 in terms of primary structure. To investigate whether Egr-2 can bind to this site 
an EMSA was performed. MF2.2D9 cells express Egr-2 after stimulation with anti-CD3 
and anti-CD28 coated beads (Figure 3.19, D). Nuclear proteins from stimulated, but not 
unstimulated, MF2.2D9 cells bound to a nucleotide probe corresponding to this site 
from the p21cip1 promoter (Figure 3.19, B lanes 1 and 2). This complex could be 
supershifted by the addition of an antibody against Egr-2 but not by an anti-Egr-3 
antibody (Figure 3.19, B lanes 3 and 4). To determine whether this is relevant in vivo, a 
ChIP assay was performed. We found that the p21cip1 promoter could be 
immunoprecipitated from Egr-2 transduced cells by anti-Egr-2, but not irrelevant 
control, antibody (Figure 3.19, C). The lack of immunoprecipitation from EGFP 
transduced control cells, in which Egr-2 is not expressed (Figure 3.19, D), confirms the 
specificity of immunoprecipitation by the anti-Egr-2 antibody (Figure 3.19, C). In 
contrast, the SOCS3 CDS was not detected in anti-Egr-2 immunoprecipitates from Egr-
2 transduced cells by PCR (Figure 3.19, C). These data demonstrate that, at least in 
MF2.2D9 cells, Egr-2 directly binds to the p21cip1 promoter. Taken together with the 
results from Egr-2 cKO T cells, these data suggest that Egr-2 directly regulates p21cip1 
expression immediately after TCR engagement and in CD44high T cells. The correlation 
of Egr-2 and p21cip1 expression in Tg4 mice, and the autoimmune syndrome in Egr-2 
cKO mice, suggests that Egr-2 mediated induction of p21cip1 may be involved in 
maintaining self tolerance. 
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Figure 3.19: Interaction of Egr-2 with the p21cip1 promoter in vitro and in 
vivo. (A) Identification of a potential Egr-2 binding site in the proximal promoter 
region of the p21cip1 gene. (B) Electrophoretic mobility-shift assay to evaluate 
the binding of Egr-2 to oligonucleotides corresponding to this sequence from the 
p21cip1 promoter. Nuclear extracts from stimulated and unstimulated MF2.2D9 
cells were incubated with radioactively labelled oligonucleotides and complexes 
were resolved by native gel electrophoresis. Where indicated anti-Egr-2 or anti-
Egr-3 antibody was added. (C) Chromatin immunoprecipitation assay. EGFP or 
Egr-2 transduced MF2.2D9 T cells were crosslinked with formaldehyde and 
chromatin immunoprecipitated with anti-Egr-2 or irrelevant control antibody. The 
immunoprecipitated DNA was purified and used as a template for PCR. (D) 
EGFP and Egr-2 transduced cells were stimulated with anti-CD3 and anti-CD28 
for 16 hours or left unstimulated. Expression of Egr-2 was analysed by western 
blot. 
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3.12 Microarray analysis of Egr-2 cKO T cells 
 
While defective expression of p21cip1 provides a plausible explanation for the hyper-
proliferation and accumulation of effector T cells in vivo, whether defective expression 
of p21cip1 can fully explain the loss of tolerance in Egr-2 cKO mice is unclear. Since 
Egr-2 is a transcription factor it could potentially regulate hundreds of genes, any 
number of which might be involved in the maintenance of tolerance. Thus, there are 
likely to be other genes regulated by Egr-2 that are relevant to autoimmune disease 
development in Egr-2 cKO mice. To examine the effects of Egr-2 in naïve and activated 
T cells, we assessed the genome-wide transcriptional profiles of unstimulated and anti-
CD3 stimulated Egr-2loxP/loxP and Egr-2 cKO CD4+ T cells using Illumina MouseRef-8 
BeadChip expression arrays. These arrays consist of 50-mer oligonucleotide probes 
directed against ~24,000 well annotated RefSeq transcripts. CD4+ T cells from 3 month 
old Egr-2loxP/loxP and Egr-2 cKO mice, which have similar percentages of CD4+CD44high 
T cells (Figure 3.7, E), were used in order to try to minimise complications from the 
increased percentage of effector T cells in Egr-2 cKO mice. CD4+ T cells were isolated, 
stimulated with anti-CD3 or left unstimulated, and RNA was extracted and purified as 
described in the methods section. RNA labelling, array scanning and data normalisation 
was performed by the Genome Centre, Queen Mary, University of London.  
Following receipt of the normalised data, we first examined the expression of several 
well characterised T cell markers on the array. CD3ε was expressed at similar levels in 
Egr-2loxP/loxP and Egr-2 cKO CD4+ T cells (Figure 3.20). Furthermore, markers of 
activated T cells such as CD44, CD25 and CD69 were upregulated normally in Egr-2 
cKO cells in response to TCR stimulation with an expression level similar to Egr-
2loxP/loxP CD4+ T cells (Figure 3.20). Consistent with the previous findings, Egr-2 was 
undetectable in unstimulated Egr-2 cKO CD4+ T cells and only very weak expression 
102 
was detected in stimulated Egr-2 cKO CD4+ T cells (Figure 3.20). These data indicate 
that the T cells were successfully activated and that the cells were effectively Egr-2 null 
as expected.  
 
 
Egr-1 was expressed at similar levels in Egr-2loxP/loxP and Egr-2 cKO CD4+ T cells, 
while Egr-3 and Egr-4 expression could barely be detected (Figure 3.21). The low 
expression of Egr-3 may be due to the time point examined since Powell and colleagues 
found expression of Egr-3 mRNA only at very early time points after TCR engagement 
(Safford et al., 2005). In any case, these results suggest that there is no compensatory 
Figure 3.20: Microarray results for well characterised T cell markers and 
Egr-2. Splenic CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice, 
stimulated with anti-CD3 for 6 hours and global gene expression profiles 
analysed by microarray. Normalised expression on the microarray is shown. 
Where the gene was present more than once (CD44, CD69), the entry with the 
highest expression is presented. 
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up-regulation of other Egr family members in the Egr-2 cKO T cells at least at this time 
point. 
 
 
To validate the microarray results, Real Time RT-PCR was performed. Thirty genes 
were validated by Real Time RT-PCR (Figures 3.22-3.28 and data not shown); of these 
only two did not correlate with the microarray (data not shown). These two genes both 
had low intensity of less than 20 (a detection p-value between 0.05 and 0.01) on the 
microarray suggesting that perhaps our criteria for selection should have been more 
stringent and that a signal intensity of less than 20 (a detection p-value greater than 
0.01) should be considered background. While the patterns of expression usually 
correlated fairly well with those from the microarray, the relative levels of expression 
sometimes differed. For example, Figure 3.22 compares the expression of IL-2 and IFN-
γ in unstimulated and stimulated Egr-2 cKO and Egr-2loxP/loxP CD4+ T cells as detected 
by the two methods. Both methods showed similar patterns of cytokine expression but 
the microarray showed only a slight increase in the expression of IFN-γ while Real 
Time PCR found a 2 fold increase in expression of this cytokine in Egr-2 cKO CD4+ T 
Figure 3.21: Microarray results for other Egr family genes. Splenic CD4+ 
cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice, stimulated with anti-
CD3 for 6 hours and global gene expression profiles analysed by microarray. 
Normalised expression on the microarray is shown.  
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cells compared to Egr-2loxP/loxP cells. This quantitative difference may be due to the 
different sensitivity of the two techniques.  
 
 
The full set of microarray data is available from the ArrayExpress database 
(www.ebi.ac.uk/arrayexpress) under accession number E-MEXP-1698. We focussed on 
genes that showed a difference of at least three-fold between Egr-2loxP/loxP and Egr-2 
cKO CD4+ T cells (see section 2.20). More than 500 genes met these criteria, of these 
nearly a third were of unknown function. More than a quarter of the remaining genes 
were metabolic enzymes, more than double any other category, consistent with a 
previous report from Egr-1, Egr-3 DKO mice (Carter et al., 2007). The next most 
common categories were cell surface receptors; cytokines, chemokines and growth 
Figure 3.22: IL-2 and IFN-γ mRNA expression in Egr-2 cKO CD4+ T cells. 
Splenic CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice and 
stimulated with anti-CD3 for 6 hours. (A) Normalised expression on the 
microarray (B) Real Time PCR validation 
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factors; signal transduction proteins and enzymes; and transcription factors; with around 
50 genes in each category. The remaining genes encoded structural cytoskeletal proteins 
and ion channels and transport molecules; with around 20 genes in each of these two 
categories. Some of the largest changes in expression levels were in cytokine genes and 
other signalling molecules. In particular, pro-inflammatory cytokines were increased 
while TH2 cytokines were decreased in stimulated Egr-2 cKO cells compared to 
stimulated Egr-2loxP/loxP cells. Given their potential relevance to T cell function, many of 
these genes were selected for Real Time PCR validation. 
 
3.12.1 Genes up-regulated in Egr-2 cKO cells  
 
3.12.1.1 Proinflammatory cytokines and related genes 
 
Inspection of the microarray results revealed that the expression of two of the IL-17 
family cytokines was higher in stimulated Egr-2 cKO CD4+ T cells than in stimulated 
Egr-2loxP/loxP CD4+ T cells. The microarray data showed a five fold increase for IL-17F 
while IL-17A was increased two fold (Figure 3.23, A). Real Time RT-PCR showed a 
3.5 fold increase for IL-17F and a three fold increase for IL-17A confirming the 
increased expression of these two cytokines (Figure 3.23, B).  
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Another pro-inflammatory cytokine, IL-1α, was increased 3 fold in stimulated Egr-2 
cKO CD4+ T cells compared to stimulated Egr-2loxP/loxP CD4+ T cells according to the 
microarray (Figure 3.24, A). Real Time RT-PCR found a four fold difference between 
IL-1α expression in these two populations (Figure 3.24, B).  
 
The microarray also indicated that the Chemokine Receptor CCR6 was increased in 
stimulated Egr-2 cKO CD4+ T cells (Figure 3.24, A). Real Time RT-PCR confirmed a 
four fold increase in stimulated Egr-2 cKO CD4+ T cells compared to Egr-2loxP/loxP 
CD4+ T cells (Figure 3.24, B).  
 
Figure 3.23: IL-17A and IL-17F mRNA expression in Egr-2 cKO CD4+ T 
cells. Splenic CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice 
and stimulated with anti-CD3 for 6 hours. (A) Normalised expression on the 
microarray (B) Real Time PCR validation 
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Interestingly, IL-21, which has been reported to be involved in the generation of IL-17 
producing CD4+ T cells (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007), was 
increased in both unstimulated and stimulated CD4+ T cells from Egr-2 cKO mice 
compared to the corresponding populations from Egr-2loxP/loxP mice, but was 
significantly higher in unstimulated T cells (Figure 3.24, A). Real Time RT-PCR found 
that the difference in stimulated cells was only ~2 fold but in unstimulated cells the 
expression of IL-21 was more than 50 times higher in Egr-2 cKO CD4+ T cells than in 
Egr-2loxP/loxP CD4+ T cells (Figure 3.24, B). In fact the expression of IL-21 in 
unstimulated Egr-2 cKO CD4+ T cells was more than three times the expression in 
stimulated Egr-2 cKO CD4+ T cells (Figure 3.24, B).  
 
Figure 3.24: IL-1α, CCR6 and IL-21 mRNA expression in Egr-2 cKO CD4+ T 
cells. Splenic CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice 
and stimulated with anti-CD3 for 6 hours. (A) Normalised expression on the 
microarray (B) Real Time PCR validation 
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3.12.1.2 Anti-inflammatory and pro-homeostatic cytokines 
 
Interestingly, the anti-inflammatory cytokine IL-10 was increased in both unstimulated 
and stimulated CD4+ T cells from Egr-2 cKO mice compared to the corresponding 
populations from Egr-2loxP/loxP mice (Figure 3.25). In stimulated cells the difference was 
around three fold, as determined by both microarray and Real Time RT-PCR, but in 
unstimulated cells the difference was more than seven times (Figure 3.25).  
 
Intriguingly, the microarray indicated that Egr-2 cKO T cells expressed increased levels 
of the IL-2 related cytokine IL-15 (Figure 3.25, A). Real Time PCR confirmed that IL-
15 was increased around 2.5 times in stimulated CD4+ T cells from Egr-2 cKO mice 
compared to stimulated Egr-2loxP/loxP CD4+ T cells (Figure 3.25, B).  
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3.12.2 Genes down-regulated in Egr-2 cKO cells  
 
3.12.2.1 TH2 cytokines 
 
The most prominent family of genes that was downregulated more than three-fold was 
TH2 cytokines. IL-4, IL-5 and IL-13 were not expressed in the absence of stimulation, 
while they were reduced at least three fold in Egr-2 cKO CD4+ T cells compared to Egr-
2loxP/loxP cells in response to anti-CD3 stimulation according to the microarray (Figure 
3.26, A and data not shown). Real Time PCR found that IL-4 was reduced more than 
Figure 3.25: IL-15 and IL-10 mRNA expression in Egr-2 cKO CD4+ T cells. 
Splenic CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice and 
stimulated with anti-CD3 for 6 hours. (A) Normalised expression on the 
microarray (B) Real Time PCR validation 
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three fold, while IL-13 was reduced more then four fold, in stimulated Egr-2 cKO CD4+ 
T cells compared to stimulated Egr-2loxP/loxP cells (Figure 3.26, B). 
 
 
3.12.2.2 Anti-apoptotic genes 
 
Although the microarray found only a slight decrease in the expression of the anti-
apoptotic gene Bcl-2 (Figure 3.27, A), Real Time PCR found that the expression of this 
gene was decreased around two fold in stimulated Egr-2 cKO CD4+ T cells compared to 
stimulated Egr-2loxP/loxP cells (Figure 3.27, B). Bcl-XL showed a similar expression 
profile; however, the level of expression was very low (data not shown). 
Figure 3.26: IL-4 and IL-13 mRNA expression in Egr-2 cKO CD4+ T cells. 
Splenic CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice and 
stimulated with anti-CD3 for 6 hours. (A) Normalised expression on the 
microarray (B) Real Time PCR validation 
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In summary, we discovered that Egr-2 cKO T cells express increased levels of pro-
inflammatory cytokines and decreased levels of TH2 cytokines.  
 
3.13 Cytokine profile of Egr-2 cKO T cells 
 
We have demonstrated that Egr-2 cKO T cells express increased levels of pro-
inflammatory cytokine mRNAs after TCR engagement in vitro. To determine whether 
this reflects increased numbers of IFN-γ and IL-17 producing CD4+ T cells in vivo, 
CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice of different ages, 
stimulated with PMA and Ionomycin and IFN-γ and IL-17 production was examined by 
Figure 3.27: Bcl-2 mRNA expression in Egr-2 cKO CD4+ T cells. Splenic 
CD4+ cells were isolated from Egr-2 cKO and Egr-2loxP/loxP mice and stimulated 
with anti-CD3 for 6 hours. (A) Normalised expression on the microarray (B) 
Real Time PCR validation 
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intracellular cytokine staining. In 3 month old Egr-2loxP/loxP mice, ~2% of CD4+ cells 
produced IFN-γ while IL-17 producing cells could barely be detected (Figure 3.28, A). 
In contrast, in 3 month old Egr-2 cKO mice more than 5% of CD4+ cells produced IFN-
γ and 1.5% produced IL-17 (Figure 3.28, A). While the cytokine profile of 8 month old 
Egr-2loxP/loxP mice was similar to 3 month old Egr-2loxP/loxP mice (Figure 3.28, A), the 
percentages of IFN-γ and IL-17 producing cells in 8 month old Egr-2 cKO mice were 
increased compared to 3 month old Egr-2 cKO mice with more than 10% of cells 
producing IFN-γ and more than 4% of cells producing IL-17 (Figure 3.28, A). Although 
the percentages of cytokine positive cells was increased in 12 month old Egr-2loxP/loxP 
mice, to ~5.5% and ~2% for IFN-γ and IL-17 respectively, this was still significantly 
less than age matched Egr-2 cKO mice in which ~15% were IFN-γ+ and ~9% were IL-
17+ (Figure 3.28, A).  
 
This progressive increase in the percentage of cells producing IFN-γ and IL-17 as the 
mice age parallels the progressive accumulation of CD44high cells (Figure 3.15, A). To 
determine whether the CD44high cells in Egr-2 cKO mice are functionally altered, we 
examined cytokine production by CD4+CD44low and CD4+CD44high cells from 8 month 
old Egr-2loxP/loxP and Egr-2 cKO mice. We found that there was very little cytokine 
production by CD4+CD44low cells in either Egr-2 cKO or Egr-2loxP/loxP mice; less than 
2% produced IFN-γ and less than 1% produced IL-17 (Figure 3.28, B). However, 
around 14% of CD4+CD44high cells from Egr-2 cKO mice produced IFN-γ and 7% 
produced IL-17, compared to less than 4% and 2%, for IFN-γ and IL-17 respectively, of 
CD4+CD44high cells in Egr-2loxP/loxP mice (Figure 3.28, B). In addition we found that the 
percentage of CD4+ cells that were CD44high IL-4+ was reduced in Egr-2 cKO compared 
to Egr-2loxP/loxP mice (Figure 3.28, C). Furthermore, the percentage of cells producing 
IL-2 was similar in Egr-2 cKO and Egr-2loxP/loxP mice (Figure 3.28, C) indicating that 
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the expansion of the CD4+CD44high T cell population was not due to enhanced autocrine 
IL-2 signalling. Thus, the CD4+CD44high T cells in Egr-2 cKO mice are predominately 
IFN-γ and/or IL-17 producing effector T cells.  
 
Figure 3.28: Cytokine production by CD4+ T cells in Egr-2 cKO mice. CD4+ 
T cells [(A) and (B)] or splenocytes (C) were isolated from Egr-2 cKO and Egr-
2loxP/loxP mice and stimulated for 5 hours with PMA and Ionomycin and 
intracellular cytokine staining was performed. (A) CD4+ T cells were isolated 
from mice of different ages as indicated and stained with IFN- and IL-17 
antibodies. (B) CD4+ T cells from 8 month old mice and stained with CD44, IFN-
 and IL-17 antibodies. Cytokine positive cells were quantified after gating for 
CD44low or CD44high. (Figure continued overleaf). 
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Figure 3.28: Cytokine production by CD4+ T cells in Egr-2 cKO mice 
(cont’d). (C) Splenocytes from 8 month old mice were stained with CD4, CD44 
and the indicated cytokine antibodies. Cells were gated on the CD4+ population 
and CD44high cytokine positive cells were quantified. 
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Chapter 4: DISCUSSION 
 
We found that Egr-2 is expressed in tolerant T cells after in vivo antigen stimulation. On 
the basis of this finding we generated Egr-2 cKO and Tg mice to examine the roles of 
Egr-2 in T cells in vivo.  
 
4.1 Egr-2 in T cell development 
 
Although Egr-2 is expressed in thymocytes and has been implicated in -selection 
(Carleton et al., 2002), we did not detect any defects in T cell development in Egr-2 
cKO mice; although we cannot formally exclude the possibility of altered positive or 
negative selection. The apparently normal thymocyte development suggests that either 
Egr-2 function at this point is redundant, as has been suggested for Egr-1 and Egr-3 
(Carter et al., 2007), or that Cre mediated deletion was incomplete at this stage.  
 
In contrast, Egr-2 Tg mice had profound defects in thymocyte development with 
accumulation of DN4 and ISP cells; those stages that immediately follow passage 
through the -selection checkpoint. These results are strikingly similar to those from 
Egr-1 and Egr-3 transgenic mice, which also show increased numbers of DN4 and ISP 
cells (Miyazaki, 1997; Xi and Kersh, 2004), and are consistent with the notion that Egr 
proteins have overlapping roles during thymocyte development (Carter et al., 2007). As 
observed for Egr-1 and Egr-3 (Miyazaki, 1997; Xi and Kersh, 2004), constitutive 
expression of Egr-2 appears to inhibit further development of these ISP cells. However, 
there are some DP cells and CD4+ and CD8+ SP cells suggesting that this block is 
incomplete. There are two distinct possible explanations for these observations both of 
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which have some support from the literature. The first is that constitutive Egr-2 
expression in ISP cells directly impairs the further development of the ISP cells. 
Supporting this idea, Kersh and colleagues found that constitutive Egr-3 expression 
impaired both the expression and the activity of the transcription factor RORγt (Xi et 
al., 2006) which is important for the DP cell phenotype (He et al., 2000; Kurebayashi et 
al., 2000; Sun et al., 2000). As the authors of that study noted, this model implies that 
silencing of Egr protein expression in ISP cells is required for efficient progression to 
the DP stage (Xi et al., 2006). The other possibility is that constitutive expression of 
Egr-2 permits the development of some cells that do not have a correctly rearranged 
TCR  chain and would normally fail the -selection checkpoint. These cells develop to 
the ISP stage but are unable to develop further due to a lack of other, presumably pre-
TCR derived, signals. In contrast, those cells that have a correctly rearranged TCR  
chain and hence a pre-TCR complex may continue to the next stage of development as 
normal despite the constitutive expression of Egr-2. So rather than inhibiting the 
development of the ISP cells, this scenario envisages that constitutive Egr-2 expression 
drives the further development of cells that would otherwise fail -selection and implies 
that these ISP cells would never progress to the DP stage as they are functionally 
deficient. Consistent with this possibility, constitutive expression of Egr-1 on a RAG-
1−/− background permitted the development of cells to the DN4 and ISP stages but no 
further, suggesting that additional signals are required for maturation to the DP stage 
(Miyazaki, 1997). While circumstantial evidence (P Wang, personal communication) 
may tend to support the former possibility, the latter possibility cannot yet be formally 
excluded. Analysis of the TCR  loci in these ISP cells in Egr-2 cKO mice should help 
to definitely distinguish between these two hypotheses. 
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4.2 Egr-2 in peripheral T cells 
 
Despite the apparently normal T cell development in Egr-2 cKO mice, we found that the 
total number of peripheral CD4+ and CD8+ T cells in three month old mice was reduced 
to around two-thirds of the level of age matched Egr-2loxP/loxP mice. While the 
expression of activation markers by peripheral CD4+ T cells was largely normal in 
young Egr-2 cKO mice, there was a slight increase in the proportion of cells expressing 
high levels of the marker CD44. The roles of Egr-2 in CD44high cells are discussed 
further below (see section 4.4).  
 
In the periphery of Egr-2 Tg mice the most striking change is the presence of a large 
number of cells that appear to be CD8+ ISP thymocytes. This population may represent 
CD8+ ISP cells that have escaped from the thymus into the periphery. In support of this 
concept, recent discoveries have indicated that immature thymocytes are indeed 
exported from the thymus (Lambolez et al., 2006). 
 
However, the continued presence of this CD8+CD3− population in the periphery raises 
another question: how do these CD8+CD3− cells survive? For naïve T cells, covert 
interactions with peptide-MHC ligands, together with exposure to cytokines such as IL-
7, is required for their homeostasis and survival in the periphery (Kirberg et al., 1997; 
Ernst et al., 1999; Seddon and Zamoyska, 2002; Surh and Sprent, 2008). Since these 
CD8+CD3− cells do not express a TCR complex there can be no TCR signalling so one 
would expect that these cells would slowly disappear over time, particularly in older 
mice which have decreased thymic output. However, we did not observe a diminution 
of this population in older Egr-2 Tg mice (P Wang, personal communication). While the 
aberrant nature of these cells means they may well have altered homeostatic 
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requirements, an intriguing possibility is that Egr-2 expression itself may help to 
facilitate the survival of these cells. Since Egr-2 is expressed by TCR signals it could be 
one of the downstream effectors of the survival signal provided by covert interactions 
with peptide-MHC ligands. Thus constitutive Egr-2 expression in these CD8+CD3− cells 
may provide this signal which, in conjunction with homeostatic cytokines, permits the 
persistence of CD8+CD3− cells in the periphery. Conversely in Egr-2 cKO mice, the 
lack of Egr-2 in naïve T cells may impair their survival resulting in the decreased 
numbers of peripheral T cells observed in young Egr-2 cKO mice. Consistent with this 
idea, Egr-1 has been reported to be induced in TCR Tg T cells upon interaction with 
APC in the absence of exogenous antigen, and Egr-1 KO mice also reportedly have 
decreased numbers of naïve splenic T cells (Bettini et al., 2003). Further experiments 
will be needed to test this hypothesis. In particular, it would be interesting to transfer 
naïve Egr-2 Tg TCR Tg T cells into MHC deficient hosts to determine whether they 
have a relative survival advantage compared to naïve wild type TCR Tg T cells. 
 
4.3 Egr-2 in T cell activation 
 
Over-expression of Egr-2 in T cell lines results in reduced production of IL-2 after TCR 
stimulation and a slight up-regulation of the E3 Ubiquitin ligase Cbl-b (Safford et al., 
2005). Based on these findings, the authors of that study hypothesised that the 
mechanism for Egr-2 in maintaining T cell tolerance was down-regulation of TCR 
signalling. However, we did not detect a difference between naïve Egr-2 cKO and naïve 
Egr-2loxP/loxP T cells in terms of ERK MAPK activation following TCR stimulation in 
vitro. In addition, we did not observe hyper-proliferation of naïve Egr-2 cKO T cells in 
response to primary TCR stimulation in vitro, which would be expected if Egr-2 
negatively regulated TCR signalling. On the contrary, we found that naïve Egr-2 cKO T 
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cells were consistently slightly hypo-responsive to primary TCR stimulation. This data 
suggests that, rather than simply inhibiting T cell activation as has been proposed 
(Safford et al., 2005), Egr-2 has a more complex role in T cell activation. 
 
One possible explanation for this result is that Egr-2 expression provides some 
protection from apoptosis rendering Egr-2 cKO cells more susceptible to AICD. 
Although we did not detect increased apoptosis after T cell activation, suggesting that 
the impaired proliferation of Egr-2 cKO cells is not due to increased cell death, we have 
not exhaustively examined all time points after stimulation and cannot formally exclude 
this possibility. Indeed, the microarray found that the expression of the anti-apoptotic 
gene Bcl-2 was slightly decreased in stimulated Egr-2 cKO cells compared to 
stimulated Egr-2loxP/loxP cells; which is consistent with this hypothesis. Furthermore, 
recently it has been reported that Egr-2 is required for maximal induction of Bcl-2 
during positive selection (Lauritsen et al., 2008). Future studies will be needed to 
definitely determine whether, and at what stages, Egr-2 cKO cells are more susceptible 
to AICD and the mechanisms involved. 
 
4.4 Egr-2 in CD44high cells 
 
While we and others had previously found that Egr-2 is induced in tolerant T cells 
following TCR stimulation (Safford et al., 2005; Anderson et al., 2006 - see also Figure 
3.1), the populations that express Egr-2 in vivo in normal mice were unknown. We have 
now demonstrated that Egr-2 is normally expressed in CD44high T cells in vivo in the 
absence of overt antigen stimulation. In addition, we found that Egr-2 deficiency results 
in the hyper-proliferation and progressive accumulation of CD44high T cells such that 
these cells became the predominant population in older Egr-2 cKO mice. Collectively, 
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this data suggests that Egr-2 is involved in controlling the homeostasis of CD44high T 
cells in vivo. 
 
4.4.1 Egr-2 in the homeostasis of CD44high cells 
 
CD44 is low on naïve cells and up-regulated after activation; thus, CD44high cells are 
generally considered to be effector or memory cells (see Surh and Sprent, 2008). 
Although CD44high cells are generated in response to antigen stimulation, CD44high cells 
are also found in TCR Tg mice in the absence of cognate antigen stimulation and in 
mice fed low molecular weight diets (see Surh and Sprent, 2008). The CD44high T cells 
in these mice are presumably generated in response to environmental antigens, such as 
commensal flora, or self-antigen (see Surh and Sprent, 2008). Therefore the responses 
of CD44high T cells have to be controlled to prevent the possible development of 
autoimmune or hypersensitivity reactions. In contrast to the resting CD44low naïve T 
cells, CD44high cells undergo intermittent proliferation in response to homeostatic 
stimuli such as peptide-MHC and cytokines (Seddon et al., 2003; Boyman et al., 2006; 
Robertson et al., 2006; Purton et al., 2007; Surh and Sprent, 2008). The finding that 
Egr-2 is expressed by CD44high cells in the absence of overt antigen stimulation suggests 
that covert homeostatic interactions with peptide-MHC, or perhaps cytokine signalling, 
may induce Egr-2. We hypothesise that the expression of Egr-2 in CD44high cells may 
be induced from these homeostatic stimuli to control the proliferation of CD44high T 
cells.  
 
However, while the expression of Egr-2 was significantly increased in CD44high cells 
compared to CD44low cells, this finding does not necessarily mean that CD44low cells do 
not express Egr-2 in response to homeostatic stimuli. This decreased expression of Egr-
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2 in CD44low cells may simply reflect the fact that CD44low cells are apparently less 
responsive than CD44high cells to antigen stimulation in vivo (Veiga-Fernandes et al., 
2000). Indeed, as outlined above (see section 4.2) some of the unexpected findings from 
Egr-2 cKO and Tg mice could perhaps be explained by a role for Egr-2 in the 
homeostasis of naïve T cells by supporting their survival.  
 
Thus in Egr-2 cKO mice, naïve CD44low T cells appear hypo-responsive while effector 
CD44high T cells are hyper-responsive. At first it may seem peculiar that naïve Egr-2 
cKO T cells are hypo-responsive while CD44high T cells are hyper-responsive. However, 
it is not without precedent that a given transcription factor should have apparently 
different roles in these disparate cell types. Indeed, mice with a mutation in a critical 
enzyme in the NF-κB2 pathway had conflicting reports – with some groups reporting 
enhanced, and others diminished, responses to stimulation – which were resolved by the 
finding that the CD44low cells are hyper-proliferative while the CD44high cells are hypo-
proliferative and enact a suppressor function on CD44low cells in co-culture (Ishimaru et 
al., 2006). This insight was only obtained by examining the responses of these two 
populations individually. Therefore, to definitively determine the effects of Egr-2 in 
CD44low and CD44high cell proliferation in response to TCR engagement, these cells 
should be isolated and stimulated separately. To date we have not been able to do this 
due to technical difficulties and this experiment remains for future investigation.  
 
Based on the expression of phenotypic markers, such as CD44 and CD62L, it is not 
possible to definitively determine whether these hyper-reactive CD44high cells are 
effector or memory cells. Therefore, whether Egr-2 primarily affects effector or 
memory cells, or affects both equally, remains to be established. The development of 
TCR transgenic Egr-2 cKO mice may help to resolve this question.  
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In our Tg4 model of tolerance the T cells were first activated with antigen in vivo and 
then rendered tolerant by persistent antigen stimulation (Anderson et al., 2006). 
Similarly, the other models that found Egr-2 expression in tolerant or anergic cells 
either used T cells that were first activated in vivo by antigen (Safford et al., 2005) or T 
cell lines that were maintained in vitro by intermittent antigen stimulation (Harris et al., 
2004). In all of these scenarios the cells would be more akin to CD44high effector cells 
rather than naïve CD44low cells. In light of these considerations, it is perhaps not 
surprising that we find that Egr-2 is expressed in CD44high cells in vivo. Therefore, 
collectively this data suggests that Egr-2 is involved in the maintenance of the self 
tolerance of CD44high cells in vivo. 
 
4.5 Lupus-like autoimmunity in Egr-2 cKO mice 
 
Consistent with the idea that Egr-2 is involved in self tolerance, we found that Egr-2 
cKO mice developed a late onset lupus-like autoimmune disease. This disease was 
characterised by proteinuria, infiltration of T cells into internal organs, serum anti-
nuclear antibodies and glomerulonephritis. Although we only observed clinical 
symptoms in older Egr-2 cKO mice we did find some signs of autoimmunity in younger 
mice suggesting that perhaps disease development is a gradual process. We observed a 
progressive increase in the serum titre of auto-antibodies directed against dsDNA and 
histone as the mice aged which was concomitant to the increase in the percentages of 
IFN-γ and IL-17 producing CD44high T cells.  
 
FasL has been reported to be regulated by Egr-2 (Mittelstadt and Ashwell, 1999; 
Rengarajan et al., 2000)  and FasL and Fas mutant mice on certain genetic backgrounds 
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develop lupus-like autoimmune disease (Watanabe-Fukunaga et al., 1992; Takahashi et 
al., 1994; Nagata and Suda, 1995) suggesting the possibility that the autoimmunity in 
Egr-2 cKO mice is due to defective FasL expression. However, the diseases in FasL and 
Fas mutant mice on these backgrounds are characterised by the presence of aberrant 
CD3+CD4−CD8−B220+ cells (see Nagata and Suda, 1995); we did not detect any cells 
with a CD3+CD4−CD8−B220+ phenotype in Egr-2 cKO mice at any stage. In addition, 
we did not detect altered FasL expression in Egr-2 cKO cells; perhaps due to 
compensation by Egr-3 (Mittelstadt and Ashwell, 1998; Rengarajan et al., 2000). These 
findings suggest that there are distinct mechanisms for lupus-like disease in Egr-2 cKO 
and FasL mutant mice. 
 
It has been reported that Cre can recognise and catalyse recombination between pseudo-
loxP sites, endogenous DNA sequences present in mammalian genomes that resemble 
loxP sites, in vitro (Thyagarajan et al., 2000). Furthermore, one report using transgenic 
mice expressing Cre have found that Cre expression alone, i.e. in the absence of 
exogenous loxP sites, can have deleterious consequences during spermatogenesis in 
vivo (Schmidt et al., 2000). Nevertheless, CD4+ T cells from hCD2 Cre+ mice had 
normal responses to TCR stimulation and no autoimmunity was observed in hCD2 Cre+ 
mice as old as 20 months (P Wang, personal communication) suggesting that the 
phenotypes seen in Egr-2 cKO mice are due to Egr-2 deletion. Consistent with this, 
defective Egr-2 and Egr-3 expression has been observed in both spontaneous and 
experimentally induced lupus models (Sela et al., 2008). 
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4.6 Homeostasis and tolerance 
 
Notably, several models that have perturbed T cell homeostasis also develop late onset 
autoimmunity (e.g. Balomenos et al., 2000; Murga et al., 2001; Salvador et al., 2002; 
Fanzo et al., 2006; Arias et al., 2007) as we observed in Egr-2 cKO mice. This raises 
the possibility that the observed perturbation of homeostasis may be a precursor to the 
development of autoimmunity. Although traditionally investigated using separate model 
systems, self-tolerance is important for homeostasis and vice versa.  
 
Firstly, the peptide-MHC ligands that are important for the homeostasis of certain T cell 
subsets are ligands to which the T cells should be tolerant, which is established by 
central and/or peripheral tolerance mechanisms. If the T cells were not tolerant to these 
antigens, then not only might it lead to autoimmunity or hypersensitivity but it would 
also perturb T cell homeostasis. I should point out that for the purposes of this 
discussion the nature of the antigen, whether it is derived from self-antigen or 
environmental antigen, is irrelevant as both autoimmunity and hypersensitivity are 
perturbations of homeostasis. Hence the tolerance of T cells to such antigens is also 
important for their homeostasis in the periphery. Secondly, the process of adaptation 
itself is effectively a homeostatic mechanism, albeit a pre-emptive one. This is best 
demonstrated by contrasting the response of tolerant cells with the initial activation of T 
cells by antigen. Primary T cell activation results in an expansion of that T cell clone 
and hence an increase in total T cell numbers. This clonal expansion is then followed by 
a contraction of that clone, once the inciting antigen has been cleared, which acts to 
return total T cell numbers to normal – a well characterised homeostatic mechanism. In 
contrast, persistent stimulation in adaptive tolerance results in a progressive down-
regulation of the response of the T cells such that the T cells eventually show only 
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minimal proliferation in response to antigen (Tanchot et al., 2001; Singh and Schwartz, 
2003; Anderson et al., 2006). Hence the process of adaptation turns an agonist signal 
that initially induces strong proliferation into one that does not. Viewed in these terms 
the process of adaptation is a homeostatic mechanism as it serves to oppose an increase 
in total T cell numbers. Thirdly, both homeostasis, to some extent depending on the cell 
type, and tolerance are dependent upon the persistence of peptide-MHC. Many T cells, 
notably naïve T cells and some subsets of effector cells, are partly dependent on 
peptide-MHC derived signals for their homeostasis in the periphery (Kirberg et al., 
1997; Ernst et al., 1999; Seddon and Zamoyska, 2002; Seddon et al., 2003; Boyman et 
al., 2006; Robertson et al., 2006; Surh and Sprent, 2008). Equally, the persistence of 
antigen is required for the maintenance of adaptive tolerance in the periphery (Tanchot 
et al., 2001; Singh and Schwartz, 2003). Therefore, at least for some cells, the 
maintenance of both homeostasis and tolerance depend on peptide-MHC derived 
signals. Furthermore, the biochemical signals that are presumably induced by peptide-
MHC in these two instances are similar. The biochemical alterations in tolerant cells 
(Anderson et al., 2006; Chiodetti et al., 2006) resemble somewhat the pattern of 
phosophorylation observed in freshly isolated T cells ex vivo (van Oers et al., 1993; 
Seddon and Zamoyska, 2002); the latter generally considered to be induced as a result 
of homeostatic stimuli. In both cases there is sub-maximal phosphorylation of TCR 
proximal signalling molecules but no detectable activation of signalling pathways such 
as Ca2+/NFAT (van Oers et al., 1993; Asai et al., 2002; Seddon and Zamoyska, 2002; 
Anderson et al., 2006; Chiodetti et al., 2006). These considerations suggest that perhaps 
those same signals that are involved in the maintenance of certain T cell populations in 
the periphery are also responsible for the maintenance of the tolerance of the T cells 
towards those very same ligands. Therefore, if part of that signal were lacking it might 
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affect both homeostasis and tolerance and perhaps this is why many models with 
perturbed homeostasis also develop autoimmunity.  
 
In lymphopaenia there is a relative increase in the level of available cytokines, access to 
APC and peptide-MHC due to the absence of competing cells and this induces vigorous 
“homeostatic” proliferation presumably due to increased stimulation. However, tolerant 
T cells do still proliferate if faced with a greatly increased level of antigen (Tanchot et 
al., 2001; Schwartz, 2003; Singh and Schwartz, 2003) suggesting that the increased 
stimulation that the cell receives in lymphopaenia may also lead to a loss of tolerance to 
that antigen and an autoimmune reaction. This implies that the inertia of the T cell 
populations in normal conditions is an important factor in the maintenance of T cell 
tolerance. Supporting this idea, autoimmunity has been reported to be accompanied by 
lymphopaenia in both mouse models and patients (Zandman-Goddard and Shoenfeld, 
2002; King et al., 2004). As the size of the total T cell population is controlled by 
homeostasis, then T cell homeostasis is a factor in the maintenance of T cell tolerance. 
So therefore, homeostasis and tolerance work together to maintain total T cell numbers 
and to control potentially autoreactive populations. Our data suggest that Egr-2 is an 
intrinsic effector involved in both homeostasis and tolerance and support the idea that 
homeostasis and tolerance are not discrete phenomena but are two overlapping facets of 
T cell biology. 
  
4.7 Other Egr-2 KO data 
 
Recently another group reported their findings from Egr-2 deficient T cells which 
initially appear to conflict somewhat with our results from Egr-2 cKO mice. They used 
foetal liver cells from TCR Tg Egr-2 KO mice to reconstitute the immune system of 
127 
irradiated Balb/c mice and found that these Egr-2 KO T cells were hyper-responsive to 
TCR stimulation (Collins et al., 2008). However, the lymphopaenia induced by 
irradiation would provoke vigorous “homeostatic” proliferation of the transferred TCR 
Tg Egr-2 KO T cells and conversion to CD44high effector phenotype (see Surh and 
Sprent, 2008). Therefore, these cells are likely to be more akin to the CD44high T cells 
that are hyper-proliferative in Egr-2 cKO mice in vivo rather than the primary quiescent 
naïve T cells we examined in vitro. When compared to the CD44high in vivo proliferation 
results, the results from this paper are consistent with the findings from Egr-2 cKO 
mice. Similarly, the previous study from this group examining the effects of Egr-2 over-
expression (Safford et al., 2005) mentioned above (see section 4.3) used a methodology 
that required that the T cells were pre-activated in vitro, rather than quiescent naïve T 
cells, and hence all the results from this group are consistent with the findings from Egr-
2 cKO mice.  
The more recent paper by these authors proposed that part of the mechanism of Egr-2 
and Egr-3 function was to inhibit Egr-1 expression and thereby inhibit T cell activation 
(Collins et al., 2008). However, this hypothesis is dependent on Egr-1 having a positive 
role in T cell activation; this is not supported by T cells from Egr-1 KO mice, which 
show normal responses to TCR stimulation (Lee et al., 1995; Singh et al., 2004). We 
found no evidence for cross-regulation of Egr proteins so far in our model, although we 
did not extensively investigate this. In any case, the importance of any potential cross-
regulation between the Egr proteins remains to be determined.  
 
Even more recently, another paper used a different method to generate Egr-2 deficient T 
cells (Lauritsen et al., 2008). They also used Egr-2loxP/loxP mice but instead of using the 
hCD2 construct to drive Cre expression they used the Lck promoter. This promoter 
directs transgene expression at an earlier stage than the hCD2 construct, with Lck driven 
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transgene expression detectable even in the earliest stages of T cell development such as 
DN1 cells (reviewed in Cantrell, 2002). Using these mice they found that Egr-2 was 
necessary for efficient positive selection but not for negative selection (Lauritsen et al., 
2008). Notably, exactly the same results were previously seen in Egr-1 KO mice 
(Bettini et al., 2002); suggesting that this is another area where there is overlap between 
Egr proteins in terms of function. As stated above we did not see this phenotype in our 
Egr-2 cKO mice; perhaps due to incomplete deletion in our model at this stage (see 
section 4.1 above). The authors observed a small decrease in Bcl-2 expression in their 
conditional Egr-2 KO model (Lauritsen et al., 2008). Consistent with this we also found 
slightly decreased expression of Bcl-2 by Egr-2 cKO T cells and, as stated above, some 
of the unexpected results from Egr-2 cKO and Tg mice could perhaps be explained by a 
pro-survival effect of Egr-2. So overall, the results from this model are consistent with 
our findings from our Egr-2 cKO mice. 
 
4.8 Mechanisms of Egr-2 function 
 
4.8.1 Egr-2 regulation of p21cip1 
 
We found that Egr-2 regulates the expression of p21cip1; a negative regulator of cell 
cycle progression (see Sherr and Roberts, 1999). Notably defective expression of 
p21cip1 has been implicated in lupus-like disease (Balomenos et al., 2000; Salvador et 
al., 2002; Arias et al., 2007) although this is controversial (Santiago-Raber et al., 2001; 
Lawson et al., 2002; Lawson et al., 2004). A study of p21cip1 KO mice on a mixed 
129/Sv × C57BL/6 background found that these mice developed a lupus-like 
autoimmune disease (Balomenos et al., 2000). However, another group reported that 
p21cip1 KO mice on a different mixed 129/Sv × C57BL/6 background developed only a 
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mild lupus-like autoimmune disease (Santiago-Raber et al., 2001). This group 
subsequently found that p21 deficiency in mice of the lupus prone BXSB background 
reduced the incidence of disease in male mice (Lawson et al., 2004). Based on in vitro 
findings of increased FasL mediated apoptosis, the authors attributed this resistance to 
disease to increased apoptosis of p21cip1 deficient T cells. However, the incidence of 
disease in female BXSB mice was not affected by p21cip1 deficiency but T cells from 
these mice showed similar increases in apoptosis (Lawson et al., 2002). The BXSB 
model of lupus is unusual as male mice are more significantly affected which is 
attributed to a region on the Y chromosome termed the Yaa (Y chromosome 
Accelerator of Autoimmunity) (Pisitkun et al., 2006). Taken together, this data from 
BXSB mice suggests that it is the combination of the Yaa with p21 deficiency that 
impairs lupus development in male p21cip1 KO BXSB mice, rather than increased 
apoptosis of p21cip1 deficient T cells (Arias et al., 2007). While progress has recently 
been made in identifying the genetic abnormalities responsible for the disease 
promoting effects of Yaa (Pisitkun et al., 2006; Deane et al., 2007), how the gene 
products interact with p21cip1, and which cell types are involved, is a matter of 
speculation. Indeed, whether p21cip1 deficiency does result in increased apoptosis has 
been called into question; a recent study of p21cip1 KO mice on the C57BL/6 
background found that apoptosis induction was not affected (Arias et al., 2007). Thus, 
the increased apoptosis seen in p21cip1 KO BXSB mice may be specific to the BXSB 
background rather than a general effect of p21cip1 deficiency. Furthermore, p21cip1 
KO mice on the C57BL/6 background also develop lupus-like autoimmune disease 
(Arias et al., 2007), although this was not as severe as that seen in the mixed 
background mice (Balomenos et al., 2000). Therefore, collectively these data suggest 
that defective p21cip1 expression may be part of the mechanism responsible for the 
breakdown of self-tolerance in Egr-2 cKO mice. In particular, the defect in expression 
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of p21cip1 provides a potential explanation of the hyper-proliferation and accumulation 
of CD44high T cells in vivo in Egr-2 cKO mice, since this also was observed in p21cip1 
deficient mice on the C57BL/6 background (Arias et al., 2007). 
 
However, whether defective expression of p21cip1 can fully explain the loss of 
tolerance in Egr-2 cKO mice is unclear. In particular, it is difficult to envisage how 
defective p21cip1 expression leads to the inflammation observed in Egr-2 cKO mice. 
Since Egr-2 is a transcription factor it could potentially regulate hundreds of genes, any 
number of which might be involved in the maintenance of tolerance. Thus, there are 
likely to be other genes regulated by Egr-2 that are relevant to autoimmune disease 
development. We performed a microarray to try and identify novel targets of Egr-2.  
 
4.8.2 Microarray analysis of Egr-2 cKO T cells 
 
Of those genes that were differentially expressed according to the microarray the most 
common functional category was metabolic enzymes; more than a quarter of the genes 
with known function fell into this category. Interestingly, a similar effect on metabolic 
genes was previously reported in Egr-1, Egr-3 DKO mice (Carter et al., 2007).  
 
The microarray also revealed that the expression of several key effector cytokines was 
altered in stimulated Egr-2 cKO T cells compared to their Egr-2loxP/loxP counterparts 
with IL-4 and IL-13 decreased and IFN-γ and, in particular, IL-17A and IL-17F 
increased (discussed further below).  
 
In addition to the increased expression of IL-17A and IL-17F the microarray also 
showed increased expression of other molecules that have been reported to be expressed 
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by, and/or to be involved in the differentiation of, IL-17 producing CD4+ T cells. 
Among these, the chemokine receptor CCR6 is involved in trafficking to inflamed sites 
and has been found to be expressed by IL-17 producing CD4+ T cells in a mouse model 
of Rheumatoid Arthritis (Hirota et al., 2007). In addition, the pro-inflammatory 
cytokine IL-1α has been reported to promote the development of IL-17 producing CD4+ 
T cells, at least in vitro (Sutton et al., 2006). While IL-1α was originally described as a 
cytokine produced by macrophages, IL-1α expression by some T cell subsets is now 
well documented (van Kooten et al., 1991; van Rietschoten et al., 2006). Finally, 
autocrine production of IL-21 has been implicated in the proliferation and/or lineage 
commitment of IL-17 producing CD4+ T cells (Korn et al., 2007; Nurieva et al., 2007; 
Zhou et al., 2007).  
 
We also found increased expression of the anti-inflammatory cytokine IL-10 by Egr-2 
cKO T cells. Although it is anti-inflammatory, IL-10 has been implicated as having a 
pathogenic role in lupus (see Moore et al., 2001) and so this increased IL-10 expression 
could be relevant to the autoimmunity observed in Egr-2 cKO mice.  
 
IL-15 is an IL-2 related cytokine that is important for T cell homeostasis (see Surh and 
Sprent, 2008). It was somewhat surprising to find increased expression of this cytokine 
on the microarray, however, since traditionally T cells were not considered to be a 
source of IL-15 in vivo (see Fehniger and Caligiuri, 2001). Nevertheless, there is one 
report that has demonstrated that IL-15 is expressed by T cells (Azimi et al., 1998; 
Fehniger and Caligiuri, 2001). However, there are multiple post-transcriptional 
mechanisms that serve to regulate IL-15 expression (see Fehniger and Caligiuri, 2001) 
so the increased expression of this cytokine needs to be confirmed at the protein level. 
Furthermore, the biological relevance of the increased expression of this cytokine 
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remains to be determined as the importance of T cell production of IL-15 in vivo is 
unclear. These arguments notwithstanding, one could envisage that increased expression 
of IL-15 could also contribute to the hyper-proliferation of CD44high T cells in Egr-2 
cKO mice in vivo by promoting homeostatic proliferation and/or supporting cell 
survival (Fehniger and Caligiuri, 2001; Boyman et al., 2006; Purton et al., 2007; Surh 
and Sprent, 2008). In addition to its well characterised role in T cell homeostasis, IL-15 
is a potent T cell chemoattractant and increased IL-15 levels have been observed in 
several models of, and patients with, inflammatory autoimmune processes (see Fehniger 
and Caligiuri, 2001). While the precise roles played by IL-15 in inflammation remain 
unclear, increased IL-15 expression could also be involved in the development of 
autoimmunity in Egr-2 cKO mice. 
 
4.8.3 Effector T cell subsets in Egr-2 cKO mice 
 
Consistent with the 3 fold reduction in TH2 cytokines detected by microarray and Real 
Time RT-PCR, the numbers of IL-4 producing CD4+ T cells were decreased in Egr-2 
cKO mice. Conversely, the numbers of IFN-γ producing CD4+ T cells were increased in 
Egr-2 cKO mice consistent with the 2 fold increase in IFN-γ mRNA expression. 
Similarly, IL-17 producing CD4+ T cells were also increased, which was by far the most 
marked alteration in terms of expression of effector cytokines by CD4+ T cells in Egr-2 
cKO mice, consistent with the 3-4 fold increase in IL-17A and IL-17F mRNA levels. 
 
Notably, the increased numbers of IFN-γ and IL-17 producing CD4+ T cells in Egr-2 
cKO mice further increased as the Egr-2 cKO mice aged. In addition, we found that the 
IFN-γ dependent IgG2a isotype was increased in the serum of Egr-2 cKO mice. These 
findings suggest that IFN-γ and IL-17 producing CD4+ T cells may be involved in the 
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development of the autoimmune disease observed in Egr-2 cKO mice. Consistent with 
this possibility, IFN-γ is important for the development of lupus-like disease 
(Balomenos et al., 1998) while IL-17 producing CD4+ T cells have recently been 
implicated in auto-antibody production (Hsu et al., 2008; Wu et al., 2008). 
 
4.9 Future Work 
 
The work presented here raises several interesting avenues for future investigation. For 
Egr-2 cKO mice the mechanism by which Egr-2 deficiency leads to increased 
production of inflammatory cytokines is the key issue. Most of the evidence indicates 
that it is the CD44high cells that are producing these cytokines but this has not been 
validated for cytokine mRNA. Isolation of CD44low and CD44high cells and separate 
stimulation should definitively resolve this. In vitro TH1/TH2/TH17 polarisation and 
further investigation of TCR and cytokine signalling pathways may facilitate future 
investigation of the molecular mechanism of Egr-2 in control of inflammatory cytokine 
production and/or effector T cell differentiation. Isolation of CD44low and CD44high cells 
and separate stimulation should also help to resolve the issue of the role of Egr-2 in T 
cell activation in CD44low and CD44high cells and facilitate future investigation of the 
molecular mechanism of Egr-2 in T cell activation. 
 
For Egr-2 Tg mice the mechanism by which constitutive Egr-2 overexpression leads to 
the observed thymocyte developmental defects is the key issue. As stated above analysis 
of the TCR  loci in ISP cells should assist with this and facilitate future investigation 
of the molecular mechanism of Egr-2 in T cell development. 
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4.10 Conclusions and model for Egr-2 function 
 
Our work has confirmed a role for Egr-2 in T cell tolerance and revealed hitherto 
unknown roles for Egr-2 in T cell homeostasis and inflammatory responses…how can 
these disparate strands be weaved into a coherent picture of the role of Egr-2 in T cells?  
 
Several studies in thymocytes suggest that Egr proteins may have a pro-survival effect 
both during -selection (Carter et al., 2007) and positive selection (Bettini et al., 2002; 
Lauritsen et al., 2008). In addition, there is one report that suggests that Egr-1 may also 
have a pro-survival role in peripheral naïve T cells (Bettini et al., 2003). We found no 
direct evidence for a pro-survival role of Egr-2 in our study. However, some of the 
unexpected results from Egr-2 cKO and Tg mice; such as the mild hypo-proliferation of 
naïve Egr-2 cKO T cells in vitro, the small decrease in peripheral T cell numbers in 
young Egr-2 cKO mice and the persistence of aberrant cells that resemble ISP 
thymocytes in the periphery of Egr-2 Tg mice; could perhaps be explained by the 
possibility that Egr-2 may have a pro-survival effect in mature peripheral naïve T cells 
as outlined above (see sections 4.2 and 4.3). However, since there is no direct evidence 
from our study to support this hypothesis, I shall not include it in the model of Egr-2 
function and instead focus on the role of Egr-2 in effector T cells. 
 
Based on our findings presented here I have formulated a general model for Egr-2 
function in effector T cells. This is that Egr-2 expression induces 2 effects; 1) retarding 
cell cycle progression and 2) restraining inflammatory responses by modulating 
differentiation (see Figure 4.1).  
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The possibility that Egr-2 may supply an inhibitory signal downstream of the TCR 
which would serve as a brake on proliferation would explain the hyper-proliferation of 
Figure 4.1: A model for Egr-2 function. (A) Proposed two effects of Egr-2. (B) 
Potential role of Egr-2 in retarding proliferation. We have shown that Egr-2 
regulates p21cip1 expression (Figures 3.18 and 3.19). Via induction of negative 
regulators such as this Egr-2 could serve to retard proliferation. (C) Potential 
role of Egr-2 in modulating inflammatory responses. Egr-2 could modulate the 
expression or function of transcription factors, such as RORγt, that are 
important for the generation of IL-17 producing CD4+ T cells, or directly interfere 
with IL-17 expression or function by some other as yet undiscovered 
mechanism to control the development of IL-17 producing CD4+ T cells. Egr-2 
could also have similar roles in the control of IFN-γ producing CD4+ T cells (Not 
shown). By regulating the development of pro-inflammatory cytokine producing 
CD4+ T cells Egr-2 could thereby control inflammatory responses. See text for 
further details. 
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the CD44high cells in Egr-2 cKO mice in vivo. Presumably, this in vivo proliferation is 
induced by homeostatic stimuli and these stimuli also appear to induce Egr-2 in normal 
mice (see Figure 3.12). Our model predicts that in normal mice Egr-2 serves to limit 
proliferation but in the absence of Egr-2, in Egr-2 cKO mice, proliferation is 
unrestrained. This possibility would also explain the results of Powell and colleagues 
who found that Egr-2 over-expression inhibits the responses of T cell lines in vitro 
(Safford et al., 2005) and the subsequent results from the same group that observed 
hyper-responsive Egr-2 KO T cells (Collins et al., 2008). However, as argued above, 
given the systems used in the latter two studies the cells would presumably be more 
akin to CD44high cells rather than naïve CD44low cells. Therefore, all the evidence that 
supports this “proliferative brake” role for Egr-2 is from effector cells. 
 
Controlling homeostatic proliferation of effector CD44high T cells is critical for T cell 
homeostasis. Therefore, our model predicts that Egr-2 is important for T cell 
homeostasis. The progressive accumulation of CD44high T cells in vivo as the mice age 
supports this idea.  
 
In all other cell types examined Egr-2 has been associated with differentiation 
(Voiculescu et al., 2001; Parkinson et al., 2004; Laslo et al., 2006).  In T cells, Egr-2 
has likewise been implicated in thymocyte differentiation; originally in -selection and 
more recently in positive selection (Carleton et al., 2002; Carter et al., 2007; Lauritsen 
et al., 2008). In mature T cells however, there is no published evidence of Egr-2 
involvement in effector T cell differentiation. Our discovery of increased numbers of 
IFN-γ and IL-17 producing CD4+ T cells in Egr-2 cKO mice suggest that Egr-2 may be 
involved in effector T cell differentiation. Notably, Egr-1 and Egr-2 have been reported 
to be involved in myeloid cell fate specification by promoting the macrophage 
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phenotype and inhibiting the competing neutrophil gene expression programme (Laslo 
et al., 2006) and a similar role has been proposed for Egr-2 in rhombomere 
differentiation (Voiculescu et al., 2001); cell lineage decisions that are, in many ways, 
analogous to effector T cell differentiation.  
 
Given that we observed increased IFN-γ and IL-17 mRNA expression by activated T 
cells from Egr-2 cKO mice one could speculate that Egr-2 mediates some of its effects 
by regulating cytokine expression. However, the T cells used in this experiment were 
total T cells not purified naïve T cells and would therefore include some effector cells. 
We observed increased numbers of IFN-γ and IL-17 producing CD4+ T cells in Egr-2 
cKO mice of comparable ages to those used in the above experiment suggesting that the 
increased IFN-γ and IL-17 mRNA expression may be due to the presence of increased 
numbers of IFN-γ and IL-17 producing CD4+ T cells rather than indicating that Egr-2 
affects cytokine expression per se. Nevertheless, there is some support for the idea that 
Egr-2 may regulate cytokine expression from the work of Skerka and colleagues who 
reported that Egr proteins were directly involved in modulating cytokine expression via 
interaction with NF-κB and NFAT (Decker et al., 1998; Decker et al., 2003; Wieland et 
al., 2005). Also at least some of the key effector cytokines can influence the expression 
of cytokines by other CD4+ T cells so if there was a primary effect on cytokine 
expression this could feedback and result in increased numbers of cytokine producing 
effector T cells. Therefore a role for Egr-2 in modulating IL-17, IL-4 or IFN-γ 
expression cannot be ruled out from the data at hand. However, we favour the idea that 
Egr-2 may be involved in effector cell differentiation as this is more in keeping with the 
roles of Egr-2 in other cell types (Voiculescu et al., 2001; Parkinson et al., 2004; Laslo 
et al., 2006).  
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For TH1 cells the transcription factor T-bet is important for the establishment of the 
IFN-γ secreting phenotype (Szabo et al., 2000). Recently, the transcription factors 
RORα and RORγt have been identified as important for the development of IL-17 
producing CD4+ T cells (Ivanov et al., 2006; Yang et al., 2008). In addition, 
transcription factors that are activated downstream of cytokine signalling are also 
important for the development of cytokine producing CD4+ T cells. Signal Transducer 
and Activator of Transcription (STAT)-1 and STAT-4 are important for the 
development of IFN-γ producing CD4+ T cells, while STAT-3 is important for IL-17 
producing CD4+ T cells (see Dong, 2008). One could imagine that Egr-2 may modulate 
the expression and/or activity of one or more of these transcription factors. Intriguingly, 
Egr-3 has been reported to indirectly inhibit the expression of RORγt and to physically 
interact with RORγt protein inhibiting its activity (Xi et al., 2006). Preliminary studies 
of T-bet and RORγt did not find any evidence for Egr-2 modulation of the expression or 
activity of these key transcription factors (P Wang, personal communication) although 
this cannot be formally ruled out. Another possibility is that Egr-2 may impact on other, 
as yet undiscovered, pathways that are involved in effector T cell differentiation. The 
exact nature of the mechanisms by which Egr-2 functions in effector T cell 
differentiation will require additional investigation.  
 
In any case, the increased numbers of CD4+ T cells producing pro-inflammatory 
cytokines observed in Egr-2 cKO mice indicates that Egr-2 is involved in the control of 
inflammatory responses. This role of Egr-2 may be important not only for self-tolerance 
but also to limit immunopathology during a productive immune response caused by 
over-zealous responses to foreign antigen. This may be particularly applicable to certain 
diseases, such as some viral lung diseases, where immunopathology rather than direct 
pathogen effects appear to be responsible for much of the pathology (Hussell et al., 
139 
2001). This role of Egr-2 would also serve to maintain homeostasis, this time of the 
whole organism rather than specifically of T cells. 
 
In adaptive tolerance T cell proliferation and effector functions are impaired (Tanchot et 
al., 2001; Singh and Schwartz, 2003; Safford et al., 2005; Anderson et al., 2006). As 
Egr-2 expression has been observed in models of adaptive tolerance, by our group as 
well as others (Safford et al., 2005; Anderson et al., 2006), the above conjecture on the 
twin roles of Egr-2 in restraining proliferation and inhibiting inflammatory responses 
could potentially explain these two aspects of the tolerant T cell phenotype. Evidence 
for a role of Egr-2 in T cell tolerance is most obviously supplied by the autoimmunity in 
Egr-2 cKO mice.  
 
Recently it has been reported that Egr-2, but not Egr-1 or Egr-3, is essential for the 
terminal maturation of NKT cells, a CD1 restricted subset of T cells that also express 
NK cell markers (Lazarevic et al., 2009). Intriguingly, this group found that in the 
absence of Egr-2, NKT cell precursors displayed increased proliferation coupled to 
impaired differentiation (Lazarevic et al., 2009). Importantly, this study demonstrates 
both phenotypic changes predicted by our model and therefore supports our hypothesis.  
 
It is worth comparing our findings on the role of Egr-2 with the roles of NFAT and 
FoxP3; two transcription factors involved in T cell tolerance that have been extensively 
investigated. FoxP3 is constitutively expressed by TReg cells and is important for the 
development of the TReg phenotype (Fontenot et al., 2003; Hori et al., 2003). Thus 
FoxP3 is important for cell extrinsic mechanisms of T cell tolerance. In contrast, all the 
evidence, both from our study and others (Harris et al., 2004; Safford et al., 2005; 
Anderson et al., 2006), supports the notion that Egr-2 is a transcription factor that is 
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involved in cell intrinsic mechanisms of T cell tolerance. While the transcription factor 
NFAT has also been reported to be important for cell intrinsic mechanisms of tolerance 
(Macian et al., 2002; Heissmeyer et al., 2004) there are differences in both the 
expression profile and proposed mechanism of action between NFAT and Egr-2. While 
both NFAT activation and Egr-2 expression is detectable in activated T cells, NFAT is 
not activated in adaptively tolerant T cells but Egr-2 is expressed (Anderson et al., 2006 
- see also Figure 3.1). Furthermore, perhaps the most striking difference between Egr-2 
and NFAT is the proposed mechanism of action. NFAT has been reported to induce E3 
ligase expression and thereby regulate TCR signalling and the T cell activation 
threshold (Heissmeyer et al., 2004). While Egr-2 has been proposed to function in a 
similar way (Safford et al., 2005) the evidence we found from Egr-2 cKO mice is 
inconsistent with this theory. Instead Egr-2 appears to regulate the homeostasis and 
inflammatory responses of effector T cells. However, the precise mechanisms by which 
Egr-2 functions are still not clear and will require further investigation. This role of Egr-
2, while more subtle than the broad effects of NFAT and FoxP3, is arguably just as 
important for self-tolerance. 
 
This general model for Egr-2 function could also apply to some of the other Egr 
proteins and could potentially explain some of the reported results; although there may 
well be some differences between individual Egr proteins in the extent of their 
involvement in particular roles. For example, while an inhibitory effect on proliferation 
could explain the hyper-reactivity of Egr-3 KO T cells and the inhibition of T cell 
responses by Egr-3 over-expression (Safford et al., 2005; Collins et al., 2008), there is 
no reported evidence of an inhibitory effect of Egr-1 on proliferation (Lee et al., 1995; 
Singh et al., 2004). Given this potential overlap between the Egr proteins, the 
importance of their function may only be apparent upon the establishment of double, 
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triple, or even quadruple KO mice. The importance of these potential roles of Egr 
proteins and the extent of overlap between them for each particular role will require 
further investigation. 
 
To summarise our model we propose that Egr-2 retards proliferation and differentially 
promotes differentiation. These two effects may well be common roles for Egr-2 across 
many different biological systems, such as neuronal cells and myeloid lineages 
(Voiculescu et al., 2001; Parkinson et al., 2004; Laslo et al., 2006), and may represent a 
general cell biological function. In effector T cells, Egr-2 mediated differential 
promotion of differentiation inhibits the development of a pro-inflammatory phenotype 
and thus Egr-2 serves to restrain pro-inflammatory responses. These two effects: 
retarding proliferation and restraining inflammatory responses, presumably through 
altered differentiation, therefore makes Egr-2 an intrinsic regulator of effector T cells 
which acts to preserve tolerance to self and environmental antigens. By regulating 
effector T cell responses in this way, Egr-2 also serves to promote homeostasis, both of 
the organism in general and of T cells in particular, and therefore Egr-2 enforces a pro-
tolerogenic and pro-homeostatic gene expression programme. 
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